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Abstract
Chapter 1 reviews the synthesis and applications of [60]fullerene amino acids and
peptides, in material science and biological activities reported so far. We segregated the
type of [60]fullerene amino acids based on their connectivity, such as, fullerenyl
substituents directly substituted to the amino acid α-carbon, [60]fullerenyl N-capped
peptides and amino acids, [60]fullerenyl C-capped peptides and amino acids and
fullerenyl amino acids that could potentially be incorporated within peptide chains.
Chapter 2 demonstrated the synthesis of the novel [60]fullerene monopeptide 201 and
dipeptide 204. [60]Fullerenoproline acid 198 was coupled to lysine amine 200 to yield
the monopeptide 201 in 62% yield, which was separately deprotected to its amine salt
202 using TFA and to its acid derivative 203 with Sn(CH3)3OH. An amide coupling
reaction of the amine 202 and the acid 203 resulted in the dipeptide 204 (57%).
Attempts to synthesise the tetrapeptide 207 using the same approach were not
successful because of its poor solubility. Monopeptide 201 and the dipeptide 204 have
been studied experimentally using spectroelectrochemical measurements by Prof.
Timothy Clark and Prof. Dirk M. Guldi at the University of Erlangen-Nuremberg,
Germany. The bis-fullerene-substituted peptide 204 provided experimental support for
density-functional theory (DFT) calculations which indicate that van der Waals
fullerene dimers can form between adjacent fullerenes in semiconductor layers resulting
in interstitial electron traps.
An alternative synthesis of the tetrapeptide 207 was examined. The lysine tetrapeptide
216 (70% yield) and its tetramine 217 (100%) were successfully synthesised. Attempts
to couple 217 with [60]fullerenoproline acid 198 to produce the tetrapeptide 207 were
also unsuccessful, possibly due to steric hindrance problems because of the sterically
iv

demanding fullerene groups. Accordingly, we thought that the cyclic peptide
tetrapeptide 220 might help to solve these steric hindrance problems. Tetrapeptide 216
was successfully converted to the novel cyclic peptide 220 in three synthetic steps.
However we did not pursue this route any further because of the poor chemical yields
and the difficulties in purifying 220.
Chapter 3 reported an extension of [60]fullerenyl oligomers with the incorporation of
spacers between the fullerenyl groups. Two types of amino acid spacers (L-lysine and
L-phenylalanine) were introduced in to the oligomers (hexapeptide 227 and hexapeptide
238). The synthesis of tripeptides with L-lysine spacers 224 in 62%, and Lphenylalanine spacers 235 (in 60%) were achieved by coupling the acid 203 with the
amine 213 and the amine 202 with the acid 234, respectively. The previously used ester
and N-Boc cleavage reaction conditions were adopted to synthesise the corresponding
acids (225 and 236) and amines (226 and 237) of 224 and 235. Their amide coupling
reaction provided the hexapeptides of 227 (44%) and 238 (40%) respectively. Currently,
these molecules are under studies to form supramolecular complexes between these
[60]fullerene peptides and porphyrin and photoinduced charge separation in Prof.
Fukuzumi’s laboratory at Osaka University, Japan.
Chapter 4 reported the synthesis and antibacterial screening of mono substituted
[60]fullerenyl peptides (243, 245, 247, 272-279) and bis-[60]fullerenyl peptide (285). A
range of tri, tetra and pentapeptides having an oxazole or isopentyl ester terminal group
were synthesised. These peptides were then deprotected to form their HCl and TFA
salts 247, 276-279. Antibacterial screening of these peptides (243, 245, 247, 272-279
and 285) was performed at the University of Western Australia in Prof. Thomas Riley’s
laboratory; unfortunately, none of these compounds showed significant activity.
v
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Introduction

Chapter 1

[60]Fullerenyl Amino Acid
Derivatives: Synthesis and Their
Applications
A large portion of synthetic [60]fullerene chemistry is directed towards its
functionalization providing biologically active derivatives and molecules with
applications also in material science.1-6 The impetus for such work was to exploit the
physical properties of [60]fullerene (such as sensitization of singlet oxygen and electron
acceptor characteristics) and combine this with the properties of biomolecules (water
solubility and precise secondary and tertiary structure).5,7-10 For example, [60]fullerene
derivatives covalently linked to peptides and proteins has been the goal of a number of
research groups concerned with the application of [60]fullerene-peptide conjugates to
biological problems.11-16 It was anticipated that the addition of biologically active
compounds to [60]fullerene in a strict regioselective fashion would aid the activity and
specificity of future therapies. In recent times, the field has matured significantly such
that there are different types of fullerenyl amino acids that can be categorised according
to properties of the amino acid itself, allowing for a broader perspective of how they
could be incorporated into different research programs. In this chapter we report on the
current progress in the synthesis of fullerenyl amino acids and related derivatives and
attempt to categorise the molecules into functional types for different uses: these include
directly attached fullerenyl amino acids, fullerenyl N- and C-capping amino acids, and
those amino acids in which the [60]fullerene group is attached to the amino acid side
chain. These first and last mentioned derivatives have the potential to be incorporated
into non-terminal positions of peptides. The applications of these substrates by

1
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integration into different biological and materials chemistry programs are then
highlighted.

1.1 Synthesis of Fullerenyl Amino Acids
From a material science and medicinal chemistry perspective, fullerenyl amino
acids are important targets potentially serving as central hubs in architecturally defined
nanostructures or 3D-templates in drug design.17-24 To date fullerenyl amino acids and
peptide derivatives have been prepared by the initial attachment of a handle to the
fullerene followed by coupling to a protected amino acid or peptide.25-27

1.2 Synthesis of Derivatives with Fullerenyl Substituents Directly
Substituted to the Amino Acid α-Carbon
There are surprisingly few examples of fullerenyl amino acids that are direct
analogues of α-amino acids, i.e. the α-carbon is bonded directly to a C60 carbon atom.
There are two examples of this type of molecule, the well-established fullerenoprolines,
and there are reports of protected versions of amino acids whereby the fullerenyl
substituent is directly coupled to the α-carbon.

1.2.1 Fullerenoproline derivatives
The first synthesis of α-substituted fullerenyl amino acids, the fullerenoprolines
(Fpr) (4), was achieved by the addition of azomethine ylides to [60]fullerene.28-30 The
azomethine ylide intermediate can be generated in two different ways, either via a
thermal ring-opening of aziridines 1 or via tautomerisation of iminium salts formed by
the condensation of α-amino esters 2 with aldehydes 3 (Scheme 1.1). These reactions

2
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allow for a significant number of Fpr derivatives to be generated by using different
combinations of aldehydes and amino esters.

Scheme 1.1: The synthesis of fulleroprolines 4 can be achieved by thermal addition of aziridines or
iminium salts to [60]fullerene.

Fpr analogues can be prepared with the pyrrolidine nitrogen protected (Scheme
1.2) or unprotected (Scheme 1.3).31 Addition of the aziridine 5 to [60]fullerene under
thermal conditions formed the N-protected Fpr 6. Subsequent treatment with TFA
provided the secondary amine salt 7, which could then be acylated with acetic anhydride
to provide 8 (Scheme 1.2).31

Scheme 1.2: Synthesis of the protected fulleroproline 8 was achieved through thermal addition of
aziridine 5 to [60]fullerene.

3
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To obtain more useful Fpr derivatives for peptide synthesis, the azomethine ylides,
which are generated in situ from the reaction of glycinate esters 9 and 10 with
paraformaldehyde, can be added to [60]fullerene to produce the free Fprs 11 and 12,
respectively. These were relatively unstable and had to be kept as dilute solutions in the
dark.31 However, the amine group was readily functionalized using standard acylation
procedures with acid anhydrides and acid chlorides (Scheme 1.3), to deliver racemic Nprotected Fpr ester of the type 13. Alternatively the amine 11 was protected as the NFmoc derivative 14, and then the tert-butyl ester converted to the acid 15 by treatment
with TFA. Subsequent coupling with ethyl L-alaninate under EDCI/HOAt conditions
afforded the diastereomers 16 and 17. The diastereomeric ratio of 13 was determined by
formation of the dioxopiperazines 18 and 19, thus eliminating the additional complexity
in characterization imposed by amide rotamers.31
A second type of fullerenyl amino acid was initially envisaged as a
methanofullerene of the type 21 (Scheme 1.4). Strategies towards such molecules
include the addition of diphenyliminoglycinates to [60]fullerene under Bingel
cyclopropanation reaction conditions which was originally reported to furnish the
corresponding methano[60]fullerene derivatives 21 (Scheme 1.4).32,33 However
subsequent extensive NMR studies revealed that the structure of the products was that
of the dihydrofullerenoproline derivatives33 22, and not the more strained threemembered (cyclopropane) ring products 21. The dihydrofullerenoproline derivative 23
was hydrolysed to its carboxylic acid using TFA to yield 24 in 90% yield.

4
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Scheme 1.3: Synthesis of Fpr peptide derivatives 16-19.
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Scheme 1.4: The addition of iminoglycinate to fullerene under Bingel cyclopropanation conditions
provides the analogous [60]fullerenyldihydropyrrole 22 not the previously reported methano[60]fullerene
21.

BF3.Et2O

and

dihydrofullerenoproline

NaCNBH3
derivative33

mediated
22

reductive
yielded

ring-opening
the

ethyl

of
N-

benzhydrylfullerenyl[60]glycinate 25, which was N-deprotected to give ethyl
fullerenylglycinate 2634 a true fullerenyl α-amino ester which was fully characterised as
its more stable N-acetyl derivative 27. Therefore, the original structure 22 could be
considered as a protected version of 26. The free amine of 26 reacted with a variety of
aldehydes and ketones in a Mannich-type process to produce 5-substituted and 5,5disubstituted Fprs 28-38. This process represents a versatile and general strategy to
synthesise Fprs.
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Scheme 1.5: Synthesis of 5-substituted and 5,5-disubstituted fulleroprolines 28-38.

The reactions of amino acid ester hydrochlorides and CS2 with [60]fullerene in
the presence of Et3N yields novel [60]fullerene derivatives 40 (major) and 41 (minor)
containing biologically active amino acids,35 thioamide, and thiourea units. The
thiolactam groups in compounds 40 are sensitive to moisture and can easily be
hydrolyzed to the corresponding lactams.

Scheme 1.6: Reactions of [60]fullerene with amino acid esters and CS2.
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1.3 Synthesis of [60]fullerenyl N-Capped Peptides and Amino Acids
The thermal addition of the diazomethane derivative 42 to [60]fullerene and
subsequent deprotection of the ester of the resulting methano[60]fullerene 43 provided
the acid 44.36 This represented the first synthesis of a fullerenyl compound which had a
synthetic handle to readily allow for peptide functionalization (Scheme 1.7). The acid
44 was converted to the reactive acid chloride 45 which underwent amide coupling with
a pentapeptide under basic conditions to provide the first reported fullerenyl peptide
46.36

Scheme 1.7: Synthesis of 46 through a diazo-addition of 42 to [60]fullerene.

This work was extended to alkyl diazoacetates of the type 47, which was added
to [60]fullerene forming the methano[60]fullerene 48, which was deprotected to the
carboxylic acid 49 and then coupled to amino acids under standard DCC coupling
reaction conditions to form fullerenyl amino acid esters of the type 50.37,38
Alternatively, a more efficient route was developed, that allowed the direct addition of
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diazoamides to [60]fullerene. For example, a solution of [60]fullerene in toluene was
treated with the diazoacetamide 51 at reflux for 48 h providing the fullerenyl amino acid
50 (R = Bn) in 30% yield (Scheme 1.8).39

Scheme 1.8: Synthesis of 50 through a diazo-addition of 47 or 51 to [60]fullerene.

Thermal reactions of [60]fullerene with other diazo compounds such as
diazomethanes,40,41 diazoacetates,42 diazoamides, diazomethylphosphonates,43 and
diazoketones, provides a broad variety of methano[60]fullerenes, having handles for
further functionalization. The methano[60]fullerene carboxylic acid 49 can be accessed
from either the tert-butyl ester 52 (Scheme 1.9) or the O-glycolic ester 47 (Scheme 1.8),
followed by ester deprotection of the fullerenyl adducts 53 and 48, respectively. The
synthetic utility of the methano[60]fullerenyl carboxylic acid 49 was further
demonstrated by its DCC/HOBt mediated coupling with peptides to produce the
fullerenyl peptides 54.44,45
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Scheme 1.9: Synthesis of peptide 54 was achieved through addition of 52 to [60]fullerene. i) H-Thr-ThrAsn-Tyr-Thr-OH, DCC, HOBt, C6H5Br/DMSO (6:1).

The Bingel reaction conditions have been modified to work, in moderate to
excellent yields, with ketones, esters and iminoglycinates. This modification has
allowed for the generation of the analogous α-haloanion in situ rather than the previous
isolation of the halogenated intermediate. This efficient and reliable one-pot reaction
has been used extensively with malonic esters 55 and derivatives, as illustrated in
Scheme 1.10.46-48

Scheme 1.10: Malonates add to [60]fullerene under Bingel cyclopropanation conditions to provide
methanofullerenes 56.

Thermolysis of sulfones 57 in the presence of [60]fullerene in 1,2,4trichlorobenzene at reflux under a nitrogen atmosphere afforded the fullerene
derivatives 58 (via the corresponding pyrimidine o-quinodimethanes) (Scheme 1.11). A
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similar reaction with 59 did not give the expected adduct but the dehydration product 61
(Scheme 1.11).49

Scheme 1.11: Synthesis of [60]fullerene based tetrahydroquinazolines.

Organic azides act as 1,3-dipoles and can undergo [3+2]-cycloaddition reactions
(either photochemically or thermally) with [60]fullerene to yield fulleroaziridines
(Scheme 1.12).50,51 Of these organic azides, photochemical or thermal reactions of
[60]fullerene with perfluorophenylazide 62 produces the fulleroaziridine 63 with an
activated

N-hydroxysuccinamide

ester.

This

active

ester

allows

further

functionalization, such as peptide coupling resulting in the formation of 64.
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Scheme 1.12: Synthesis of fulleroaziridine

The reaction of [60]fullerene with organolithium and Grignard reagents have
been exploited to incorporate a protected carboxylic acid functionality onto the C60
sphere.52 The organolithium reagent made from the stable bicyclic orthoester 65,
prepared by following the general procedure described by Corey,53,54 has been
successfully added to [60]fullerene to give adduct 66. This was converted to the acid 68
by two sequential hydrolysis steps and then coupled with L-alanine ethyl ester
hydrochloride to give 69 (Scheme 1.13).

Scheme 1.13: Synthesis of 1-hydro-2-[3ʹ-(L-Ala-OEt)propyl]-1,2-dihydro[60]fullerene 69.
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Methano[60]fullerene carboxylic acid derivatives 49 and 70-72 were converted to
their active esters of N-hydroxysuccinimide (NHS) 73-76 and pentafluorophenol
(PFP)55 77-80 and coupled with amino acids and peptides. These active esters have been
reacted selectively with the amino group of the amino acid or peptide, or the hydroxy
group but only under DMAP catalysis. Analysis by MALDI-TOF-MS revealed the
potential utility of these active esters for the preparation of fullerene-modified amino
acids or peptides for applications in biological studies (Scheme 1.14).

Scheme 1.14: Derivatization of carboxylic acids 49 and 70-72 with amino acids and peptides.
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1.4 Synthesis of [60]Fullerenyl C-Capped Peptides and Amino Acids
Alternative

methods

to

generate

methano[60]fullerene

derivatives

via

addition/elimination mechanisms have employed sulfonium and phosphonium
ylides.56,57 Deprotection of the ester moieties in these methano[60]fullerenes, as well as
the malonate derivatives, has provided access to versatile handles, including the
carboxylic acid 49 which was generated by the addition of the sulfonium ylide 85 to
[60]fullerene, followed by cleavage of the tert-butyl ester 53 with p-TsOH (Scheme
16).58 The acid 49 was then converted to its acid chloride 86, which was subsequently
treated with tributyltin azide to deliver the acyl azide 87 in good yield. Exposure of 87
to o-xylenes at reflux was expected to have afforded the isocyanate 88, which was not
isolated but trapped as the tert-butyl carbamate derivative 89. Treatment of 89 with
TfOH provided the amine salt 90, which was coupled to various acyl chlorides 91 to
generate the corresponding amide derivatives 92 (Scheme 1.15).59

Scheme 1.15: Synthesis of amides 92 was achieved via the Curtius rearrangement.
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Thermal ring opening of methylenecyclopropanone ketal 93 in chlorobenzene in
the presence of [60]fullerene followed by silica gel hydrolysis of the resulting ketene
acetal gave a mixture of cycloadducts 94 and 95.60 The corresponding fullerenyl amino
ester derivatives 96 and 97 were subsequently prepared from 94 by DCC coupling
(Scheme 1.16).61

Scheme 1.16: Synthesis of fullerenyl amino ester derivatives via [3+2]-cycloaddition reactions.

Protected bis-fulleropyrrolidine amino acids derivatives 101 and 102 have been
synthesised and characterised from two successive [3+2]-cycloaddition reactions of
azomethine ylides to [60]fullerene, prepared in situ from the reactions of N-glycine
derivatives and formaldehyde (Prato reaction). These reactions resulted in two different
fullereopyrrolidine couples having unsymmetrical, orthogonally protected amino and
acid functional groups.62 These peptides could be used as models for fullerene-based
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peptidomimetics with the carbon sphere inserted into the peptide backbone (Scheme
1.17).

Scheme 1.17: Synthesis of mono-fulleropyrrolidines and unsymmetrical bis-fulleropyrrolidines.

The 1,3-dipolar cycloaddition reaction of the N-substituted glycine derivative
103 to [60]fullerene produced the fulleropyrrolidine 104 having a hydroxyl group at the
terminus of the N-substituent (Scheme 1.18). Subsequent esterification of this alcohol
16
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with the C-terminus of the protected amino acids gave 105 and 106. Deprotection of
106 to its TFA salt 107 and then coupling with a hexapeptide followed by final
deprotection with TFA resulted in the fullereno peptide 108, having an oxidised
methionine residue.63

Scheme 1.18: Synthesis of [60]fulleropeptides.

1.5 Synthesis of Fullerenyl Amino Acids That Could Potentially be
Incorporated Within Peptide Chains
The synthesis of highly functionalized benzo-annulated indane-based α-amino
acid (AAA) derivatives was reported via a [4+2]-cycloaddition strategy using the sultine
derivative 109, containing an AAA ester moiety, as a reactive diene component. By
adopting this strategy, a new α,α-dialkylatedindane-based [60]fullerene containing a
rigid AAA unit 110 was realized (Scheme 1.19).64
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Scheme 1.19: Synthesis of α,α-dialkylatedindane-based [60]fullerene containing AAAs.

A Diels-Alder approach has been developed to prepare dicarba analogues of
cystine. Treatment of diene 111 with [60]fullerene in toluene at reflux furnished the
stable cycloadduct 112 in good yield (Scheme 1.20).65

Scheme 1.20: [60]Fullerene-based dicarba analogue of cysteine 112.

Ketone 115 has been used to synthesise [60]fullerene substituted Dphenylalanine derivatives (Scheme 1.21).14 The para-amino substituted phenylalanine
derivatives 113 and 114 readily undergo condensation reactions with 115 forming the
analogous imines 116 and 117, which were converted to their corresponding amines 118
and 119 by borane reduction. The N-Boc-glycine derivative 118 was coupled to ethyl
glycinate under HBTU mediated coupling conditions to provide the peptide 120.
Treatment of the methyl glycinate derivative 119 with BBr3 led to the isolation of the
free glycine analogue 121.
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Scheme 1.21: Synthesis of [60]fullerenyl amino acids 120 and 121.

A rhodium catalyzed reaction of [60]fullerene with the boronic acid derivative
of phenylalanine 122 is shown in Scheme 1.22. This reaction gave the fullerene-tagged
amino acid 123 in 47% yield.66

Scheme 1.22: Synthesis of 1-substituted 1,2-dihydro[60]fullerene derivatives.
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A direct route was developed to produce fullerenyl peptides 125 by prolonged
thermolysis of diazoamides (e.g. 124) in the presence of [60]fullerene (Scheme 1.23).39

Scheme 1.23: Thermal addition of diazoamide to [60]fullerene provides access to fullerenyl amino esters.

[60]Fullerene functionalized amino acids with 4–6 methylene spacers from the
α-carbon to the nitrogen atom of fulleropyrrolidine 126, and their corresponding Nprotected versions 128, have been synthesized from the reactions of N-glycine
derivatives, formaldehyde and [60]fullerene under Prato’s reaction conditions as shown
in Scheme 1.24.67

Scheme 1.24. Synthesis of [60]fullerene functionalized amino acids with 4-6 methylene spacers.

The

[4+2]-cycloaddition

of

the

2-trimethylsilyloxybutadiene

129

to

[60]fullerene provided the ketone 115, after hydrolysis. Subsequent reduction with
DIBAL-H afforded the racemic alcohol 130, a versatile synthon for the generation of
fullerenyl amino acid derivatives (Scheme 1.25). For example, the DCC mediated
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esterification of 130 with alanine and glutamate derivatives provided the protected
fullerenyl amino acids 131.13

Scheme 1.25. Synthesis of [60]fullerenyl amino acids 131.

[60]Fullerene pyrrolidine derivative (137), bearing two carboxylic acid
functional groups has been reported (Scheme 1.26).68 The crucial glycine precursor 135,
was synthesised from commercially available starting materials and reacted with
[60]fullerene and formaldehyde under Prato’s reaction conditions to yield the diester
136. The tert-butyl groups of 136 were deprotected under acidic conditions, which
eﬃciently provided the stable bis-acid derivative 137. This diacid derivative was readily
functionalized under solid phase conditions to yield the derivatives dipeptide 138 and
PEG 139. In addition, the reaction of 136 with TFA and TFAA provide an anhydride
intermediate, which was used to synthesise [60]fullerene derivatives bearing two
different amide moieties 140.
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Scheme 1.26. Synthesis of bis-carboxylic acid group functionalized [60]fullerene derivatives.

The [60]fullerene derivative 141 was deprotected with TFA to give a free amino
functional linker containing [60]fullerene derivative 142. This was then reacted with NFmoc-L-glutamic acid α-tert-butyl ester to yield a [60]fullerene functionalized amino
acid. The tert-butyl ester was deprotected under acidic conditions to give the carboxylic
acid 143, which was subjected to solid-phase peptide synthesis with peptide 144. The
product 145 was cleaved from the resin support and was found to be water soluble.69
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Scheme 1.27. Solid phase synthesis of fullereno peptide 145.

1.6 Applications of [60]fullerene amino acids and peptides
The potential uses of amino acid and peptide derivatives of fullerenes range
from the biological to the material sciences. This section will outline the major areas of
achievement.

1.6.1 Biological Applications
The fullereopeptide 108 (Scheme 1.18) was biologically active against sera from
Mixed Connective Tissue Disease (MCTD) and Systemic Lupus Erythematosus (SLE)
patients (ELISA experiments).
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The peptide 144 (Scheme 1.27) itself was not active against Staphylococcus
aureus (S. aureus) and Escherichia coli (E. coli), whereas the analogous
[60]fullerenopeptide 145 showed antimicrobial activity against S. aureus and E. coli
(Table 1.1 ).69
Table 1.1. Antimicrobial activity of peptides 144 and 145, Reported as MIC (Minimum
Inhibitory Concentrations). Results are the mean of a minimum four independent evaluations run in
duplicate (na = nonactive).

Peptide
144
S. aureus na
E. coli
na

145
8 µM
64 µM

The antioxidant properties of the water soluble amino acid derivatives of the
sodium

salts

of

fullerenylaminobutyric

acid

(C60-γ-ABNa,

146)

and

fullerenylaminocaproic acid (C60-ω-ACNa, 147) as well as that of the hybrid structure
based on a N-fullerenoproline and the natural oxidant carnosine (C60-Pro-carnosine,
148) have been studied. Their roles in the inhibition of herpes virus infection have also
been described.70 The amino acid fullerene derivatives 146 and 147 of [60]fullerene
were found to have significant antioxidant activities and were not cytotoxic (IC 50 1000
and 1200 μg mL–1 (mln. cells), for 149 and 146, respectively). These derivatives were
also studied as inhibitors of cytomegalovirus (CMV) infection. The introduction of C60γ-ABNa 146, into infected human embryonic fibroblasts (HEF) reduced the
concentration of virus proteins in the cells to values approaching that in non-infected
cells (Table 1.2). The malonic dialdehyde (MDA) concentration in the infected HEF
culture also decreased to the concentration in intact HEF. The drug ganciclovir also
decreased the lipid peroxidation (LPO) level in the HEF culture but had significantly
lower antioxidant and inhibitory effects than 146 (Table 1.2). These results indicated
that the antioxidant activity of these fullerene derivatives played an important role in
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their antiviral effect against CMV infection. Compound 146 was considered as a
potential drug against CMV infections. Its chemotherapeutical index (CTI) was found to
be 5000, which fivefold exceeds that of ganciclovir.
Table 1.2. Contents of the protein and MDA in the HEF cultures

Protein content

[MDA].10–5

/mg (mln. cells)–1

/mol.L–1(mln.cells)-1

HEF

0.07±0.02

3.75±0.03

HEF-CMV

0.284±0.03

6.8±0.01

HEF-CMV- gancyclovir

0.22±0.04

5.4±0.03

HEF-CMV-C60-γ-ABNa (146)

0.072±0.02

3.8±0.03

Sample

Note. The concentration of ganciclovir and C60-γ-ABNa 146, in the cell culture was 2.10–5 mol L–1 (mln.
cells)–1. The average values of five measurements were presented. HEF (human embryonic fibroblasts),
CMV (cytomegalovirus infection), MDA (malonicdialdehyde).

Figure 1.1: [60]Fullerene based water soluble amino acids.

The antioxidative/anti-inflammatory activities of the fullerene-polyamine (FULPA) conjugates 149-156 have been described.71 Conjugation of [60]fullerene with
spermine (SPM) or spermidine (SPD) resulted in a large improvement of both the antilypoxygenase (LOX) and the anti-lipid peroxidation activity of the unconjugated
molecules. An enhancement in the anti-inflammatory potency of [60]fullerene was
observed only with the conjugate 150 (42%), which was comparable in activity to the
reference compound indomethacin (47%). Most of the FUL-SPD conjugates, and
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especially compounds 150 and 152, were of comparable toxicity, even at the highest
concentration tested (50 mM), therefore they could be potentially safely used for
possible biomedical applications.71

Figure 1.2: Biologically active novel fullerene-polyamine (FUL-PA) conjugates.

The glycopeptide antibiotic derivative teicoplanin ψ-aglycone has been
covalently attached to a fullerenopyrrolidine derivative using azide-alkyne “click
chemistry”. The aggregation of the resulting antibiotic-fullerene conjugate 157 in
aqueous solution has been studied resulting in nano-sized clusters.72 The conjugate
exhibited antibacterial activity against Enterococci resistant to teicoplanin (Table 1.3).
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Table 1.3. Antibacterial activity of compound 157.

Bacteria

Teicoplanin

Compound 157

MIC (µg/mL)
Bacillus subtilis ATCC 6633

0.5

16

S. aureus MSSA ATCC 29213

0.5

8

S. aureus MRSA ATCC 33591

0.5

4

S. epidermidis ATCC 35984 biofilm

4

2

S. epidermidis mec A

16

1

E. faecalis ATCC 29212

1

6

E. faecalis 15376 VanA

256

16

E. faecalis ATCC 51299 VanB

0.5

16

Note. MIC: Minimum Inhibition Concentration, ATCC: American Typed Culture Collection, MRSA:
Methicillin Resistant Staphylococcus aureus, vanA: vanA gene positive, vanB: vanB gene positive.

Figure 1.3: Teicoplanin ψ-aglycon-fullerene conjugate 157.

The water-soluble dendrofulleropyrrolidine 158 (synthesised from 102) and its
bis-analogues 159 and 160 have been prepared (Figure 1.4).73 These cationic species
can efficiently complex plasmid DNA as demonstrated by gel electrophoresis studies.
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These molecules showed excellent DNA binding efficiencies and were therefore
considered to be potential candidates for DNA binding therapies.
The

fulleropyrrolidine

peptides

162-172

containing

only

GABA

(γ-

aminobutyric) residues, having zero or one glycine moiety were reported (Figure 1.5).74
The authors claim that these may be used as nanobioparticles, however, no results
related to these properties were reported.

Figure 1.4. Monoadduct 158 and bisadducts 159 and 160 of highly water soluble polycationic
[60]fullerenes.
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Figure 1.5. Fulleropeptides 162-172 synthesized from fulleropyrrolidinic acid 161.

Mitsutoshi et al. reported the inhibitory effects of [60]fullerene derivatives 173
and

[60]fullerene-ethylenediamine-N,Nʹ-diacetic

acid

174

(Figure

1.6)

on

acetylcholine-induced (endogenous NO) relaxation in endothelium-intact rabbit thoracic
aorta precontracted by phenylephrine (10-6 M).75 These [60]fullerene derivatives 173
(10-5 M) and 174 (10-5 M) reduced the maximum amplitude of the acetylcholineinduced relaxation without significantly changing the pD2 values obtained from the
concentration response curves.

Figure 1.6. [60]Fullerene derivatives 173 ([60]fullerene-proline-N-acetic acid) and 174 ([60]fullereneethylenediamine-N,Nʹ-diacetic acid).

Water soluble [60]fullerene derivatives 175-177 (WSFD), have been studied to
show the potential to prevent NO-induced cytotoxicity without obvious toxicity (Figure
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1.7).76 These fullerene derivatives apply protective activities by direct interaction with
NO and neutralization of O2-. The folacin fullerene derivative 177 (FFD) self-assembles
to form spherical aggregates because of hydrogen bonding, and the aggregate ion
morphology impacts on the NO-scavenging activities of WSFD. Pretreatment of the
cells with WSFD, prior to sodium nitroprusside (SNP) exposure blocks NO-induced
cellular events including oxidation of membrane lipids, depolarization of mitochondrial
membranes, reduction of superoxide dismutase (SOD), catalase (CAT) and glutathione
peroxidise (GSH-Px) activities and caspase-mediated apoptotic cell death. Apart from
the biological studies, the authors have revealed the synthesis of novel fullerene
derivatives with anti-apoptotic properties.76,77

Figure 1.7. The structures of AFD (175), VFD (176) and FFD (177).

Oxidized [60]fullerene glutathione derivatives have been synthesized and
characterized.78 The [60]fullerene glutathione derivative 178 (Figure 1.8) was soluble in
dimethylsulfoxide, dimethylformamide and dimethylacetamide. Rat pheochromocytoma
(PC12) cells were treated with hydrogen peroxide and then cytotoxicity and apoptotic
death was estimated by a MTT assay, flow cytometry analysis, PI/Hoechst 33342
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staining and glutathione assay. These results indicated that the glutathione [60]fullerene
derivative 178 has the potential to prevent oxidative stress-induced cell death without
toxicity.77

Figure 1.8. Oxidized glutathione [60]fullerene derivative 178

1.6.2 Materials Chemistry Applications
A new class of peptide nanotubes from α,γ-cyclic peptides (CPs) 179 (Figure
1.9) tethered to a methanofullerene moiety has been reported.79 These CPs are able to
form nanotubes in which the fullerenes point outward from the nanotube on both sides
(180° orientation). The fullerenes form two parallel wires separated by the insulating
peptide nanotube. The authors suggest that these materials may have applications as
nanowire components and/or in optical and electronic devices.

Figure 1.9: Structure of tethered α,γ-cyclic peptide (CP) 179.
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Two molecules (180 and 181, Figure 1.10) having a pyrrolidino[60]fullerene
tethered through an intramolecular hydrogen bonding peptide linker to a nitroxide
radical have been synthesised.80 These peptide moieties have a rigid 310-helical
structures that possess a strong molecular dipole. The direction of the molecular dipole
moment can be reversed by switching the position of the fullerene and the nitroxide
with respect to the peptide nitrogen and carbon terminus. The fullerene-peptide-radical
systems 180 and 181 were compared to the behaviours of otherwise identical peptides
but without either [60]fullerene or the free radical moiety with retention of the number
of intramolecular hydrogen bonds.

Figure 1.10: Structures of [60]fullerene based peptides with intramolecular hydrogen bonds showing
their molecular dipoles.

A strategy of photocurrent generation out of thin layers composed by the
amphiphilic [60]fullerene and pyrene derivatives was investigated by Shunsaku’s
group.81,82 Three different types of compounds, namely pyrene derivative 182 (R-Pyr)
having diethylene glycol and a long alkyl chain, [60]fullerene-PEG conjugate 183 (C60PEG) without cyclic peptide scaffold and [60]fullerene-cyclic peptide-PEG conjugate
184 (cyclo8-C60-PEG), were synthesised (Figure 1.11). The study of photoinduced
electron transfer concluded that a bilayer structure with desired orientation of functional
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units is important for efficient photoinduced electron transfer and that the cyclic peptide
scaffold is useful to locate hydrophobic functional groups in a thin layer.

Figure 1.11. The structures of R-Pyr 182, C60-PEG 183 and cyclo8-C60-PEG 184.

1.7 Background of this Project
There is much current research interest in the synthesis and design of chemical systems
for use in organic solar cells such as in organic photovoltaic applications as bulk
heterojunction solar cells.83-85 Solladie et al. have been successful in synthesising such
potential systems based on polypeptide-porphyrin structures (Scheme 1.28).86-88
Porphyrins with their highly conjugated structures and light adsorption features are well
suited materials to act as electron donors.86 Additionally, the design of suitable electron
acceptor systems has focussed on the use of fullerenes which can reversibly accept up to
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six electrons (Figure 1.12).89 It has been shown that by interchelation of fullerenes to
two porphyrin moieties in polypeptide-porphyrin structures, self-organized helical
systems suitable for use in organic solar cells readily form.86,87 A schematic structure of
one potential amino acid/fullerene-porphyrin composite system is shown in Figure 1.12.

hn

n
Figure 1.12. Supramolecular complex of 194 with [60]fullerene of 310 helix of porphyrin oligomer86
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The synthesis of the polypeptide-porphyrin structure 194 was realised from the starting
material 185 (Scheme 1.28).86-88 A selective deprotection of allyl ester to the acid 186
was performed under Pd(PPh3)4/dimethylacetamide/piperidine reaction conditions to
give the acid 186 in 84% yield. The Boc group removal to the amine 187 was
successfully performed using TMSCl and phenol in 1 M CH2Cl2 solution to give amine
187 in 91% yield. An amide coupling reaction of acid 186 and amine 187 under DCC
and HOBt conditions gave the dipeptide 188 in 88% yield (Scheme 1.28). By repeating
the reaction conditions mentioned above for the synthesis of acid 186, amine 187 and
dipeptide 188, the polypeptide-porphyrin structure 194 (Scheme 1.28) was achieved
which was used to construct a supramolecular complex with [60]fullerene (Figure
1.12).86-88
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1.8 Aims of this Project
While the Solladie group are developing helical porphyrin oligomers to intercalate
fullerene (Figure 1.12), we plan to build fullerenes into the peptide oligomer structure
which may allow for the insertion of porphyrins as shown in Figure 1.13. We planned to
prepare octapeptide88 and hexadecapeptide derivatives from L-lysine which are
functionalized with fullerenes at their lysine amino termini. Beyond a certain degree of
oligomerisation the development of a secondary structure, such as a 310 helix, may be
observed (Figure 1.13). This would force the fullerenes to arrange in a defined spatial
arrangement as shown in Figure 1.13. These fullerenyl peptides can be studied for the
accommodation of guests like porphyrin rings in between two helices. Preparation of
supramolecular complexes using these fullerene-peptide oligomers as hosts and
porphyrins as guest molecules could be expected to be potentially useful as organic
photovoltaic cells (as shown in Figure 1.13).
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Figure 1.13. Potential structure of a amino acid/porphyrinic-peptide system for use in organic solar cells.

An additional object of this project was to investigate the [60]fullerene moiety as a
hydrophobic anchor in the synthesis of dicationic peptoids as potential anti-biotic
agents. A more comprehensive background to this part of the project is presented at the
beginning of Chapter 4.

Therefore, the specific aims of this thesis were:

 The design, synthesis, isolation and characterization of [60]fullerene based
oligomers (ex. tetrapeptide, octapeptide, dodecapeptide and hexadecapeptide).

 Supramolecular complexation with suitable electron acceptor-donor substrates,
including; porphyrins for potential solar cell applications.
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 The design, synthesis, isolation and characterisation of [60]fullerene based peptides.
 The synthesis of water soluble dicationic [60]fullerene peptide salts for antibacterial studies.
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CHAPTER 2
The Synthesis of [60]Fullerenyl Amino Acids Oligomers

2.1 Applications as Solar Cells in Material Science
The major aim to this project was to build fullerenyl-peptides which may allow the
intercalation of porphyrins as shown in Figure 1.13 see page 39. Specifically, we
planned to prepare octapeptide and hexadecapeptide derivatives from L-lysine which
are functionalized with fullerenes at the lysine side chain amino termini. Beyond a
certain degree of oligomerisation the development of a secondary structure, such as a
310 helix, may be observed (Figure 1.13). This would force the fullerenes to arrange in a
defined spatial arrangement as shown in Figure 1.13. These fullerenyl-peptides can be
studied for the accommodation of guests, including porphyrins, in between two helices.
Preparation of supramolecular complexes using these fullerene-peptide oligomers as
hosts and porphyrins as guest molecules could be expected to be potentially useful as
organic photovoltaic cells as discussed in the previous Chapter (as shown in Figure
1.13).
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2.2 Strategy 1: Synthesis of [60]fullerenolysine monopeptide 201,
dipeptide 204, tetrapeptide 207 and octapeptide 195 by sequential
coupling

2.2.0 Proposed synthetic strategy for the initial [60]fullerenolysine
octapeptide 195.
The retro-synthesis of the [60]fullerenolysine octapeptide 195, starting from the
previously reported 5,5-diphenylfullerenedihydropyrrole-2-carboxylic acid33 198, is
outlined in Scheme 2.1. A key step was the coupling of the fullerenyl acid 198 to the
diprotected L-lysine 200 to give the crucial monopeptide 201. The coupling partner
amine 200 could be readily prepared from the known triprotected L-lysine 199 (Scheme
2.1). The monopeptide 201, could then be deprotected to its amine derivative 202 and
acid derivative 203 and these could then be coupled under standard peptide coupling
reaction conditions to yield the dipeptide 204. By repeating the deprotection and
coupling reaction protocol the targeted octapeptide 195 could then be realised (Scheme
2.1).
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Scheme 2.1 Retrosynthetic analysis for the synthesis of [60]fullerenolysine octapeptide 195 from the tetrapeptide 207.
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Scheme 2.1 continued: Retrosynthetic analysis for the synthesis of [60]fullerenolysine tetrapeptide 207 from the known diprotected lysine 200, and known
[60]fullerenoproline acid 198.
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2.2.1 Addition of tert-butyl 2-((diphenylmethylene)amino)acetate to
[60]fullerene under Bingel conditions followed by acidolytic
cleavage of the tert-butyl group
Slightly modified literature synthetic procedures were adopted to synthesize the
[60]fullerene adducts 197 and 198.33,90

To a solution of [60]fullerene, carbon

tetrabromide and the imine 196 in toluene was added DBU dropwise. The reaction
mixture was stirred at rt for 6 h before the crude material was subjected to flash silica
gel chromatography. Elution with CH2Cl2/hexanes (1:1) led to the isolation of
compound 197 in 60% yield, which was carried forward for the acidolytic cleavage of
the tert-butyl group with TFA and CH2Cl2 (1:4 v/v) to form the acid 198 in 90% yield
(Scheme 2.1). The spectroscopic data of 198 were in agreement with that previously
reported.90 Examination of the 1H NMR spectrum of 198 revealed the loss of the tertbutyl resonance at δ 1.60 (s, 9H) when compared to that of 197, along with the
appearance of a broad singlet, with a relative integration of 1H, at δ 8.63 attributed to
the carboxylic acid proton. Analysis of the mass spectrum of 198 showed a base peak at
m/z 958 assigned to the protonated molecular ion (M+H)+.

Scheme 2.2: Synthesis of the fullerenyl amino acid 198.
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2.2.2 Base-promoted N-Fmoc removal for the triprotected L-lysine 199,
followed by amide coupling to give the monopeptide 201
The Fmoc protecting group is widely utilized in the synthesis of peptides

91, 92

as it can

be cleaved from the desired amine by the use of a simple base – most commonly
piperidine.93 Therefore, in a typical procedure94 a solution of triprotected L-lysine 199
in piperidine/acetonitrile (1:9 v/v) was stirred overnight at rt to produce the free amine
200, in 100% crude yield, which was carried forward to the successive reactions without
additional purification (Scheme 2.3).
The molecular structure of this salt was verified by the appearance of an ion at m/z 287
in the ESIMS, which was assigned to the protonated molecular ion ([M+H]+,
C14H27N2O4).

Scheme 2.3: Reagents and conditions: (a) (a) piperidine, CH3CN, rt, 4 h; (b) EDCI, HOBt, Et3N,
CH2Cl2, rt, 4 h, 62%.

The increased lability of the Fmoc group is attributable to its aromatic fluorenyl
structure and the presence of the sp3 methine carbon bridging the two benzene rings. As
a result, this methine proton is susceptible to deprotonation by moderate bases (pKa
~25) and this produces a delocalized 14-electron aromatic carbanion (Scheme 2.4).95
The aromatic carbanion then rapidly decomposes to generate dibenzofulvene (DBF),
CO2, and the desired free amine. The pKa of piperidine is much lower (pKa ~11)35 than
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that of the Fmoc methine proton and only a minute percentage of the molecules will
ever be deprotonated at any one time. However, any aromatic carbanion that forms will
immediately undergo an irreversible decomposition, the released CO2 gas escapes the
reaction mixture and this continually pushes the reaction to the side of deprotection.

Scheme 2.4: Mechanism of base-promoted Fmoc deprotection by piperidine with the dibenzofulvene
scavenging pathway (red) shown.

While high yielding, the piperidine-promoted reaction also produces copious quantities
of an insoluble, white by-product, i.e. the dibenzofulvene (DBF)-piperidine adduct. This
side reaction (Scheme 2.4 – red pathway) results from interaction of the piperidine base
with DBF and it is known to occur with most amine bases.92,93 The excess piperidine
thus functions as a scavenger as well as preventing the desired product amine from
reacting with the dibenzofulvene.92,93 The DBF-piperidine adduct is soluble in DMF and
hence, solid-phase peptide synthesis allows the adduct to be washed away via
filtration.93 Since solution-phase synthesis was employed in this study, DMF was
avoided as a reaction solvent due to its relatively high boiling point. The DBFpiperidine adduct was found to be partially soluble in acetonitrile and therefore could
not be removed by simple filtration. Thus, chromatography was necessary to isolate the
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pure amine 200, which was the most polar compound in the reaction product mixture.
This problem could have been avoided by employing an amine base that produces an
adduct with DBF that is soluble in aqueous phosphate buffer, such as 4(aminomethyl)piperidine or tris(2-aminoethyl)amine.93 Therefore, an aqueous extractive
work-up could be utilized in the future and chromatography possibly avoided.
Amide coupling
The formation of amide bonds from carboxylic acids and amines (e.g. amino acids) was
a key reaction in the synthesis of the target [60]fullerenolysine derivatives. The
transformation was employed for coupling of C-terminal amino acid onto the Nterminal amino acid for the synthesis of dipeptide scaffold. Previous syntheses of
peptides

have

utilized

dimethylaminopropyl)carbodiimide

the

common

hydrochloride),

EDCI
HOBt

(1-ethyl-3-(3(1-hydroxy-1H-

benzotriazole) peptide coupling reagent system in dichloromethane/chloroform to form
the necessary peptide bonds.94,96,97 Therefore, a general procedure was developed and
utilized in all subsequent amide coupling reactions (see Scheme 2.3). For example, the
synthesis of the crucial monopeptide 201 (Scheme 2.3) was realized in 62% yield by
stirring in dichloromethane, a solution of previously synthesised amine 200 and the 5,5diphenylfullerenedihydropyrrole-2-carboxylic acid33 198 with the coupling reagents
EDCI and HOBt at rt for 4 h. Purification of the crude reaction product by flash column
chromatography followed by simple trituration from diethyl ether yielded the desired
monopeptide 201 in 62% yield (Scheme 2.3).

The broad singlet at δ 8.55 (-COOH) in the 1H NMR spectrum of acid 198 (see
Appendix) was no longer observed in the spectrum of 201 but two signals appeared at δ
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3.52-3.58 (m, 2H, CH2N (Lys)) and δ 7.88 (bs, 1H, NH), assigned to the methylene and
a newly formed amidic proton of monopeptide 201. This evidence indicated that the
methylene protons, adjacent to the primary amine in precursor 200, experienced a
downfield shift as a result of the newly installed amide bond. Additionally, the

13

C

NMR spectrum showed resonance at δ 162.1, assigned to the new amide carbonyl
group. The molecular structure of the product 201 was verified by the appearance of a
peak at m/z 1248.2494 in the HRMS, that was assigned to the sodiated molecular
formula ([M + Na]+ C89H35N3O5Na).

The synthesis of the amide bond in 201, and the large number of amide bonds (i.e.
iterative amide coupling) in later compounds in this study, were made feasible due to
the reliable and mild conditions afforded by the amide coupling reagents EDCI and
HOBt. The uncatalysed reaction between the carboxylic acid and amine components
generates an ammonium carboxylate salt; their subsequent amide condensation would
require intense heat, which would be incompatible with such multi-functionalized
molecules.98 Therefore, peptide coupling reagents (or ‘activators’) are utilized to
increase the electrophilicity of the acyl moiety, which allows amide bond formation via
aminolysis of an activated acyl species under much milder conditions.98-100
Carbodiimides (e.g. EDCI) are employed to generate an active O-acylisourea
intermediate (Scheme 2.5) by reaction with the carboxylate anion. This intermediate can
undergo aminolysis by the precursor amine to give the desired product amide.98 In a
possible side reaction, the highly activated O-acylisourea intermediate can undergo
intramolecular acyl transfer to give an inactive N-acylurea by-product (Scheme 2.5 –
red pathway),98,100 thus consuming the precursor acid without formation of the desired
amide product.
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Scheme 2.5 Mechanism of EDCI/HOBt promoted amide coupling: both the product pathway (blue) and
the undesired side reaction (red) are displayed.

To avoid this deleterious side reaction and the possibility of racemization, nucleophilic
additive (e.g. HOBt) was added to the reaction.98-100 HOBt reacts with the active Oacylisourea intermediate to generate an activated HOBt ester with the key acyl moiety
(Scheme 2.5 – blue pathway). Crucially, this reaction occurs faster than the
intramolecular acyl transfer, thus preventing the side reaction but still generating an
activated acid derivative for subsequent aminolysis to the product amide.98
Epimerization of the stereogenic α-carbon on the O-acylisourea intermediate is another
50

Synthesis of [60]Fullerenyl Amino Acids Oligomers

Chapter 2

possible side reaction and it can occur through two mechanisms – simple enolate
formation by deprotonation of the α-hydrogen and then re-protonation (resulting in loss
of chirality) or via formation of the planar 5(4H)-oxazolone intermediate, in which the
α-hydrogen is readily deprotonated due the resonance stabilization of the resulting
carbanion. HOBt helps to prevent racemization as the intermediate HOBt ester that is
preferentially formed is less activated than the O-acylisourea, i.e. the -OBt functionality
is less electron-withdrawing than the corresponding isourea substituent and therefore
the adjacent α-hydrogen is less prone to enolization.100 Furthermore, the use of the
Fmoc group (and other carbamates) for protection of the α-nitrogen during coupling is
known to reduce the prevalence of 5(4H)-oxazolone mediated racemization by induced
destabilization of the resultant oxazolone carbanion. The lack of epimerization observed
during the performed amide coupling reactions in this study was a result of these
combined factors (e.g. HOBt and carbamate protection). Such an epimerization process
would result in the formation of diastereomeric products that could be detected by 1H
NMR and/or TLC analysis. Based on such analyses, the isolated amide products were
obtained as single diastereomers. Based on these findings and the analysis that dipeptide
204 has a single diastereomer we conclude that product 201 is a single enantiomer.

2.2.3 N-Boc and tert-butyl ester removal via acidolysis, allyl ester
hydrolysis by using (CH3)3SnOH
The acidolytic cleavage of the Boc and tert-butyl ester protecting groups in this study
could be easily achieved with a variety of acids. However, trifluoroacetic acid (TFA)
was used most often in this study.91,101 The ability of these groups to be cleaved
separately or simultaneously under relatively mild acidic conditions was an essential
feature of this general reaction. As such, a previously published general procedure97 was
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employed, with modifications, for the deprotection N-Boc alone and/or tert-butyl ester
group at rt for 4 h. The N-Boc derivative 201 was dissolved in a mixture of TFA and
CH2Cl2 (1:1 v/v) and stirred at rt for 4 h which gave a 90% yield of the TFA salt of the
target amine 202 (Scheme 2.6).

Scheme 2.6: Reagents and conditions: (a) TFA: CH2Cl2 (1:1), rt, 4 h, 90%. (b) 1,2-DCE, (CH3)3SnOH,
80 0C, 6 h, 88%.

The 1H NMR spectrum of compound 202 (see Appendix) was lacking the prominent 9H
resonance at δ 1.44 that was present in the spectrum of carbamate 201 and was assigned
to the tert-butyl methyl protons. ESIMS analysis of compound 202 showed a peak at
m/z 1126 which was assigned to the protonated molecular ion ([M + H]+, C84H28N3O3).

In this chapter the Boc and tert-butyl ester protecting groups were cleaved using TFA.
The cleavage mechanism is similar for both substituents (Schemes 2.7) and proceeds via
protonation followed by heterolytic cleavage and release of a relatively stable tert-butyl
carbocation. The tertiary nature of the tert-butyl cation stabilizes the positive charge by
donating electron density onto the tertiary carbon (Scheme 2.7). Release of the cationic
species from the N-protected substrate results in a carbamic acid (Schemes 2.7), which
decomposed by the loss of CO2 and gave the product amine as the TFA salt.
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The simple acidolytic conditions required for removal of the N-Boc protecting group
allowed for the isolation of the crude TFA salts by simple solvent removal. Due to the
volatility of the Boc deprotection by-products, no resultant impurities were observed.
Overall, it was the relative ease, speed, and resultant product purity of the acidolytic
deprotection method that allowed for the efficient turn-over of TFA salt of the
corresponding amine or free amine.

Scheme 2.7. Mechanism of tert-butylcarbamate acidolysis by TFA to give the desired amine (blue) and
by-products (red)

Allyl ester cleavage
(CH3)3SnOH had been previously used by Mascaretti and co-workers102-105 to cleave
phenacyl ester anchored amino acids and peptides from a polystyrene resin and to
hydrolyze methyl phenylacetate (Figure 2.1). By utilizing this reagent, K. C. Nicolaou
and co-workers developed a method to hydrolyse esters on highly epimerization
sensitive systems106 (Figure 2.2). This method remarkably resulted in quantitative
conversion of a dipeptide allyl ester to the corresponding acid with negligible erosion of
the stereochemical integrity (Figure 2.2).
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Figure 2.1. Literature precedent for (CH3)3SnOH cleavage of esters.

Figure 2.2. Mild and selective cleavage of an ester with (CH3)3SnOH.

A probable mechanistic interpretation can be seen in Figure 2.3. The hydroxide moiety
of the reagent engages the generic ester to create a polar tetracoordinated transition
state. This results in the formation of a tin ester intermediate (confirmed by 1H, 13C, and
119

Sn NMR spectroscopy)104 which is easily hydrolysed upon aqueous workup to the

desired acid. Additionally, the Sn atom most likely facilitates the reaction by
participating as a weak Lewis acid and coordinating to the carbonyl oxygen of the ester
starting material.

Figure 2.3. A proposed mechanism of (CH3)3SnOH mediated hydrolysis of esters.

The [60]fullerenolysine monopeptide 201 was treated with (CH3)3SnOH under the
above mentioned reaction conditions to selectively hydrolyse the allyl ester to give the
acid 203 in 88% yield (Scheme 2.6).
The 1H NMR spectrum of compound 203 (see Appendix) was lacking the prominent
allyl ester resonances at δ 4.58 (m, 2H), 5.28 (d, J = 10.0 Hz, 1H), 5.30 (d, J = 17.0 Hz,
1H) and 5.84 (m, 1H), that were present in the spectrum of ester 201. HRMS analysis of
compound 203 contained a peak at m/z 1208.2145 that was assigned to the sodiated
molecular ion ([M + Na]+, C86H31N3O5Na). This compound was not sufficiently soluble
to generate an adequate 13C NMR spectrum.
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2.2.4 Amide coupling to synthesize dipeptide 204, followed by
deprotection reactions to obtain 205 and 206
The synthesis of the dipeptide 204 (Scheme 2.8) was realized in 57% yield by stirring in
dichloromethane, a solution of previously synthesised monopeptide amine 202 and the
monopeptide acid 203 under the coupling conditions described in Section 2.2.2.
Purification of the crude reaction product by flash column chromatography followed by
simple trituration from diethyl ether yielded the desired dipeptide 204 in 57% yield
(Scheme 2.8). Subsequent deprotection of dipeptide 204 yielded the dipeptide amine
205 (in 90%), and the dipeptide acid 206 (in 86%), using the reaction conditions
adopted from Section 2.2.3.

Scheme 2.8: Synthesis of a dipeptide 204, dipeptide amine 205 and dipeptide acid 206. Reagents and
conditions: (a) EDCI, HOBt, Et3N, CH2Cl2, rt, 4 h, 57%; (b) TFA: CH2Cl2 (1:1), rt, 4 h, 90%. (c) 1,2DCE, (CH3)3SnOH, 80 0C, 6 h, 86%.

The 1H NMR spectrum of dipeptide 204 (see Appendix) showed the prominent allyl
ester resonances [at δ 4.58 (m, 2H), 5.28 (d, J = 10.0 Hz, 1H), 5.30 (d, J = 17.0 Hz, 1H)
and 5.84 (m, 1H)], that were present in the spectrum of amine 202 and the Boc methyl
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resonances (δ 1.45, s, 9H), that was present in the spectrum of acid 203. Additionally,
an amidic proton was also present at δ 6.68 (bs, 1H, NH), due to the newly formed
amide bond. Furthermore, the 13C NMR spectrum showed a resonance at δ 162.7, which
was assigned to the newly formed amide carbonyl group. The molecular structure of the
product 204 was verified by the appearance of the peak at m/z 2315.4114 in the HRMS,
that was assigned to the sodiated molecular ion ([M+Na]+ C170H56N6O7Na).
The dipeptide amine 205 showed the disappearance of a prominent Boc group
resonance at δ 1.45 (s, 9H), that was present in the 1H NMR spectrum of dipeptide 204.
The molecular structure of the product 205 was verified by the appearance of the peak
m/z 2193.3764 in the HRMS, that was assigned to the protonated molecular ion
([M+H]+ C165H48N6O5).
The deallylation of dipeptide 204 to its acid 206 was supported by the loss of
resonances [at δ 4.58 (m, 2H), 5.28 (d, J = 10.0 Hz, 1H), 5.30 (d, J = 17.0 Hz, 1H) and
5.84 (m, 1H)], in the 1H NMR spectrum, that were present in the dipeptide 204, which
were assigned to the allyl protons. The molecular structure of the product 206 was
verified by the appearance of the peak at m/z 2276 in the ESIMS, that was assigned to
the sodiated molecular ion ([M+Na]+ C167H51N6O7Na).

2.2.5 Coupling of amine 205 and acid 206 to the tetrapeptide 207
The general synthetic procedure was employed to synthesise tetrapeptide 207, was as
described in section 2.2.2. The synthesis of the tetrapeptide 207 (Scheme 2.9) was
realized by stirring in chloroform, a solution of previously synthesised dipeptide amine
205 and the dipeptide acid 206 under the coupling conditions mentioned in Section
2.2.2. TLC analysis of tetrapeptide 207 showed the presence of dipeptide acid 206 along
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with a new spot (Rf = 0.6), which was assumed to be the tetrapeptide 207. Further base
(sat. NaHCO3) treatment did not completely remove the acid 206 from the crude
mixture. Purification of the crude product by flash column chromatography followed by
simple trituration from diethyl ether did not yield the desired tetrapeptide 207, in
satisfactory purity. Further purification by preparative thin layer chromatography
(PTLC) followed by trituration from dichloromethane/diethyl ether (1:1) resulted in
51% yield of tetrapeptide 207 (Scheme 2.9), which we believe to have a small amount
of acid 206 impurity remaining in it. In a subsequent reaction, a change of solvent from
chloroform to chloroform/pyridine (1:1) for the coupling reaction of compounds 205
and 206 yielded tetrapeptide 207 in 50% crude yield. Unfortunately subsequent base
(sat. NaHCO3) wash, flash column chromatography and PTLC could not remove all the
acid 206 impurity from the tetrapeptide 207.

Scheme 2.9: Synthesis of the tetrapeptide 207. Reagents and conditions: (a) EDCI, HOBt, Et3N, CHCl3,
rt, 4 h, ~51%; or EDCI, HOBt, Et3N, CHCl3/Pyridine (1:1), rt, 4 h, ~50%.

The 1H NMR spectrum of tetrapeptide 207 showed the prominent allyl ester resonances
[at δ 4.56 (m, 2H), 5.25 (d, J = 9.0 Hz, 1H), 5.27 (d, J = 17.0 Hz, 1H) and 5.82 (m,
1H)], that were present in the spectrum of amine 205 and the Boc methyl resonances (δ
1.44, s, 9H), that was present in the spectrum of acid 206. Additionally, an amidic
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proton was also appeared at 7.80 (bs, 1H, NH), due to the newly formed amide bond.
Unfortunately, the products from both coupling procedures were not sufficiently soluble
in most of the organic solvents to generate an adequate 13C NMR spectrum and were not
sufficiently soluble in MeOH to generate an adequate ESI-MS. Thus we could not
verify if this reaction was successful.

2.2.6 Optimization of coupling reaction to synthesise tetrapeptide 207
To optimize the coupling reaction of dipeptide amine 205 and dipeptide acid 206 to
provide the tetrapeptide 207 in purer form and perhaps better solubility, several
different reaction conditions were tried. These included changes to the coupling reagent,
solvent, base and the reaction temperatures. Unfortunately, none of these attempts could
evolve as suitable conditions to synthesise tetrapeptide 207 in purer form, instead an
inseparable mixture was the end result (Table 2.1).
Table 2.1 Attempted optimisation reaction conditions:
Entry

Solvent

Coupling

Base

Reaction

Resultb

conditionsa

reagent
1

CH2Cl2

DCC, HOBt

Et3N

rt

mixture

2

CH2Cl2

EDCI, HOBt

Et3N

rt

mixture

3

CH2Cl2

HBTU

Et3N /DIPEA

rt-40 0C

mixture

4

CHCl3

DCC, HOBt

Et3N /DIPEA

rt

mixture

5

1,2-DCE

DCC, HOBt

Et3N

rt-80 0C

mixture

6

1,2-DCE

EDCI, HOBt

Et3N /DIPEA

rt-80 0C

mixture

7

1,2-DCE

HBTU

Et3N /DIPEA

rt-80 0C

mixture

8

1,2-DCE

HATU

Et3N /DIPEA

rt-80 0C

mixture

9

1,2-DCB

EDCI, HOBt

Et3N /DIPEA

rt-80 0C

mixture

10

1,2-DCB

HBTU

Et3N /DIPEA

rt-80 0C

mixture

11

1,2-DCB

HATU

Et3N /DIPEA

rt-80 0C

mixture
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(a). All the reactions were tried on 15 mg scale and verified by the TLC analysis. (b). Possible
compounds in the mixture are tetrapeptide 207 along with dipeptide acid 206.

2.2.7 Strategy 2: Synthesis of tetrapeptide 207, by synthesising a lysine
tetramine 217 first and then coupling with acid 198.
In an alternative strategy, the synthesis of the tetrapeptide 207 was proposed from the
previously unknown lysine tetrapeptide tetramine 217 and the previously known
[60]fullerenoproline acid 198. Compound 207 was proposed in seven synthetic steps
(Scheme 2.10) starting from the known lysine acid 210 and amine 211. This strategy
was adopted due to the relative ease of handling peptides in terms of solubility,
purification and the size of the molecule. The previous attempts (Sections 2.2.5 and
2.2.6) were unsuccessful in providing pure samples of 207, perhaps because of steric
hinderance due to the steric bulk of the incoming dipeptides 205 and 206. This strategy
could possibly overcome these adverse steric effects, with the reaction between the
relatively smaller peptide 217 and [60]fullerenoproline acid 198.

59

Synthesis of [60]Fullerenyl Amino Acids Oligomers

Chapter 2

Scheme 2.10 Retrosynthetic analysis for the synthesis of [60]fullerenolysine tetrapeptide 207 from the
unknown lysine tetrapeptide tetramine 217 and a known acid 198.

2.2.8 Synthesis of lysine dipeptide 212 and its amine 213
The synthesis of the lysine dipeptide 212 (Scheme 2.11) was realized in 85% yield by
stirring a solution of commercially available acid 210 and the amine 211 in
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dichloromethane under the coupling conditions mentioned in section 2.2.2. Purification
of the crude reaction product by flash column chromatography followed by simple
trituration from diethyl ether yielded the desired dipeptide 212 in 85% yield (Scheme
2.11). Subsequent Boc deprotection of dipeptide 212 with TFA realised the amine salt
213 in 90%, by the conditions adopted from Section 2.2.3.

Scheme 2.11: Reagents and conditions: (a) EDCI, HOBt, Et3N, CH2Cl2, rt, 4 h, 85%; (b) TFA: CH2Cl2
(1:1), rt, 4 h, 90%.

The broad singlet at δ 8.55 (CHNH3+) in the 1H NMR spectrum of 211 was no longer
observed in the spectrum of 212 but two signals appeared at δ 4.12 (m, 1H) and δ 4.18
(m, 1H), assigned to the two different lysine α-methine protons in 212. This evidence
indicated that the α-proton, adjacent to the primary amine in precursor 211, experienced
a downfield shift as a result of the newly installed amide bond. Additionally, the
molecular structure of the product 212 was verified by the appearance of the peak at m/z
881.7 in ESI-MS, that was assigned to the sodiated molecular ion, [M + Na] +. The 1H
NMR spectrum of compound 213 was lacking the prominent 9H resonance at δ 1.42
that was present in the spectrum of carbamate 212 and was assigned to the tert-butyl
methyl protons. ESIMS analysis of compound 213 indicated peak at m/z 759 that was
assigned to the protonated molecular ion ([M + H]+, C45H50N4O7).
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2.2.9 Synthesis of lysine tripeptide 214 and its amine 215
The synthesis of the lysine tripeptide 214 (Scheme 2.12) was realized in 83% yield by
stirring in dichloromethane, a solution of previously synthesised dipeptide amine 213
and the monopeptide acid 210 under the coupling conditions mentioned in section 2.2.2.
Purification of the crude reaction product by flash column chromatography followed by
simple trituration from diethyl ether yielded the desired dipeptide 214 in 83% yield
(Scheme 2.12). Subsequent Boc deprotection of tripeptide 214 in TFA realised the
amine salt 215 in 98%, by the conditions adopted from Section 2.2.3.

Scheme 2.12: Synthesis of the lysine tripeptide 214 and amine 215. Reagents and conditions: (a) EDCI,
HOBt, Et3N, CH2Cl2, rt, 4 h, 83%; (b) TFA: CH2Cl2 (1:1), rt, 4 h, 98%.

Analysis of the 1H NMR spectrum of 214 showed a loss of the resonance attributable to
the carboxylic acid proton in 210 and the presence of resonances for the characteristic
protons of both the carboxylic acid 210 and amine 213. A multiplet at δ 3.43-3.44
(-CHNH2) in the 1H NMR spectrum of 213 was no longer observed in the spectrum of
214 but a multiplet at δ 4.14-4.15 with an integration of 6H was assigned to the three
lysine α-methine protons and three Fmoc methine protons. This evidence indicated that
the α-proton, adjacent to the primary amine in precursor 213, experienced a downfield
shift as a result of the newly installed amide bond. This sample turned into a gum over a
period of time, so without measuring the

13

C NMR spectrum, the material was carried

forward to the subsequent reaction. Additionally, the molecular structure of the product
was verified by the appearance of the peak at m/z 1231 in the ESI MS, that was assigned
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to the sodiated molecular ion ([M + Na]+ C71H80N6O12Na). Compound 215 was
characterised by the appearance of the peak at m/z 1109 in the ESI MS, that was
assigned to the protonated molecular ion ([M + H]+ C66H73N6O10).

2.2.10 Synthesis of lysine tetrapeptide 216 and its tetramine 217
The synthesis of the lysine tetrapeptide 216 (Scheme 2.13) was achieved in 70% yield
by stirring in dichloromethane, a solution of lysine tripeptide amine 215

and the

monopeptide acid 210 under the coupling conditions described in section 2.2.2.
Purification of the crude reaction product by flash column chromatography followed by
simple trituration from diethyl ether yielded the desired tetrapeptide 216 (Scheme 2.13).
To remove the Fmoc groups in 216 a solution of tetrapeptide 216 in
piperidine/acetonitrile (1:9 v/v) was stirred overnight at rt to produce the lysine
tetramine 217, which was carried forward to the next reaction.

Scheme 2.13: Synthesis of the lysine tetrapeptide 216 and tetramine 217. Reagents and conditions: (a)
EDCI, HOBt, Et3N, CH2Cl2, rt, 4 h, 70%; (b) piperidine, CH3CN, rt, 4 h, 100%.

The 1H NMR spectrum of tetrapeptide 216 showed the prominent allyl ester resonances
[at δ 4.46 (bs, 2H), 5.11 (d, J = 10.5 Hz, 1H), 5.21 (d, J = 17.5 Hz, 1H) and 5.78 (m,
1H)], that were present in the spectrum of amine 215 and Boc methyl resonances (δ
1.29, s, 9H), that were present in the spectrum of acid 210. Additionally, an amidic
proton was also appeared at δ 8.18 (bs, 1H, NH), this was due to the newly formed
amide bond. Additionally, the 13C NMR spectrum of 216 showed resonances at δ 155.5,
assigned to the Boc carbonyl and δ 172.3 that was assigned to the ester carbonyl. This
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indicated the presence of carbonyl signals from both the reactants. The molecular
structure of the product 216 was verified by the appearance of the peak at m/z
1581.7362 in the HRMS, that was assigned to the sodiated molecular ion ([M+Na]+
C92H102N8O15Na). Compound 217 was characterised by the appearance of the peak at
m/z 671 in the ESI MS, that was assigned to the protonated molecular ion ([M+H]+
C32H62N8O7).

2.2.11 Coupling of lysine tetrapeptide tetramine 217 and acid 198 to
synthesise tetrapeptide 207
The general synthetic procedure was employed to synthesise tetrapeptide 207 using two
different combinations of solvents (chloroform and 1:1 mixture of chloroform/pyridine)
for better solubility. The attempted synthesis of the tetrapeptide 207 (Scheme 2.14)
produced a mixture of products in both the cases; three significant compounds (10 mg,
14 mg and 56 mg) were separated by column chromatography and the ESIMS showed
molecular ions at m/z 1167, 1387 and 1417, respectively. Unfortunately, none of these
MS data matched with the possible fullerene substituted peptides, including the monofullerene, di-fullerene, tri-fullerene or the desired tetra-fullerene coupled tetrapeptide
207. This could possibly be due to steric hindrance between the incoming
[60]fullerenoproline acid 198 units. Therefore, a less sterically hindered cyclic peptide
was considered.

64

Synthesis of [60]Fullerenyl Amino Acids Oligomers

Chapter 2

Scheme 2.14: Attempted synthesis of the tetrapeptide 207. Reagents and conditions: (a) EDCI, HOBt,
Et3N, CHCl3, rt, 8 h, mixture of products; or EDCI, HOBt, Et3N, CHCl3/Pyridine (1:1), rt, 8 h, mixture of
products.

2.2.12 Strategy 3: Synthesis of [60]fullerenolysine cyclic tetrapeptide
222, by synthesising a lysine cyclic tetrapeptide amine 221 first
and then coupling with acid 198.
The synthesis of the cyclic tetrapeptide 222 was proposed from the unknown cyclic
tetrapeptide tetramine 221 and the [60]fullerenoproline acid 198. Compound 221 was
proposed in four synthetic steps (Scheme 2.15) starting from previously synthesised
lysine tetrapeptide 216. This strategy was adopted to reduce the steric hindrance
between the incoming fullerenyl units on to the cyclic peptide. The unsuccessful results
described in Sections 2.2.5, 2.2.6 and 2.2.11 were thought to arise from the steric bulk
of the dipeptides 205 and 206, and therefore the less hindered cyclic peptide 221 might
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have a higher reactivity towards acid 198 due to less steric hindrance as shown for the
proposed synthesis of the fullerenyl peptide 222 in Scheme 2.15.

Scheme 2.15: Retrosynthetic analysis for the synthesis of [60]fullerenolysine cyclic tetrapeptide 222
starting from the tetrapeptide 216.
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2.2.13 Synthesis of lysine tetrapeptide amine salt 218 and acrolyl
coupled tetrapeptide 219
The synthesis of the lysine tetrapeptide amine salt 218 (Scheme 2.16) was realized in
98% by using TFA (1:1) in dichloromethane as solvent by following the procedure
described in Section 2.2.3. This product was carried forward to the subsequent coupling
reaction with acrylic acid under the coupling conditions mentioned in Section 2.2.2.
Purification of the crude reaction product by flash column chromatography followed by
simple trituration from diethyl ether yielded the desired product 219 in 75% yield
(Scheme 2.16).

Scheme 2.16: Synthesis of compound 218 and 219. Reagents and conditions: (a) TFA: CH2Cl2 (1:1), rt,
4 h, 98%. (b) EDCI, HOBt, Et3N, CH2Cl2, rt, 4 h, 75%.

Compound 218 was characterised by the appearance of the peak at m/z 1459 in the
ESIMS, that was assigned to the protonated molecular ion ([M+H]+ C87H94N8O13). The
1

H NMR spectrum of compound 219 showed the prominent allyl ester resonances [at δ

4.56 (bs, 2H), 5.20-5.33 (m, 2H), and 5.63-5.65 (m, 1H)], and acrylyl group resonances
[at δ 5.81-5.83 (m, 1H, NHCOCH=CHH), 6.06-6.20 (m, 1H, NHCOCH=CHH)].
Additionally, the molecular structure of the product 219 was verified by the appearance
of the peak at m/z 1535 (100%) in the ESIMS, that was assigned to the sodiated
molecular ion ([M+Na]+ C90H96N8O14Na).

67

Synthesis of [60]Fullerenyl Amino Acids Oligomers

Chapter 2

2.2.14 Synthesis of cyclic tetrapeptide 220 by ring closing metathesis
(RCM)
A solution of 219 in CH2Cl2 (100 mL) was heated at reflux then Grubbs’ II catalyst107
was added in one portion. The colour became pink then purple and then darkened to
orange. The reaction was heated at reflux for 4 h, after which TLC analysis showed
complete consumption of 219. The crude reaction mixture was then subjected to flash
silica chromatography, elution with MeOH/CH2Cl2 (1:25) provided the cyclic
compound 220 as an off-white solid (Scheme 2.17).

Scheme 2.17: Synthesis of compound 220. Reagents and conditions: (a) CH2Cl2, Grubb’s II catalyst,
reflux, 4 h, 19%.

The cyclic peptide 220 was characterised by the appearance of the peak at m/z 1486
(80%) in the ESIMS, that was assigned to the protonated molecular ion ([M+H]+
C88H93N8O14). This compound was not sufficiently soluble to generate an adequate 1H
or 13C NMR spectrum.
This strategy was not pursued any further because of the difficulty of characterising
compounds due to their poor solubilities and the low chemical yields.
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2.2.15 Material Science Applications of compounds 201 and 204 as
Fullerene van der Walls Oligomers
The results from this section were generated by collaborators in Germany (Prof.
Timothy Clark and Prof Dirk M. Guldi, University of Erlangen-Nuremberg).
[60]Fullerenes are used extensively as electron acceptors, for instance in phenyl-C60butyric acid methyl ester (PCBM) based organic solar cells and in devices based on
polycrystalline fullerene films. In most cases, van der Waals interactions between
fullerenes are present. An exciting possibility for low-voltage organic field-effect
transistors (FETs) is to combine the dielectric and the semiconductor functionalities in a
single molecule that can form a self-assembled monolayer (SAM).108 When the
semiconductor moiety in such molecules is a substituted fullerene, an n-type
semiconductor layer results that can become negatively charged under conductance
conditions. This results in considerable hysteresis in the voltage-current characteristics
of the device.109 When our collaborators in Erlangen were analyzing semiempirical
molecular orbital calculations on such SAMs,110 they noticed that the local electron
affinity111,112 indicated electron traps in the interstitial volumes between adjacent
fullerenes in the semiconductor layer and that these traps were particularly deep when
three fullerenes were involved.110 A literature survey revealed that several groups have
studied covalently linked fullerenes, their radical anions and dianions,113-123 but that
little attention has been paid to non-bonded van der Waals aggregates of fullerenes.124
The covalently bonded C60-dimer radical anion/dianion, A•/2 can be considered to be
the result of an addition to a Csp2-Csp2 bond in the fullerene cage, whereas a reduced van
der Waals dimer, B can form one-electron bonds125 between fullerene “super atoms”
(Figure 2.4).126 A third possibility is the dimer adduct formed by a formal [2+2]
cycloaddition of two 5,6-bonds, C (Figure 2.4).113
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Figure 2.4: Structures of fullerene dimers A, B and C.

The “super atom” picture of fullerenes is interesting in this context because the lowest
unoccupied molecular orbitals of C60 are triply degenerate. This means that additional
electrons can occupy low-lying intermolecular molecular orbitals, leading to the
possibility that larger van der Waals C60-oligomer dianions can form multi-center twoelectron bonds to give trimers (D) analogous to H3+ 127 and tetramers (E) analogous to
the 1,3-dehydro-5,7-adamatanediyl dication.128

Figure 2.5: Structures of fullerene trimer D and tetramer E.

Table 2.2 shows the results obtained by Prof. T. Clark et al. from density-functional
theory (RI-BP86129,130/TZV) calculations on fullerene dimers, trimers and tetramers and
one- and two-electron reduced forms. They used an empirical correction to account for
dispersion,131 although the correctness of such treatments for fullerenes has recently
been placed in doubt.132 They have investigated the three structures A-C in Figure 2.4
for  C60 2 and  C60 22 . A has a long covalent bond of 1.6 to 1.7 Å, whereas B features a
shortened van der Waals contact distance of approximately 2.6 Å between the fullerenes
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(the van der Waals radius of carbon is 1.7 Å). Surprisingly the non-bonded structure B
is found to be more stable than the covalently bonded isomer A (by up to 11.3 kcal mol–
1

for the radical anion and 4.8 kcal mol–1 for the singlet dianions). The D3-dispersion

correction lowers these values (stabilizes the dimers) by approximately 5 kcal mol–1.
Table 2.2 Relative energies (ERel, kcal mol–1) of C60 oligomers 1-5, the corresponding anions and
dianions, relevant Electron Affinities (EA, eV) and reaction energies (ER, kcal mol–1) calculated at
the
RIBP86/TZV
Dissociation
level of theory.
Species
ERel
EA
Reaction
ER
C60
2.82
0.0 (0.0)
B
3.24
+11.9
 2C60
+1.2 (–5.4)
C
3.25
+17.3
 2C60
D
3.49
+34.2
 3C60
E
3.62
+66.9
 4C60
C60–.
A–.
B –.
C –.
D –.
E –.

+11.3 (+6.0)
0.0 (0.0)
+1.53 (–5.6)

–0.21
2.98
1.11
1.03
1.58
1.86

 C60+C60–.
 C60+C60–.
 C60+C60–.
 2C60+C60–.
 3C60+C60–.

+15.8
+21.7
+27.3
+49.7
+85.6

Because this result could easily be caused by the self-interaction error in DFT, Prof. T.
Clark et al. also calculated the energies of A• and B• using increasing amounts (0 to
50%) of Hartree-Fock exchange in a modified hybrid B3LYP functional133,134 and
performed additional calculations using the long-range corrected CAM-B3LYP135
functional. The results are shown in Figure 2.6.
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Figure 2.6. Calculated potential energy diagrams for the dissociation of (C60)2-•.

The data shown in Table 2.2 and Figure 2.6 demonstrate that the van der Waals dimer
radical anion and dianion are probably more stable than the covalently bound isomer B
investigated previously or comparable to the [2+2] adduct C in the same oxidation
states. These values lie between those obtained at the RI-BP86-D3/TZV level (–15.8
and –21.7 kcal mol–1, for A–• and B–•, respectively). All calculations find the deepest
minimum to be 2 kcal mol–1, with a significantly shortened van der Waals contact
(between 2.4 and 2.9 Å). Thus, the range of DFT functionals tested agrees that B• is
more stable than A•. HF-TPSS and HF-PBE calculations with the def2-SVP basis set
also predict B–• to be more stable than A–• by 15 kcal mol-1, with a barrier of ca. 3 kcal
mol-1 between them.
They also performed CASSCF136/CASPT2137,138(5,4) calculations on DFT-optimized
geometries to verify the DFT and HF-DFT results (Figure 2.7). CASPT2(5,4)
calculations also show that A–• and B–• are close in energy, with a barrier of 6.2 kcal
mol–1 between them. Unfortunately, the size of the system limits calculations to the
CASPT2(5,4)/ANO-L-VDZ level.139,140

72

Synthesis of [60]Fullerenyl Amino Acids Oligomers

Chapter 2

Figure 2.7. CAS (5,4) formally singly occupied orbital of B–•. The calculated occupancy is given in
parentheses. This orbital corresponds to a one-electron -bond between the two fullerenes.

The calculated IR and UV-Vis spectra suggest that A–• and B–• can be distinguished
easily. Structure 2–• is characterized by very intense absorptions at 1430-1486 and 1600
cm1 that are far weaker in the separated monomers and A.. Once again, the van der
Waals dimer radical anion B–• is clearly distinguished by a strong absorption in the
infrared at 1760 nm (5672 cm1). This absorption is far more intense than that found at
slightly longer wavelength (1848 nm) for A–•, which also exhibits a second weaker
absorption at 1441 nm. Separated fullerene and its radical anion do not absorb in this
region.
To investigate the proposed effect experimentally, they performed cyclic voltammetry
and spectroelectrochemical experiments on the fullerene-substituted peptides 201 and
204. Both the monomer 201 and dimer 204 are soluble in chloroform, chlorobenzene
and ortho dichlorobenzene. Monomer 201 is more soluble in these organic solvents than
the dimer 204 possibly because of the absence of interactions between the fullerene
balls, whereas this effect is more possible dimer 204. These two compounds offer the
opportunity to observe and compare a system in which interactions between non-bonded
fullerenes are possible (204) with one in which they are not (201). The redox properties
of the mono- and dipeptides were studied by means of cyclic voltammetry (CV). The
measurements were performed at room temperature in chlorobenzene with

73

Synthesis of [60]Fullerenyl Amino Acids Oligomers

Chapter 2

tetrabutylammonium hexafluorophosphate as supporting electrolyte. Chlorobenzene, an
aprotic solvent, was chosen to avoid protonation of the charged species. Figure 2.8
shows the reductive scans between -0.2 to -1.6 V of 201 and 204. They compared the
spectra obtained upon fast and slow scanning. Both compounds show a reduction,
which is assigned to the one-electron reduction of C60. At fast scan rates (0.2 Vs1), the
reduction appeared to be quasi-reversible and occured at nearly the same potential for
both 201 and 204. In contrast, slowing down the scan rate to 0.005 Vs1 lead to an
irreversible reduction of 204, while 201 remains reversible. Moreover, at slower scan
rates 204 was more easily reduced than 201. The change to an irreversible reduction of
204 at slower scan rates is consistent with the formation of a van der Waals dimer of the
fullerenes in 204.

2016- 0.005
- 0.005V/s
V/s
2016- 0.2
V/s
- 0.2
V/s
- 0.005V/s
V/s
2047- 0.005
- 0.2
V/s
2047- 0.2
V/s

1.0x10-6

current / A

5.0x10-7
0.0
-5.0x10-7
-1.0x10-6
-1.5x10-6

-1.5

-1.6

-1.4

-1.2

-1.0

-0.8

-0.6

-1.0

-0.4

-0.5

0.0

-0.2

potential / V
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Figure 2.8. Cyclic voltammograms of 201 and 204 with a scan rate of 0.0050 Vs1 and 0.200 Vs1.
Measurements were performed in chlorobenzene containing 0.05 M TBAPF 6 as supporting electrolyte
with a glassy carbon working electrode, a platinum counter electrode, and a silver pseudo-reference
electrode. Corrected for ferrocene as an internal standard.

With this information in hand, they carried out spectroelectrochemical experiments to
gather information about the absorption features of the reduced species. A differential
absorption spectra for 204 in chlorobenzene solution is shown in Figure 2.9. The
corresponding spectrum for 201 shows the features known from the literature for Nmethylfulleropyrrolidine.141 In particular, a sharp peak with a 1028 nm maximum is
observed for the one electron reduced C60. In contrast, the differential spectrum of 204
is characterized by a broad absorption between 700 and 1200 nm and with a local
maximum at 860 nm. These spectral attributes are assigned to a van der Waals dimer of
204 and are in sound agreement with the calculated spectrum shown for the relevant
conformation of 204.

Figure 2.9. Normalized differential absorption spectrum of 204 with an applied voltage of −0.85 V.
Measurements were performed in chlorobenzene containing 0.05 M TBAPF6 as supporting electrolyte
with a platinum gauze as working electrode, a platinum plate as counter electrode, and a silver wire as
pseudoreference electrode. Calculated spectra for 204a•− and 204b•− (204a•− has separated fullerenes,
whereas 204b•− has fullerenes in van der Waals contact) shown in red and blue, respectively.
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204b•−

The calculations presented are on a system for which it is difficult to obtain definitive
results because of its size and the electronic characteristics. However, standard
functionals with and without dispersion corrections, HF-DFT calculations, modified
functionals with increasing amounts of HF-exchange and long-range corrected
functionals all gave consistent results that indicate that fullerene can function as a
“super-atom” that forms a one-electron intermolecular bond, resulting in an electron
trap that is even more stable than the isolated fullerene, which is itself an unusually
strong electron acceptor.
These experimental results were all consistent with 204 existing as at least two
conformations in solution, with a minority conformation having a van der Waals contact
between the two fullerenes (e.g. 204b). At slow CV scan rates, 204b can be formed by
rearrangement and stabilized by the inter-fullerene one-electron bond. At fast scan rates,
only the majority conformations without inter-fullerene contact are observed. The
observed spectrum of 204. corresponds to a superposition of those of the majority noncontact conformation and 204b. or a similar conformation.
Although definitive calculations are not yet possible, they used standard densityfunctional theory to calculate the electron affinities of fullerene van der Waals
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oligomers. These results are shown in Figure 2.10. The first electron affinity increases
from 2.7 eV for the monomer to 3.6 eV for the tetramer, which exhibits a second
electron affinity of almost 2 eV. The tetramer is also calculated to just be able to bind a
third electron. Van der Waals fullerene oligomers can thus exhibit first electron
affinities as much as one electron volt more strongly binding than the isolated fullerene
and second electron affinities up to approximately ~2 eV. These interstitial electron
traps represent an unexpected feature of non-covalently bonded aggregates of fullerenes
that can affect the performance of electronic devices strongly. Deep electron traps can
be expected in amorphous and crystalline fullerene layers or in self-assembled
monolayers of fullerene-substituted organic molecules, all of which are often used as ntype semiconductor components in organic electronics.142

Figure 2.10. Calculated (RI-BP/TZV) electron affinities (eV) of (C60)n.

2.2.16 Future directions and conclusions
The synthesis of [60]fullerenoproline monopeptide 201, dipeptide 204 and a lysine
tetrapeptide 216 were achieved for the first time and were successfully characterised.
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Unfortunately, the tetrapeptides 207 and 220 which were thought to be prepared, could
not be fully characterised due to their poor solubilities.
Because of steric hindrance problems in some of our peptide coupling reactions, it was
thought that the inclusion of a spacer between two fullerenyl units could be better
option. Hence, a new strategy was adopted towards the synthesis of a different hexa and
dodecapeptide oligomer (Chapter 3).
The [60]fullerene amino acid monomer 201 and the bis-fullerene 204 were studied
experimentally

using

spectroelectrochemical

measurements.

The

bis-fullerene-

substituted peptide 204 provided experimental support for density-functional theory
(DFT) calculations which indicate that van der Waals fullerene dimers can form
between adjacent fullerenes in semiconductor layers resulting in interstitial electron
traps. The fullerenes behave like “super atoms” and the interstitial electron traps
represent one-electron intermolecular σ-bonds. The proposed electron traps are relevant
for all organic electronics applications in which non-covalently linked fullerenes in van
der Waals contact with one another are used as n-type semiconductors.142
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CHAPTER 3
The Synthesis of [60]Fullerenyl Amino Acids Oligomers
With Spacers

3.1 Material Science Applications as Solar Cells
With the aim of resolving the identified steric hindrance problems in Chapter 2, it was
thought that the inclusion of a spacer between two fullerenyl units could be a better
option (Figure 3.1 and 3.2). Hence, a new strategy was adopted towards the synthesis of
two different hexa and dodecapeptide oligomers (Scheme 3.1 and 3.4).
The aim of this chapter was to synthesise two different combinations of [60]fullerenyl
based oligomers 223 (Figure 3.1) and 230 (Figure 3.2) having spacers (e.g. lysine and
phenylalanine) in between the fullerenyl units. The first target dodecapeptide 223,
which could be prepared from the peptide coupling reaction of hexapeptide acid 228
and hexapeptide amine 229 is shown in Scheme 3.1. Similarly, the second target
dodecapeptide 230 (Figure 3.2) could be prepared from the acid and amine precursors of
the hexapeptide 239 and 240 under peptide coupling conditions mentioned in section
2.2.2.
These targeted dodecapeptides 223 and 230 showing every fourth lysine unit bearing
[60]fullerene on the peptide. Beyond a certain degree of oligomerisation the
development of a secondary structure, such as a 310 helix, may be observed (Figure 3.1
and 3.2). This would force the fullerenes to arrange in a defined spatial arrangement as
shown in Figure 3.1 and 3.2. These fullerenyl peptides can be studied for the
accommodation of guests like porphyrin rings in between two helices. Preparation of
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supramolecular complexes using these fullerene-peptide oligomers as hosts and
porphyrins as guest molecules could be potentially useful as organic photovoltaic cells
(as shown in Figure 3.1 and 3.2).

Figure 3.1. Potential structure of a fullerene-peptide system for use in organic solar cells.
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3.2 Target 1: Synthesis of [60]fullerenolysine dodecapeptide 223, by the
multiplication of coupling reactions.

3.2.1

Proposed

synthetic

strategy

for

the

[60]fullerenolysine

dodecapeptide 223.
The retro-synthesis of the [60]fullerenolysine dodecapeptide 223, starting from the
previously synthesised [60]fullerenomonopeptide acid 203, is outlined in Scheme 3.1. A
key step was the coupling of the acid 203 to the lysine dipeptide amine 213, to give the
crucial tripeptide 224. The tripeptide 224, could then be deprotected to its acid
derivative 225 and amine derivative 226 and these could then be coupled under standard
peptide coupling reactions to yield the hexapeptide 227. By repeating the deprotection
and coupling reaction protocol the targeted dodecapeptide 223 could then be potentially
realised (Scheme 3.1).
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Scheme 3.1 Retrosynthetic analysis for the synthesis of [60]fullerenolysine dodecapeptide 223 from the hexapeptide 227.
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Scheme 3.1 continued. Retrosynthetic analysis for the synthesis of [60]fullerenolysine hexapeptide 227
from the previously synthesised lysine dipeptide amine 213, and [60]fullerenomonopeptide acid 203.
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3.2.2 Synthesis of tripeptide 224 from acid 203 and amine 213, followed
by deprotection to its acid 225 and the amine salt 226
The synthesis of the tripeptide 224 (Scheme 3.2) was realized in 62% yield by stirring
in dichloromethane, a solution of previously synthesised lysine dipeptide amine 213 and
the [60]fullerenomonopeptide acid 203 under standard coupling conditions described in
Section 2.2.2. Purification of the crude reaction product by flash column
chromatography followed by simple trituration from diethyl ether yielded the desired
tripeptide 224 in 62% yield (Scheme 3.2). Subsequent deprotection reactions of
tripeptide 224 yielded the tripeptide acid 225 (in 77%), and the tripeptide amine 226 (in
89%), using the reaction conditions adopted from Section 2.2.3 (Scheme 3.2).
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Scheme 3.2: Synthesis of a tripeptide 224, tripeptide acid 225 and tripeptide amine 226. Reagents and
conditions: (a) EDCI, HOBt, Et3N, CH2Cl2, rt, 4 h, 62%; (b) 1,2-DCE, (CH3)3SnOH, 80 0C, 6 h, 77%; (c)
TFA: CH2Cl2 (1:1), rt, 4 h, 89%.

The 1H NMR spectrum of tripeptide 224 showed the prominent allyl ester resonances at
δ 4.37-4.43 (m, 2H), 5.22-5.26 (m, 2H), and 5.82-5.88 (m, 1H), that were present in the
spectrum of amine 213 and the Boc methyl resonance (δ 1.40, s, 9H), which was present
in the spectrum of acid 203. Additionally, an amidic proton resonance also appeared at δ
6.74-6.82 (m, 1H, NH) which was associated with the newly formed amide bond.
Furthermore, the molecular formula of product 224 was verified by the appearance of
the peak at m/z 1948.5831 in the HRMS, that was assigned to the sodiated molecular ion
([M+Na]+ C131H79N7O11Na).
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The deallylation of tripeptide 224 to its acid 225 was supported by the loss of
resonances at δ 4.37-4.43 (m, 2H), 5.22-5.26 (m, 2H), and 5.82-5.88 (m, 1H), in the 1H
NMR spectrum, that were present in the tripeptide 224, which were assigned to the allyl
protons. The molecular formula of product 225 was verified by the appearance of the
peak at m/z 1909.5359 in the HRMS, that was assigned to the sodiated molecular ion
([M+Na]+ C128H75N7O11Na).

Tripeptide amine salt 226 showed the disappearance of a prominent Boc group
resonance (δ 1.40, s, 9H) that was present in the 1H NMR spectrum of tripeptide 224.
The molecular formula of product 226 was verified by the appearance of the peak at m/z
1826.5789 in the HRMS, that was assigned to the protonated molecular ion ([M+H] +
C126H71N7O9).

3.2.3 Coupling of acid 225 and amine 226 to the hexapeptide 227
The general synthetic procedure stated in Section 2.2.2 was employed to synthesise the
hexapeptide 227. The synthesis of the hexapeptide 227 (Scheme 3.3) was realized from
the coupling reaction of tripeptide acid 225 and the tripeptide amine 226. Purification of
the crude reaction product by flash column chromatography followed by simple
trituration from diethyl ether yielded the desired hexapeptide 227 in 44% yield (Scheme
3.3).
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Scheme 3.3: Synthesis of a hexapeptide 227. Reagents and conditions: (a) EDCI, HOBt, Et3N, CH2Cl2,
rt, 4 h, 44%.

The 1H NMR spectrum of the hexapeptide 227 showed the prominent allyl ester
resonances [at δ 4.50-4.62 (m, 2H), 5.20-5.22 (m, 2H), and 5.81-5.86 (m, 1H)], that
were present in the 1H NMR spectrum of amine 226 and the Boc resonance (δ 1.39, s,
9H), that was present in the 1H NMR spectrum of acid 225. Additionally, an amidic
proton resonance also appeared at δ 6.83-6.84 (m, 1H, NH) which was associated with
the newly formed amide bond. This compound was not sufficiently soluble to generate
an adequate

13

C NMR spectrum and not sufficiently soluble in MeOH to generate an

adequate ESI-MS.

This strategy was not pursued any further because of the difficulty of characterising
compounds due to their poor solubilities and the relatively low chemical yields.
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phenylalanine

dodecapeptide 230, by the multiplication of coupling reactions.

3.3.1

Proposed

synthetic

strategy

for

the

[60]fullerenolysine

phenylalanine dodecapeptide 230.
The retro-synthesis of the [60]fullerenolysine dodecapeptide 230, starting from the
previously synthesised [60]fullerenomonopeptide amine 202, is outlined in Scheme 3.4.
A key step was the coupling of the amine 202 to the L-phenylalanine dipeptide acid
234, to give the crucial tripeptide 235. The tripeptide 235, could then be deprotected to
its acid derivative 236 and amine derivative 237 and these could then be coupled under
standard peptide coupling reactions to yield the hexapeptide 238. By repeating the
deprotection and coupling reaction protocol the targeted dodecapeptide 230 could then
be realised (Scheme 3.4).
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Figure 3.2. Potential structure of a amino acid/porphyrinic-peptide system for use in organic solar cells.
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Scheme 3.4 Retrosynthetic analysis for the synthesis of [60]fullerenolysine phenylalanine dodecapeptide 230 from the hexapeptide 238.

90

Synthesis of [60]Fullerenyl Amino Acids Oligomers With Spacers

Chapter 3

Scheme 3.4 continued. Retrosynthetic analysis for the synthesis of [60]fullerenolysine phenylalanine
hexapeptide 238 from previously synthesised dipehnylalanine dipeptide acid 234, and [60]fullerenomonopeptide
amine 202.
.
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3.3.2 Amide coupling of acid 231 and amine 232 to synthesize a dipeptide
233, followed by ester hydrolysis to its acid 234
The synthesis of the phenylalanine dipeptide143 233 (Scheme 3.5) was realized from the
peptide coupling reaction of commercially available phenylalanine acid 231 and the amine
232. Purification of the crude reaction product by flash column chromatography followed by
simple trituration from diethyl ether yielded the desired tripeptide 233 in 92% yield (Scheme
3.5). Subsequent removal of tert-butyl group of dipeptide 233 yielded the dipeptide acid 234
(in 90%) using the reaction conditions adopted from Section 2.2.3.

Scheme 3.5: Reagents and conditions: (a) EDCI, HOBt, Et3N, CH2Cl2, rt, 4 h, 62%; (b) TFA: CH2Cl2 (1:1), rt,
4 h, 90%.

The 1H NMR spectrum of dipeptide 233 showed the prominent tert-butyl ester resonance at δ
1.36 (s, 9H), that was present in the 1H NMR spectrum of amine 232 and the Fmoc protecting
group methine and methylene resonances at δ 4.28 (bs, 1H, CH), 4.40-4.43 (m, 2H, CH2),
that were present in the 1H NMR spectrum of acid 231. Additionally, an amidic proton
resonance was evident at δ 6.31 (bs, 1H, NH) that was associated with the newly formed
amide bond. Additionally, the

13

C NMR spectrum of 233 showed resonances at δ 155.9,

assigned to the Fmoc carbonyl, and δ 170.2, that was assigned to the ester carbonyl. This
indicated the presence of carbonyl resonances from both the reactants. Furthermore, the
molecular structure of the product 233 was verified by the appearance of the peak at m/z
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591.2865 in the HRMS, that was assigned to the protonated molecular ion ([M+H]+
C37H38N2O5).
The ester hydrolysis of dipeptide 233 to its acid 234 was supported by the loss of the tertbutyl 1H NMR resonance at δ 1.36 (s, 9H) that were present in the dipeptide 233. The
molecular structure of the product 234 was verified by the appearance of the peak at m/z
535.2238 in the HRMS, that was assigned to the protonated molecular ion ([M+H]+
C33H30N2O5).

3.3.3 Amide coupling of acid 234 and amine 202 to synthesize a tripeptide
235, followed by ester hydrolysis to its acid 236 and Fmoc removal to
the amine 237
The synthesis of the [60]fullerenyl tripeptide 235 (Scheme 3.6) was realized from the peptide
coupling reaction of the previously synthesised phenylalanine dipeptide acid 234 and the
monopeptide amine 202. Purification of the crude reaction product by flash column
chromatography followed by simple trituration from diethyl ether yielded the desired
tripeptide 235 in 60% yield (Scheme 3.6). Subsequent allyl ester hydrolysis of tripeptide 235
yielded the tripeptide acid 236 (in 75% yield) using the reaction conditions adopted from
Section 2.2.3, and the tripeptide amine 237 (in 99% yield), using the reaction conditions
adopted from Section 2.2.2.
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Scheme 3.6: Synthesis of a tripeptide 235, tripeptide acid 236 and tripeptide amine 237. Reagents and
conditions: (a) EDCI, HOBt, Et3N, CH2Cl2, rt, 4 h, 60%; (b) 1,2-DCE, (CH3)3SnOH, 80 0C, 6 h, 75%;
(c) piperidine, CH3CN, rt, 4 h, 99%.

The 1H NMR spectrum of tripeptide 235 showed the prominent allyl ester resonances at δ
4.39-4.59 (m, 2H), 5.19-5.25 (m, 2H) and 5.84-5.90 (m, 1H), that were present in the 1H
NMR spectrum of the monopeptide amine 202 and the Fmoc protecting group methine and
methylene resonances [at δ 4.06-4.11 (m, 1H, CH), 4.39-4.59 (m, 2H, CH2)], that were
present in the 1H NMR spectrum of acid 234. Additionally, an amidic proton resonance was
observed at δ 6.57 (bs, 1H, NH), that was associated to the newly formed amide bond.
Furthermore, the 13C NMR spectrum showed a resonance at δ 162.4, which was assigned to
the newly formed amide carbonyl group. The molecular formula of the product 235 was
verified by the appearance of the peak at m/z 1641.4235 in the HRMS, that was assigned to
the protonated molecular ion ([M+H]+ C117H55N5O7).
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The deallylation of tripeptide 235 to its acid 236 was carried forward to the subsequent
reaction without any spectroscopic analysis, because of its poor solubility.
The molecular formula of the amine product 237, from removal of the Fmoc protecting group
from 235 was verified by the appearance of the peak at m/z 1419.3529 in the HRMS, that was
assigned to the protonated molecular ion ([M+H]+ C102H45N5O5).

3.3.4 Amide coupling between tripeptide acid 236 and amine 237 to
synthesize a hexapeptide 238
The synthesis of the [60]fullerenyl hexapeptide 238 (Scheme 3.7) was realized from the
peptide coupling reaction of the previously synthesised tripeptide acid 236 and the tripeptide
amine 237. Purification of the crude reaction product by flash column chromatography
followed by simple trituration from diethyl ether yielded the desired hexapeptide 238 in 40%
yield (Scheme 3.7).

Scheme 3.7: Reagents and conditions: (a) EDCI, HOBt, Et3N, CH2Cl2, rt, 4 h, 40%.

The 1H NMR spectrum of hexapeptide 238 showed the prominent allyl ester resonances [at δ
4.37-4.61 (m, 2H), 5.17-5.25 (m, 2H) and 5.86-5.92 (m, 1H)], that were present in the 1H
NMR spectrum of the tripeptide amine 237 and the Fmoc protecting group methine and
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methylene resonances [at δ 4.04-4.15 (m, 1H, CH), 4.37-4.61 (m, 2H, CH2)], that were
present in the 1H NMR spectrum of acid 236. Additionally, an amidic proton was also
appeared at δ 6.65 (bs, 1H, NH), that was associated with the newly formed amide bond. This
compound was not sufficiently soluble to generate an adequate

13

C NMR spectrum and not

sufficiently soluble in MeOH to generate an adequate ESIMS.

3.3.5 Future directions and conclusions
The synthesis of [60]fullerenolysine/phenylalanine tripeptides

224 and 235, and their

amine/acid derivatives 225, 226 and 236, 237 respectively, were achieved for the first time
and characterised. Attempts were made to prepare the hexapeptides 227 and 238 from the
coupling reactions of 225 and 226, and 236 and 237, respectively. The products of these
reactions, however, could not be fully characterised due to their poor solubilities.
Currently, some of these molecules (224, 227, 235 and 238) are under study to form
supramolecular complexes between the [60]fullerenes and porphyrin, and photoinduced
charge separation experiments in Prof. Fukuzumi’s laboratory at Osaka University, Japan.
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CHAPTER 4
Synthesis of Mono and Bis[60]fullerene
Based Di-Cationic Peptoids as Potential AntiBacterial Agents
4.1 Introduction
There are significant health care issues posed by multidrug resistant human pathogenic
bacteria.144-147 Of particular concern is the emergence of Gram-positive bacteria, e.g.
Staphylococcus aureus and Enterococcus faecium, resistant to the glycopeptide
antibiotic, vancomycin.148,149 Recent work undertaken within our research laboratories
has revealed a new peptide class of antibiotics, exemplified by binaphthyl-anchored
peptide (Figure 4.1)96. These dicationic binaphthyl-templated linear peptides possess
some similarity to structural aspects of vancomycin (Fig. 4.1) and could potentially act
in a similar way but have added flexibility for interacting strongly with the changed
peptido-glycan cell wall moiety150 in vancomycin-resistant bacteria.151 Also, the
significant antimicrobial activity in some biaryl-based cyclic β–hairpin cationic
peptidomimetics is noteworthy.152 While medicinal chemistry investigations of
binaphthyl-anchored peptide as antibacterial agents made significant progress, with the
evolution of the amino acids required94,97,153 and the better termini,96 early
investigations into alternatives to the binaphthyl unit were restricted to macrocycles
anchored by hydrophobic scaffolds based on 3,3′-amino acid linked 1,1′-binaphthyls,154
carbazoles,155,156 indoles,157 benzenes107 and benzo[b]thiophene.158 Within these studies,
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acyclic versions of the hydrophobic anchored peptide derivatives were tested with little
success. Considering that all of these approaches investigated reducing the size of the
hydrophobic anchoring unit, we thought that alternative hydrophobic units could match
the space occupied by the binaphthyl unit. Given the diameter of [60]fullerenes is 6.8 Å
and the distance from distal points of the binaphthyl moiety is 8.3 Å, we considered the
possibility of replacing the binaphthyl unit with a [60]fullerene. Structure Activity
Relationships (SAR) will be compared with the replacement of hydrophobic binaphthyl
moiety with [60]fullerene unit. This chapter describes the synthesis of the [60]fullerene
based peptoids, 243, 245, 247, 272-279 and 285 and their antibacterial activities.

Figure 4.1. Binaphthyl-anchored peptide anti-biotic agents, Vancomycin and [60]Fullerene dicationic
peptides.
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4.2 Strategy 1: Coupling of a [60]fullerenoglycine derivative with a
dipeptide followed by standard peptide couplings.

4.2.1 Proposed synthetic strategy for the initial peptoid 247.
The retro synthesis of the initial [60]fullerene based peptoid target 247, starting from
the previously reported 5,5-diphenylfullerenedihydropyrrole acid33 198, is outlined in
Scheme 4.1. A key step was the coupling of the fullerenyl acid 242 to the peptide 213 to
give the tripeptide 243.
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Scheme 4.1 Retrosynthetic analysis for the synthesis of [60]fullereno tetrapeptoid 247 from
diphenylfullerenyldihydropyrrole acid 198 and amine 213.

4.2.2 N-Boc, N-Pmc/Pbf and tert-butyl ester removal via acidolysis and
HCl salt formation
A general procedure97 mentioned in Section 2.2.3 (Scheme 2.7) was employed, with
modifications, for the deprotection of N-Boc alone and/or tert-butyl ester group at rt for
4 h, and for all N-Boc and N-Pmc/Pbf containing intermediates at rt overnight. To form
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the HCl salt, the residue was resuspended in a minimal volume of CH2Cl2 and the
solution was then treated with an excess amount of 2 M HCl/ether (2 mL/0.01 mmol)
solution and the solvent then evaporated. The product was purified by precipitation
from CH2Cl2, with hexane and diethyl ether.

In this thesis the Boc, tert-butyl and Pbf/Pmc protecting groups were cleaved using
TFA. The cleavage mechanism is similar for both substituents (Schemes 2.7 and 4.2)
and proceeds via protonation followed by heterolytic cleavage and release of a stable
carbocation. The acid-labile nature of the Boc and Pbf/Pmc groups lies in their ability to
stabilize the resultant cationic species – for Boc it is a result of the tert-butyl
carbocation and for Pbf/Pmc it is the 2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran and
2,2,5,7,8-pentamethylchromane respectively.101,159 The tertiary nature of the tert-butyl
cation stabilizes the positive charge by donating electron density onto the tertiary carbon
(Scheme 2.7). Release of the cationic species from the N-protected substrate results in a
carbamic acid for the Boc mechanism and the deprotected guanidine product in the
Pbf/Pmc mechanism (Schemes 2.7 and 4.2). In the Boc mechanism, proton transfer
followed by decomposition of the deprotonated carbamic acid gives CO2 and the
product amine as the TFA salt. In the Pbf/Pmc cleavage mechanism, the generated
(alkylamino)(sulfonylamino)methaniminium undergoes decomposition to generate SO2
and a guanidium salt (Scheme 4.2 – blue circle). 101,159
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Scheme 4.2: Proposed mechanism for the acidolysis of an N-Pbf/Pmc group to give the product
guanidine and by-products

The simple acidolytic conditions required for removal of both the N-Boc and N-Pbf
groups allowed for the isolation of the crude TFA salts by simple solvent removal.
Solvent-aided anion-exchange with anhydrous HCl allowed for the simple isolation of
the final compounds as the mono- or di-hydrochloride salts by precipitation from
diethyl ether. The general procedure that was developed allowed for at least a full 14 h
reaction time, even though the Boc protecting groups have been observed to be fully
deprotected in as little as 15 min. The longer reaction time was implemented to ensure
complete deprotection of the Pbf/Pmc group, as shorter reaction times have been
observed to give incomplete acidolysis. Due to the volatility of the Boc deprotection byproducts, no resultant impurities were observed. The precipitation and repeated
trituration of the final di-hydrochloride salt removes the majority of the
benzofuran/chromene by-product. In the event of inefficient trituration, three small but
distinctive peaks were noted in the 1H NMR spectrum between δ 2.00 – 2.20 that were
assigned to the benzofuran/chromene by-product (3 x CH3). Overall, it was the relative
ease, speed, and resultant product purity of the acidolytic deprotection method that
allowed for the efficient turn-over of multiple derivatives.
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4.2.3 From fullerenyldihydropyrrole derivatives towards fullerenyl
peptides

4.2.4 Amide coupling of carboxylic acid 198, followed by ester
deprotection yielding carboxylic acid 242
[60]Fullerenyl peptide 242 was prepared as shown in Scheme 4.3, from the fullerenyl
carboxylic acid 198.

Scheme 4.3: Synthesis of the fullerenyl amino acid 242.

Under EDCI/HOBt amide coupling reaction conditions the fullerenyl carboxylic acid
198 was found to readily couple to tert-butyl glycinate in CH2Cl2 at rt in 5 h. The
solution was washed with water then the solvent was reduced in volume to
approximately half before being applied directly to the top of a silica gel column.
Elution with CH2Cl2 provided the fullerenyl peptide 241 in 48% yield, which was
converted to the acid 242 by treatment of a solution of 241 in CH2Cl2 with TFA at rt for
3 h (Scheme 4.3). Hexanes were then added and the precipitate was collected providing
the acid 242 in 90% yield.
Evidence for the successful coupling was provided by analysis of the 1H NMR spectrum
of 241 which indicated loss of the resonance attributable to the carboxylic acid proton
and the presence of a singlet, with a relative integration of 9H at  1.42, assigned to the
tert-butyl protons. The presence of another singlet with an integration of 2H at δ 3.85
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also provided strong evidence of the α-methylene protons of the tert-butyl glycine
moiety. Analysis of the ESI-MS revealed an ion at m/z 1093 assigned as the sodiated
molecular ion [(M+Na)+ C81H22N2O3Na]. Successful deprotection of the tert-butyl
group was provided by analysis of the 1H NMR spectrum of 242, which indicated loss
of the resonance attributable to the tert-butyl group ( 1.42 (9H, s)) along with the
appearance of a broad singlet, with a relative integration of 1H, at 8.56 attributed to
the carboxylic acid proton. Analysis of the ESI-MS, which showed a base peak at m/z
1015 assigned as the protonated molecular ion [(M+H)+ C77H15N2O3].

4.2.5 Synthesis of the [60]fullereno tripeptide 243
The crucial [60]fullerenyl tripeptide 243 was prepared as shown in Scheme 4.4, starting
with the coupling reaction of the fullerenyl carboxylic acid compound 242 and the
dipeptide 213.

Scheme 4.4: Synthesis of [60]fullereno tripeptide.

Under EDCI/HOBt amide coupling reaction conditions the fullerenyl acid 242 was
found to readily couple to a TFA salt of dipeptide 213 in CH2Cl2 at rt in 5 h in 45%
yield. However, optimisation of the yield of this peptide coupling reaction under HBTU
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rather than EDCI/HOBt, resulted in better yield of 67% for compound 243, after
purification by silica gel column chromatography. Analysis of the 1H NMR spectrum of
243 showed a loss of the resonance attributable to the carboxylic acid proton and the
presence of resonances for the characteristic protons of both the carboxylic acid 242 and
amine 213. A multiplet at δ 3.43-3.44 (-CHNH2) in the 1H NMR spectrum of 213 was
no longer observed in the spectrum of 243 but a broad singlet at δ 4.51 with an
integration of 2H was assigned to the two lysine α-methine protons. This evidence
indicated that the α-proton, adjacent to the primary amine in precursor 213, experienced
a downfield shift as a result of the newly installed amide bond. Additionally, the

13

C

NMR spectrum showed a resonance at δ 171.7, assigned to the new amide carbonyl
group. The molecular structure of the product was verified by the appearance of the
peak at m/z 1778.4565 in the HRMS, that was assigned to the sodiated molecular
formula ([M + Na]+ C122H62N6O9Na).

4.2.6 Selective deallylation of tripeptide 243 using (CH3)3SnOH to
provide carboxylic acid 244
The [60]fullereno tripeptide 243 was treated with (CH3)3SnOH under the above
mentioned reaction conditions to selectively hydrolyse the allyl ester to give the acid
244 in 84% yield (Scheme 4.5) without any noticeable cleavage of the Fmoc carbamate
protecting group. The acid 244 was then carried in to the subsequent reaction without
any further characterisation, because of its poor solubility.
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Scheme 4.5: Synthesis of the [60]fullereno tripeptide acid 244.

4.2.7 Synthesis of novel tetrapeptide 245 from acid 244 under amide
coupling conditions
The synthesis of tetrapeptide 245 (Scheme 4.6) was realized in 62% yield after stirring
a CH2Cl2 solution of the commercially available amine, (S)-isopentyl 2-amino-4methylpentanoate, and the acid derivative 244 with the coupling reagents EDCI and
HOBt at rt for 4 h. Flash column chromatography followed by simple trituration from
diethyl ether yielded the desired novel tetrapeptide product 245.

Scheme 4.6: Synthesis of [60]fullereno tetrapeptide 245. Reagents and conditions: (a) isopentyl Lleucinate hydrochloride, EDCI, HOBt, TEA, CH2Cl2, rt, 4 h.

A broad singlet at δ 8.76 (-CHNH2) in the 1H NMR spectrum of (S)-isopentyl 2-amino4-methylpentanoate was no longer observed in the spectrum of 245 but a triplet
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resonance for the isopentyl ester –OCH2 (δ 4.04 (2H, t, J = 6.5 Hz)) was observed. A
multiplet at δ 4.11-4.17 for 4H was assigned to the leucine-α-methine proton including
other protons, this evidence indicated that the α-proton, adjacent to the primary amine in
precursor (S)-isopentyl 2-amino-4-methylpentanoate, experienced a downfield shift as a
result of the newly installed amide bond. Additionally, the molecular structure of the
product was verified by the appearance of a peak at m/z 1898.6011 in the HRMS, which
was assigned to the protonated molecular formula ([M+H]+, C130H79N7O10). This
compound however, was not sufficiently soluble to generate an adequate

13

C NMR

spectrum.

4.2.8 Base-promoted N-Fmoc removal for the tetrapeptide 246,
followed by HCl salt formation to give peptoid 247
A solution of tetrapeptide 245 in piperidine/acetonitrile (1:9 v/v) was stirred overnight
at rt to produce the free amine 246, which was carried forward to form the HCl salt by
treatment with an excess amount of 1 M HCl/diethyl ether solution. The crude product
was purified by precipitation from CH2Cl2, with hexane and diethyl ether (Scheme 4.7)
to achieve a 70% yield of the hydrochloride salt 247.
The molecular structure of this salt was verified by the appearance of a peak m/z
1454.4750 in the HRMS, which was assigned to the protonated molecular formula
([M+H]+, C100H59N7O6). Unfortunately, this compound was not sufficiently soluble to
generate an adequate 1H or 13C NMR spectrum.
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Scheme 4.7: Synthesis of [60]fullereno peptoid salt 247. Reagents and conditions: (a) piperidine,
CH3CN, rt, 4 h; (g) 1 M HCl.Et2O, 0 °C-rt, 0.5 h.

4.3 Strategy 2

4.3.1 Proposed synthetic strategy for the synthesis of [60]fullereno
peptoids 272-279.
The synthesis of the second series of novel [60]fullereno peptoids 272-279 started from
the previously mentioned 5,5-diphenylfullerenedihydropyrrole acid 198 and a variety of
tri- and tetra-peptides was proposed in seven synthetic steps for the [60]fullereno
pentapeptides, and six steps for the [60]fullereno tetrapeptides (Scheme 4.8). This
strategy was adopted because of the relative ease of handling peptides in terms of
solubility and purification without the fullerene moiety present, and additionally to
minimise the exposure of the [60]fullerene containing peptide to acidic conditions,
because of the possible cleavage of the [60]fullerene group especially under TFA
reaction conditions.
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Scheme 4.8 Retrosynthetic analysis for the synthesis of [60]fullereno tetra and pentapeptoids from the
known diphenylfullerenyldihydropyrrole acid 198, and amino acids 262, 269-271.

4.3.2 Synthesis of the known dipeptides 250-253 and the Fmoc
deprotected dipeptides 254-257
The synthesis of the previously reported94,96,97 free amine containing dipeptides 254-257
(Scheme 4.9) were achieved from commercially available starting materials 248 and
249. Under EDCI/HOBt amide coupling reaction conditions the D/L-Arg-(Fmoc)-OH
or D/L-Lys-(Boc)-OH acids were found to readily couple to free amines 248 and 249 in
CH2Cl2 at rt in 5 h to produce dipeptides 250-253 in 65-75% yield. Fmoc deprotection
of these compounds, then gave compounds 254-257, respectively. These compounds
exhibited NMR spectroscopic data that closely matched with those previously
reported.94,96,97 The yields for these individual reactions are summarised in Scheme 4.9.
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Scheme 4.9: Reagents and conditions: (a) Fmoc-D-arg-(Pmc/Pbf)-OH, Fmoc-L-arg-(Pmc)-OH or
Fmoc-D-lys(Boc)-OH, EDCI, HOBt, CH2Cl2, rt, 4 h; (b) piperidine, CH3CN, rt, 4 h.

4.3.3 Synthesis of the tripeptides 258-261 and the Fmoc deprotected
tripeptides 262-265
Tripeptides 258-261 were prepared in 72-86% yields, by reacting 254-257 with Fmoc-D
or L-Lys-(Boc)-OH under our standard amide coupling procedures (Section 2.2.2).
Subsequent deprotection of the Fmoc group resulted in the compounds 262-265 in
yields of 77-88%.

Scheme 4.10: Reagents and conditions: (a) Fmoc-D or L-Lys-(Boc)-OH, EDCI, HOBt, CH2Cl2, rt, 4 h,
79% for 258, 80% for 259, 86% for 260 and 72% for 261; (b) piperidine, CH3CN, rt, 4 h, 88% for 262,
77% for 263, 84% for 264, and 85% for 265.

A broad singlet at δ 8.62 (-CHNH2) in the 1H NMR spectrum of 254 was no longer
observed in the spectrum of 258 but a signal appeared at δ 4.43-4.45 (m, 1H), that was
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assigned to the arginine α-methine proton. This evidence indicated that the α-proton,
adjacent to the primary amine in precursor 254, experienced a downfield shift as a result
of the newly installed amide bond. Additionally, the 1H NMR singlet at δ 12.10 for the
acid –OH in Fmoc-D-Lys-(Boc)-OH was absent in the 1H NMR spectrum of compound
258. Further analysis of the

13

C NMR spectra showed a signal at δ 172.5, assigned to

the new amide carbonyl. The molecular structure of the product was verified by the
appearance of the peak at m/z 1074.0 in the ESI MS, that was assigned to the protonated
molecular ion, [M + H]+.
Analysis of the 1H NMR spectrum of amine 263 provided clear evidence for Fmoc
deprotection as there was a notable absence of signals at approximately δ 4.10 (2H, m)
and 4.32 (1H, t, J = 6.5 Hz) that were present in the spectrum of compound 259 and had
been assigned to the three non-aromatic Fmoc protons (i.e. -OCH2-CH-Ar).
Furthermore, two distinct multiplet resonances at δ 7.26-7.29 (2H, m) and δ 7.35-7.38
(2H, m) in the spectrum of 259, assigned as aromatic Fmoc protons, were no longer
observed. This indicated the successful removal of the fluorenyl moiety and its eight
aromatic protons. Analysis of the 13C NMR data confirmed the absence of a deshielded
methylene carbon signal at δ 67.4 and a methine carbon at δ 47.3 (assigned as the Fmoc
CH2 and CH carbons, respectively), as well as four aromatic signals between δ 120.2144.1. The protonated molecular ion ([M + H]+) of 263 was assigned to the peak at m/z
838.0 in the ESIMS.
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4.3.4 Synthesis of the tetrapeptides 266-268 and the Fmoc deprotected
tetrapeptides 269-271
The tetrapeptides 266-268 were prepared in 71-82% yields, by the coupling reactions of
263-265 with Fmoc-Gly-OH. Subsequent deprotection of their Fmoc groups resulted in
the compounds 269-271, respectively in yields of 80-88% yield.

Scheme 4.11: Reagents and conditions: (a) Fmoc-Gly-OH, EDCI, HOBt, CH2Cl2, rt, 4 h, 75% for 266,
71% for 267 and 82% for 268; (b) piperidine, CH3CN, rt, 4 h, 80% for 269, 88% for 270, and 86% for
271.

A broad singlet at δ 6.29 (-CHNH2) in the 1H NMR spectrum of 263 was no longer
observed in the spectrum of 266 but a signal appeared at δ 4.58 (1H, m), which was
assigned to the lysine α-methine proton. This evidence indicated that the α-proton,
adjacent to the primary amine in precursor 263, experienced a downfield shift as a result
of the newly installed amide bond. Additionally, the 1H NMR signal at δ 12.50 for the
acid –OH of Fmoc-Gly-OH had disappeared in the spectrum of compound 266. Further
to this the

13

C NMR signal at δ 172.9 was assigned to the new amide carbonyl group.

The molecular structure of the product was also supported by the appearance of the peak
at m/z 1117.6 in the ESIMS, that was assigned to the protonated molecular ion, [M +
H]+.
Analysis of the 1H NMR spectrum of amine 269 provided clear evidence for Fmoc
deprotection as there was a notable absence of signals at δ 4.17 (t, J = 6.5 Hz, 1H) and
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4.33 (d, J = 7.0 Hz, 2H) that were present in the spectrum of compound 266 and had
been assigned to the three non-aromatic Fmoc protons (i.e. -OCH2-CH-Ar).
Furthermore, a clear absence of two distinct doublet resonances at δ 7.57 (d, J = 6.5 Hz,
2H) and δ 7.73 (d, J = 8.0 Hz, 2H) in the spectrum of 269, which were present in the
spectrum of 266, and assigned as aromatic Fmoc protons. This indicated the successful
removal of the fluorenyl moiety and its eight aromatic protons. Analysis of the

13

C

NMR data of compound 269 was also conclusive by the absence of characteristic
signals of deshielded methylene carbon at δ 67.4 and a methine carbon at δ 47.3
(assigned as the Fmoc CH2 and CH carbons, respectively), as well as four aromatic
signals between δ 121.9-144.3. The protonated molecular ion ([M + H]+) was assigned
to the peak at m/z 895.6 in the ESIMS of 269 (Scheme 4.11).

4.3.5 Synthesis of the [60]fullereno tetra and pentapeptides 272-275
and their salts 276-279
The protected fullerenyl peptoids 272-275 (Scheme 4.12) were successfully synthesised
by coupling [60]fullerenyldihydropyrrole acid 198 with the presynthesised peptides
269, 264, 270 and 271 under EDCI/HOBt peptide coupling conditions. In a typical
example, the tetrapeptide 269 was added dropwise to a solution of acid 198 and HOBt
in CH2Cl2, which was sonicated for 15 min. to aid solubility. EDCI was added at the
same temperature and the reaction mixture was stirred for 4 h at room temperature. As
the reaction progressed, the turbid solution transformed to a clear brown solution and
upon workup, and the first-in-class [60]fullerenyl anchored tetrapeptide 272 was
isolated. Synthesis of compound 273 was possible by coupling of the oxazole
terminated tripeptide 264, and the tetrapeptide version of 270, with the extra glycine
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amino acid in to the peptide chain producing 274. Coupling the acid 198 with peptide
271, which contained two Boc protected lysines with an oxazole terminus, yielded 275.
This reaction used CHCl3:CH2Cl2 (1:1) as a solvent due to better solubility of the diBoc
protected lysine containing peptide whereas the synthesis of compounds 273 and 274
only required CH2Cl2 as the single solvent (Scheme 4.12).
To improve the solubility of the [60]fullerene based peptides for antibacterial testing, it
was necessary to use them as dicationic salts, which were prepared using either TFA
and/or 1 M HCl in diethyl ether. Peptides 273 and 274 were made as the HCl salts 277
and 278, respectively, by treating them with TFA/CH2Cl2 (1:1) to deprotect the Pmc/Pbf
and N-Boc functional groups. Then, after removing the solvents under reduced pressure,
the residue was resuspended in a minimal volume of CH2Cl2 and treated with an excess
1 M HCl in diethyl ether to obtain the targeted HCl salts. The peptides 272 and 275
were made as their TFA salts 276 and 279 by treating them with TFA/CH2Cl2 (1:1) to
deprotect the Pmc/Pbf and N-Boc groups (Scheme 4.12).
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Scheme 4.12: Synthesis of C60 fullerenyl anchored amino acid oxazoles and iso pentyl esters. Reagents
and conditions: (a) EDCI, HOBt, CH2Cl2, rt, 4 h; (b) TFA/ CH2Cl2 (1:1), rt, 16 h; (c) 1 M HCl.Et2O, 0-rt
0.5 h.

A broad singlet at δ 7.85 (-CHNH2) in the 1H NMR spectrum of 269 was no longer
observed in the spectrum of 272 but a signal appeared at δ 4.28 (bs, 2H), assigned to the
glycine methylene protons. This evidence indicated that the methylene, adjacent to the
primary amine in precursor 269, experienced a downfield shift as a result of the newly
installed amide bond. Additionally, a 1H NMR signal at δ 8.63 assigned to the acid –OH
proton in [60]fullerenyldihydropyrrole acid 198 was not observed in compound 272.
Further, the

13

C NMR signal at δ 172.9 assigned to the new amide carbonyl group in

272. The molecular structure of the product was verified by the appearance of the peak
at m/z 1856.5916 in HRMS, that was assigned to the sodiated molecular formula ([M +
Na]+, C118H83N9O11SNa) (Scheme 4.12).
The salts 276-279 were characterised by HRMS, and additionally, compounds 276, 277
and 278 returned 1H NMR spectra of good quality, but not the compound 279.
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Unfortunately, due to the limited solubility of these salts, we were unable to obtain
adequate 13C NMR spectra.
The 1H NMR spectrum of the compound 276 lacked the prominent 9H peak at δ 1.42
that was present in the spectrum of carbamate 272 and was assigned to the tert-butyl
methyl protons. Furthermore, multiple diagnostic signals observed at δ 1.46, 2.08, 2.50,
2.57 and 2.95 assigned to the Pbf protecting group of carbamate 272, were not observed
in the 1H NMR spectrum of the final compound 276, indicating the successful removal
of the Boc protecting group as well as Pbf group. HRMS analysis of compound 276
showed a peak at m/z 1482.4717 that was assigned to the protonated molecular ion ([M
+ H]+, C100H59N9O6).

4.3.6 [60]Fullerenyl bispeptides
Focus was then shifted to extending the carboxyl deprotection and coupling reactions,
established on the mono-adducts (Section 4.3.1), to bisadducts (Scheme 4.13).
Therefore, the synthesis of the tethered bisadduct 283 was performed using the
previously reported procedures.33,160 Hydrolysis of ester group on the tethered bisadduct
283 and subsequent amide coupling reaction with presynthesised peptide 262, was
anticipated to give the first target bispeptide 285.
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Scheme 4.13 Retrosynthetic analysis for the synthesis of [60]fullereno bispeptide of type 285 from the
known diphenylfullerenyldihydropyrrole bisacid 284, and peptide 262.

4.3.7 Regioisomerism
In the formation of bis-methanofulleryl adducts, there are nine possible addition sites
for functionalisation, assuming the reaction occurs across 6,6-fused bonds (Figure
4.2).161,162,163,164,165,166,167,168,169,170,171,172,173,174 The basis for the positional algorithm is
the contiguous numbering of carbon atoms of a [60]fullerene derivative in a spiral
fashion.171 If the second addition occurs in the same hemisphere as the first, it is
assigned the cis regiochemistry with the numbering scheme (cis-1, cis-2, cis-3)
increasing as the second addend retreats from the first site of addition.

Trans

regioisomers occur in the opposing hemisphere with the numbering scheme (trans-1,
trans-2, trans-3, trans-4) increasing as the second addend approaches the first site of
addition (Figure 4.2) (Table 4.1).
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cis-1 (CS)

cis-2 (CS)
cis-3 (C2)
e-edge (Cs)
trans-4 (CS)
trans-3 (C2)

e-face (Cs)

trans-2 (C2)

trans-1 (D2h)
Figure 4.2: Positional notation and symmetry operations for regioisomeric methanofullerene
bisadducts.165

No of Fulleryl 13C NMR
No of 1/2 Intensity 13C NMR
Symmetry
Resonances
Resonances
Operation
cis-1
32
4
CS
cis-2
32
4
CS
cis-3
30
0
C2
e-face
60
0
CS
e-edge
60
0
CS
trans-1
8
0
D2h
trans-2
30
0
C2
trans-3
30
0
C2
trans-4
32
4
CS
Table 4.1: Summary of regioisomeric assignments for methanofullerene bisadducts, the number of
observed fullerenyl 13C NMR resonances, and corresponding symmetry operations determined from 13C
NMR spectra.
Assignment

4.3.8 Regioselective multifunctionalisation of [60]fullerene using
tethered bis-N-(diphenylmethyleneglycinate) diesters

4.3.8.1

Double Bingel reactions with bis-N-(diphenylmethylene
glycinate) diesters

The previously reported double Bingel reaction of 28233,160 with [60]fullerene was
attempted using carbon tetrabromide (2.0 equiv.) and DBU (3.5 equiv.) (Scheme 4.14).
The reaction mixture was stirred at rt, and typically took 6 h to reach completion.
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Purification and separation of the resulting products 283 and 286 was achieved by
elution of the crude reaction mixture through two silica gel columns with
CH2Cl2:petroleum spirit (90:10) as the eluent. Final recrystallizations of these
regiosiomers yielded pure samples of 283 and 286 in 36% and 12%, yields,
respectively. The ESIMS spectrum of both 283 and 286 displayed a molecular ion at
m/z 1298.

Scheme 4.14 (a) DBU, CBr4, rt, toluene, C60, 6 h, 45%.

The 1H NMR spectra of 283 and 286 revealed the loss of the methylene resonance (δ
3.17) associated with the N-(diphenylmethyleneglycinate) ester (282) as a result of
Bingel reaction.

Tether macrocyclisation induced the benzyl protons to become

diastereotopic and these appeared as doublets [δ 5.06 and 5.71; J = 11.2 Hz for 283; δ
5.32 and δ 5.41; J = 11.0 Hz for 286] in contrast to the singlet resonance (δ 5.09) of the
starting material (282).
The aromatic region of these bisfullerene derivatives exhibited a doubling up of
resonances as a result of macrocyclisation. As with the monosubstituted derivatives, the
ortho protons (Ha) exhibit a characteristic downfield shift [(δ 7.92, 2H, d, J = 8.4 Hz
and δ 8.04, 2H, d, J = 8.4 Hz for 283; δ 8.17, 2H, d, J = 7.6 Hz, δ 8.21, 2H, d, J = 7.6
Hz for 286] compared to those corresponding protons in the starting material [282, (δ
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7.64, 4H, dd, J = 8.4, 1.6 Hz)]. The 13C NMR spectrum of 283 matched that previously
reported.33,90

4.3.8.2

Diester deprotection of 283 followed by amide coupling to
synthesise [60]fullerenyl bispeptide

We intended to synthesise fulleryl bispeptides by extension of the protocols of carboxyl
deprotection and coupling reactions, established on the mono-adducts (Section 4.2.3), to
bisadducts (Scheme 4.15). Therefore, a solution of 283 in 1,2-DCE was treated with
(CH3)3SnOH at 80 oC for 24 h before being quenched with 5% HCl solution. The
product bisacid 284 was then isolated as a brown solid. The previously reported90 BBr3
mediated diester deprotection of 283 was also performed, but the former conditions
((CH3)3SnOH) resulted in a better yield of 65% compared to that of 58% using BBr3.

Scheme 4.15 (a) (CH3)3SnOH, DCE, 80 oC, 24 h, 65%. (b) BBr3, CH2Cl2, -10 oC - rt, 18 h, 58%. (c)
pyridine/chloroform (1:2), EDCI, HOBt, 8 h, 50%.

Analysis of the 1H NMR spectrum of bisacid 284 indicated the loss of the resonances
attributed to the diastereotopic benzylic protons (δ 5.05 and 5.70). In addition, the
aromatic region of the spectrum contained less peaks, notably the loss of the downfield
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singlet (δ 7.18, 1H, s) assigned as the proton attached to C2 of the aromatic ring of the
tether. In addition, the emergence of a broad singlet at δ 8.71, with a relative integration
of 2H, indicated the presence of the carboxylic acid protons. ESIMS (+ve) analysis of
compound 284 showed peaks at m/z 1195 (40%, [M+H]+) and 1200 (100%, [M+Li]+)
which were assigned as the protonated molecular ion and the lithiated molecular ion,
respectively.
Attempts to synthesize the [60]fullerene bispeptoid 285 using the standard
coupling reaction conditions developed in Section 4.2.5, failed, due to poor solubility of
the bisadduct 284. No progress in the coupling reaction was observed even after longer
reaction times and an increase in reaction temperature to 60 °C. Therefore, a change in
solvent to a 1:2 ratio of pyridine/chloroform was used resulting in a 50% yield of the
desired dipeptide 285 (Scheme 4.15). Unfortunately, attempted deprotection of 285 with
TFA gave an insoluble product that could not be characterized.
Confirmation of the structure of the bispeptide 285 was provided by analysis of
its 1H NMR spectrum. The loss of the broad singlet at δ 8.71 (bs, 2H) corresponding to
the carboxylic acid protons of 284 and the appearance of a broad 2H multiplet at δ 7.08,
assigned to the amide protons of 285, indicating that the dipeptide had been formed.
Furthermore, compound 285 showed a singlet (18H) at δ 1.28 ppm, assigned to the two
Boc groups attached to the lysine side chains. The presence of a single peak for these
two groups indicates that both peptide side chains are in an equivalent environment and
this is consistent with the expected Cs symmetry of the trans-4 disubstituted [60]fullerene (Table 4.1).175 The presence of 30 sp2 resonances and 2 sp3 resonances (32
signals in total) further confirms this symmetry. Analysis of the HRMS of 285 indicated
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a peak at m/z 2884.1675, which was assigned to the sodiated species of 285,
C174H164N16O20S2Na.

4.3.9 Solubility and Antimicrobial Testing
The solubilities of the dicationic salts 247, 276-279 in DMSO/H2O were determined
(Table 4.2); they had relatively poor solubilities ranging from 70-350 μg/mL
Table 4.2. Solubility of deprotected salts in DMSO/H 2O
Compound

247

276

277

278

279

Solubility
in

5% DMSO
in H2O

5% DMSO in
H2O

5% DMSO in
H2O

5% DMSO in
H 2O

5% DMSO in
H2O

DMSO/H2O

(270 μg/mL)

(135 μg/mL)

(350 μg/mL)

(145 μg/mL)

(70 μg/mL)

number

As an initial screen for biological activity, the [60]fullerenyl peptides 243, 245, 272-275
and 285 and the dicationic salts 247, 276-279 were subjected to in vitro antibacterial
testing (Table 4.3) under the supervision of Prof. Thomas Riley at the University of
Western Australia. These twelve [60]fullerene derivatives were tested using the broth
microdilution method against Staphylococcus aureus NCTC 6571 and Escherichia coli
ATCC 10418 with positive controls for E. coli NCTC 10418 being Kanamycin (4
µg/mL) and chloramphenicol (2 µg/mL) while the positive controls used for S. aureus
NCTC 6571 were Kanamycin (4 µg/mL) and Vancomycin (1 µg/mL). Unfortunately all
fullerenyl-based compounds were inactive, even at higher concentrations, with
minimum inhibitory concentrations (MICs) greater than 100 to 340 (µg/mL), which
correlated well with their solubilities.
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Table 4.3. Microdilution testing of fullerene compounds

Compound

Highest test
Concentration
(µg/mL) *

272
273
274
275
285
243
245
276
277
278
279
247

210
340
135
135
100
315
190
165
155
100
210
210

MIC
S. aureus
NCTC 6571
> 210
> 340
> 135
> 135
> 100
> 315
> 190
> 165
> 155
> 100
> 210
> 210

E. coli
ATCC 10418
> 210
> 340
> 135
> 135
> 100
> 315
> 190
> 165
> 155
> 100
> 210
> 210

* Concentration may be an overestimation as compounds were not fully solubilised in DMSO at the
highest test concentration, with the exception of compounds 247 and 279.

4.3.10 Future directions and conclusions
The synthesis of peptides anchored by [60]fullerenes was successful with a series
of monosubstituted and disubstituted fullerene derivatives being realised. Although
these derivatives did not show any substantial anti-bacterial activity, their synthesis has
progressed the development of the important field of fullerenyl amino acids and peptide
derivatives, in particular, their synthesis and isolation as peptide salts. This is
highlighted by the modest solubility of the deprotected compounds in DMSO/water
(Table 4.2) and the relative ease of purification of the protected fullerenyl peptides by
column chromatography. Further, these fullerenyl amino acids have a more rigid, and
thus more defined, tethered structure than most other fullerenyl peptides reported, which
traditionally employ a flexible fullerene-peptide linkers. These more rigid properties
could become increasingly important in the fields of medicinal chemistry or materials
science.
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This work can be applied to the potential synthesis of other bisadducts of the type 285,
and trisadducts as well as their corresponding salts for the better aqueous solubility.
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Conclusions and Future Directions
This thesis has demonstrated the successful synthesis of [60]fullerenyl based
peptides and oligomers (Chapters 2 and 3) that may have potential solar cell
applications. We also demonstrated the synthesis and biological screening of dicationic
peptoids (Chapter 4) as possible antibacterial agents.
Chapter 2 has demonstrated the synthesis of the novel [60]fullerene monopeptide 201
and dipeptide 204 (Figure 5.1). [60]Fullerenoproline acid 198 was coupled to lysine
amine 200 to yield the monopeptide 201, which was deprotected to its amine salt 202
using TFA and to its acid derivative 203 with Sn(CH3)3OH. An amide coupling reaction
of the amine 202 and the acid 203 resulted in the dipeptide 204. Monopeptide 201 and
the dipeptide 204 have been studied experimentally using spectroelectrochemical
measurements with collaborators Prof. Timothy Clark and Prof. Dirk M. Guldi at the
University of Erlangen-Nuremberg, Germany. The bis-fullerene-substituted peptide 204
provided experimental support for density-functional theory (DFT) calculations which
indicate that van der Waals fullerene dimers can form between adjacent fullerenes in
semiconductor layers resulting in interstitial electron traps.142
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Figure 5.1: Structures of monopeptide 201 and dipeptide 204

With the aim of preparing the tetrapeptide 207 (Figure 5.2), the dipeptide 204 was
separately deprotected to the amine 205 and the acid 206. A range of amide coupling
reaction conditions were employed to couple these two components. These reactions
were not successful in providing a pure sample of the tetrapeptide 207. This material
was difficult to purify and analyse because of its poor solubility properties.

Figure 5.2: Structures of tetrapeptide 207

An alternative synthesis of the tetrapeptide 207 was examined. The lysine tetrapeptide
216 and its tetramine 217 (Figure 5.3) were successfully synthesised. Attempts to
couple 217 with [60]fullerenoproline acid 198 to produce tetrapeptide 207 were also
unsuccessful, possibly due to steric hindrance problems because of the sterically
demanding fullerene groups.
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Figure 5.3: Structures of lysine tetrapeptide 216 and its tetramine 217

Accordingly, it was postulated that the cyclic peptide tetrapeptide 220 (Figure 5.4)
might help to solve these steric hindrance problems. Tetrapeptide 216 was successfully
converted to the novel cyclic peptide 220 in three synthetic steps. However this route
was not pursued because of the poor chemical yields and the difficulties with purifying
220.

Figure 5.4: Structures of cyclictetrapeptide 220

Chapter 3 reported an extension of [60]fullerenyl oligomers with the incorporation of
spacers between the fullerenyl groups. Two types of amino acid spacers (L-lysine and
L-phenylalanine) were introduced in to the oligomers (hexapeptide 227 and hexapeptide
238, Figure 5.5). The synthesis of tripeptides with L-lysine spacers, 224, and Lphenylalanine spacers 235 were achieved by coupling the acid 203 with the amine 213
and the amine 202 with the acid 234, respectively. The previously used ester and N-Boc
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cleavage conditions were adopted to synthesise the corresponding acids (225 and 236)
and amines (226 and 237) of 224 and 235 followed by amide couplings to provide the
hexapeptides of 227 and 238. Currently, these molecules are under study to form
supramolecular complexes between [60]fullerene and porphyrin, and photoinduced
charge separation experiments in Prof. Fukuzumi’s laboratory at Osaka University,
Japan.

Figure 5.5: Structures of tripeptides 224 and 235, and hexapeptides 227 and 238
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Chapter 4 reported the synthesis and antibacterial screening of mono substituted
[60]fullerenyl peptides (243, 245, 247, 272-279, Figure 5.6) and bis-[60]fullerenyl
peptide (285). A range of tri, tetra and pentapeptides having an oxazole or isopentyl
ester terminal group were synthesised. These peptides were then deprotected to form
their HCl and TFA salts 247, 276-279. Antibacterial screening of these peptides (243,
245, 247, 272-279 and 285) was performed at the University of Western Australia in
Prof. Thomas Riley’s laboratory, unfortunately, none of these compounds showed
significant activity.
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Figure 5.6: Structures of [60]fullerene-peptides 245, 247, 272-279 and 285
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In future work, a cyclic peptide synthetic route leading to the synthesis of compound
222 (Scheme 2.15, Chapter 2) followed by ring opening metathesis could be pursued
depending on the availability of the starting material to achieve the tetrapeptide 207 in
pure form.
Density functional theory calculations indicate that van der Waals fullerene dimers and
larger oligomers can form interstitial electron traps in which the electrons are even more
strongly bound than in isolated fullerene radical anions. Spectroelectrochemical
measurements on the bis-fullerene-substituted peptide 204 provide experimental
support. In the future, larger oligomers, including tetrapeptides 207, 227 and 238, could
be studied for their spectroelectrochemical properties and these could possibly show
better efficiencies as electron traps.
Currently, studies on the formation of supramolecular complexes between our
[60]fullerene-peptides (227 and 238) and porphyrin are going on in Prof. Fukuzumi’s
laboratory at Osaka University, Japan. Based on the pending results, other spacers
(Chapter 3) could be incorporated in to the [60]fullerene oligomer to which have less
steric hindrance and are viable to synthesise in pure form to enhance the desired
complexation and photoinduced charge separation properties.
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Scheme 5.1: Proposed synthetic strategy to achieve tetrapeptide 207 from the cyclic tetrapeptide 222.

There is wide scope for the synthesis of a variety of peptides or peptidomimetic
replacements to incorporate in to the [60]fullerene to form more water soluble peptoids
(Chapter 4) of the type 286 and 287 (Figure 5.7), hopefully leading to increased
antibacterial activities. Expansion of substitution on to the [60]fullerene to form tris
adducts 288 can also be considered for the better solubility and biological activity.
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Figure 5.7: Structures of extended water soluble group incorporation in to the [60]fullerene mono, bis
and tris peptides.

Reductive ring opening of compounds 286, 287 and 288 followed by peptide coupling
could provide ring-opened fullerenyl derivative 289, 290 and 291 (Scheme 5.2), which
are consider to be true fullerenyl “capped” amino acids and could potentially provide
better water solubilities and biological activities.
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Scheme 5.2: Proposed synthetic strategy of mono, bis and tris ring opened [60]fullerenyl “capped”
peptides 289, 290 and 291.
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6.1

General Experimental Procedures

Reagents and solvents were purchased reagent-grade and used without further
purification. Toluene and THF were distilled from sodium benzophenone ketyl under a
nitrogen atmosphere. CH2Cl2 was stored over CaCl2 and distilled from CaH2. MeCN
was distilled from potassium carbonate. [60]Fullerene was purchased from MER
Corporation Tucson, Arizona AZ 85706, USA. All reactions were performed in
standard glassware under an atmosphere of nitrogen unless otherwise specified.
Microwave reactions were performed using a Discover CEM Focused Microwave
Synthesis System in 10 mL closed vessels. Flash column chromatography was
performed using silica 60 (230-400 mesh, 0.040-0.063 mm) purchased from Merck.
Petroleum spirit refers to a hydrocarbon fraction with a boiling point of 40-60 oC. The
mass spectra of a fullerenyl derivatives were run on a Thermo Finnigan LTQ (Waltham,
MA) fitted with a conventional IonMax electrospray ionization source. Spectra were
obtained by infusion of a standard solution in CHCl3/MeOH (2:1). Typical settings were
spray voltages between 4 – 6 kV, capillary temperature 270 oC and sheath gas flow rates
at 10 (arbitrary units). High resolution mass spectra were obtained using a QTOF mass
spectrometer.

1

H NMR spectra were acquired on a Varian Unity 300 or 500

spectrometer at 300.1 and 499.9 MHz, respectively. 13C NMR spectra were acquired on
Varian Unity 300 or 500 spectrometer at 75.4 and 125.0 MHz, respectively. Deuterated
solvents CDCl3, CD3OD, (CD3)3SO were obtained commercially (Sigma-Aldrich or
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Cambridge) and were greater than 99.5 atom % d. All chemical shifts are reported
relative to TMS (δ 0.00).
1

H NMR spectral data are listed in the following order, chemical shift, multiplicity,

integration, J value, and assignment. All fullerenyl carbon signals were reported as
either a full resonance, (e.g. 148.0), or as a half-intensity peak denoted by a * or as an
integer of a full resonance when there is peak overlap (e.g. 148.0, (2 x C)). When a
reference is provided in the compound title it signifies that this reference procedure was
used. Conversely, when a reference is provided with NMR spectroscopic data it
signifies that our data is in agreement with those already reported using a different
procedure.
Melting points (m.p.) were determined using a Gallenkamp (Griffin) melting point
apparatus. Temperatures are expressed in degrees Celsius (°C) and are uncorrected.
Optical rotations were measured using a Jasco polarimeter with a 10 mm path length
and a wavelength of 589 nm. Concentrations are expressed as c (10 mg/mL). Infrared
(IR) spectra were recorded using neat samples on a Nicolet Avatar 360 FT-IR
spectrometer fitted with a Smart Omni-Sampler germanium crystal accessory.
Protocol 1: Peptide coupling
To a solution of the acid in CH2Cl2 (10 mL/0.10 mmol) at rt was added EDCI (1.2
equiv.), HOBt (1.2 equiv.), and the amine (1 equiv.). If the amine was a hydrochloride
or TFA salt, Et3N (1.2 equiv.) was also added. After stirring for 3-6 h, the solvent was
removed under reduced pressure, and then the resulting residue was subjected to silica
gel column chromatography MeOH/CH2Cl2 (0.5:99.5-1:99 for peptides and 1:49-1:4 for
C60 attached peptides) as the eluent to afford the coupled product.
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Protocol 2: N-Fmoc deprotection
The Fmoc-protected amine was stirred in 1 equiv. of piperidine/acetonitrile (5 mL/0.10
mmol) overnight at rt, unless otherwise stated. The solvent was removed under reduced
pressure and the residue was subjected to column chromatography, using
MeOH/CH2Cl2 (1:19) to yield the free amine.
Protocol 3: N-Boc, Pbf and Pmc deprotection
The N-Boc, Pbf or Pmc protected amine was stirred for 4 h (for Boc) or overnight (for
Pbf and Pmc) in 1:1 CH2Cl2/TFA (6 mL/0.10 mmol) solution at rt. The solvent was
removed under reduced pressure, and the residue was resuspended in a minimal volume
of CH2Cl2. The solution was then treated with an excess amount of 1 M HCl/diethyl
ether (2 mL/0.01 mmol) solution and the solvent evaporated. The product was obtained
by precipitation from CH2Cl2, with hexane and/or diethyl ether.
Protocol 4: Allyl and bis-1,3-benzyl ester hydrolysis
To a solution of the ester in 1,2-dichloroethane (100 mL/0.10 mmol) at rt was added
Sn(CH3)3OH (4 equiv.) and the solution was heated at 80 oC for 4 h, then further
Sn(CH3)3OH (4 equiv.) was added at the same temperature and the reaction was
continued for 4 h. The reaction mixture was evaporated under reduced pressure and the
resulting residue was taken up in CH2Cl2 (15-20 mL). The organic layer was washed
with 5% HCl (3 x 10-15 mL), brine (3 x 10 mL) dried (Mg2SO4) and evaporated under
reduced pressure to yield the corresponding acid.
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(S)-Allyl6-(9H-fluoren-9-yl)methoxycarbonylamino-2-(tert-butoxycarbonyl)
aminohexanoate (199)
To

a

suspension

of

N6-(((9H-fluoren-9-

yl)methoxy)carbonyl)-N2-(tert-butoxycarbonyl)-L-lysine
(1.20 g, 2.56 mmol) in CH2Cl2 (50 mL) was added HOBt
(0.415 g, 3.07 mmol) and EDCI (0.587 g, 3.07 mmol) and
the mixture was stirred for 15 min before a solution of allyl
alcohol (1.74 mL, 25.6 mmol) in CH2Cl2 (10 mL) was added dropwise. The resulting
solution was stirred at rt for 14 h before the solvent was removed under reduced
pressure. The crude residue was then subjected to flash silica gel chromatography,
gradient elution with EtOAc/hexane (1:9 to 1:1) provided the title compound 199 as a
colourless solid (0.954 g, 73%). m.p: 118-120 °C; [α]25
D -32.8 (c 4.16, CHCl3); IR (neat,
cm-1): 3331 (w), 1722 (s), 1679 (s), 1530 (s); 1H NMR (500 MHz, CDCl3): δ 1.39-1.40
(m, 2H, CHCH2CH2), 1.44 (s, 9H, Boc), 1.49-1.56 (m, 2H, CH2CH2NH), 1.62-1.70 (m,
1H, CHCHHCH2), 1.80-1.84 (m, 1H, CHCHHCH2), 3.18-3.19 (m, 2H, CH2N (Lys)),
4.21 (t, J = 6.3 Hz, 1H, CH (Fmoc)), 4.32 (bs, 1H, Lys-α-proton), 4.40 (d, J = 6.3 Hz,
2H, OCH2 (Fmoc)), 4.61-4.64 (m, 2H, OCH2), 4.81 (bs, 1H, NHBoc), 5.04 (bs, 1H,
NHFmoc), 5.25 (d, J = 10.5 Hz, 1H,

CH=CH(Z)H), 5.32 (d, J = 17.5 Hz, 1H,

CH=CH(E)H), 5.89-5.90 (m, 1H, CH=CH2), 7.31 (t, J = 7.0 Hz, 2H, ArCH), 7.39 (t, J =
7.5 Hz, 2H, ArCH), 7.59 (d, J = 7.5 Hz, 2H, ArCH), 7.76 (d, J = 7.5 Hz, 2H, ArCH);
13

C NMR (CDCl3, 125 MHz): δ 22.8 (CHCH2CH2), 28.2 (C(CH3)3), 29.0 (CH2CH2NH),

32.4 (CHCH2CH2), 39.8 (CH2NH), 47.2 (CH (Fmoc)), 53.2 (COCHNH), 65.8
(CH2CH=CH2), 66.5 (CH2 (Fmoc)), 79.9 (C(CH3)3), 118.9 (CH=CH2), 120.3 (2 x
ArCH), 125.1 (2 x ArCH), 128.4 (2 x ArCH), 129.7 (2 x ArCH), 131.5 (CH=CH2),
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141.3 (2 x ArC), 142.5 (2 x ArC), 156.2 (CO (Boc)); 162.1 (CONH), 172.3 (CO, ester);
HRMS (ESI +ve) calcd for C29H36N2O6Na, 531.2471, found 531.2446.
(S)-Allyl 6-amino-2-(tert-butoxycarbonyl)aminohexanoate (200)
To

a

suspension

of

allyl

N6-(((9H-fluoren-9-

yl)methoxy)carbonyl)-N2-(tert-butoxycarbonyl)-L-lysinate

199

(0.52 g, 1.02 mmol) in acetonitrile (30 mL) was added piperidine
(0.072 mL, 1.22 mmol) and the mixture was stirred at rt for 14 h before the solvent was
removed under reduced pressure. The residue (0.292 g, 100%) was then taken through
the next reaction without further purification. ESI-MS (+ve): m/z 287 (100%, M+H+).
(S)-Allyl-6-(5,5-diphenylfullerenyldihydropyrrole-2-carbonylamino)-2-(tertbutoxycarbonyl)aminohexanoate (201)
This compound was prepared via protocol 1 using 5,5diphenylfullerenyldihydropyrrole-2-carboxylic

acid

198

(0.180 g, 0.187 mmol) and (S)-allyl 6-amino-2-(tertbutoxycarbonyl)aminohexanoate 200 (0.064 g, 0.224 mmol)
to yield the title compound 201 as a brown solid (0.142 g,
62%). 1H NMR (500 MHz, CDCl3): δ 1.23-1.25 (m, 2H, CHCH2CH2), 1.44 (s, 9H,
Boc), 1.48-1.58 (m, 2H, CH2CH2NH), 1.68-1.82 (m, 2H, CHCH2CH2), 3.52-3.58 (m,
2H, CH2N (Lys)), 4.36 (bs, 1H, Lys-α-proton), 4.58-4.64 (m, 2H, OCH2), 5.04 (bs, 1H,
NHBoc), 5.28 (d, J = 10.0 Hz, 1H, CH=CH(Z)H), 5.30 (d, J = 17.0 Hz, 1H,
CH=CH(E)H), 5.84-5.94 (m, 1H, CH=CH2), 7.42 (t, J = 7.5 Hz, 2H, ArCH), 7.53 (t, J =
7.5 Hz, 4H, ArCH); 7.88 (bs, 1H, NH), 8.43 (d, J = 7.5 Hz, 4H, ArCH);

13

C NMR

(CDCl3, 125 MHz): δ 22.8 (CHCH2CH2), 28.2 (C(CH3)3), 29.0 (CH2CH2NH), 32.4

139

Chapter 6

Experimental

(CHCH2CH2), 39.8 (CH2NH), 53.2 (NHCHCO), 65.8 (OCH2), 79.9 (C(CH3)3), 82.2*
(C60sp3), 83.3* (C60sp3), 95.3 (CPh2), 118.9 (CH=CH2), 128.4 (2 x ArCH), 129.7
(ArCH), 131.5 (CH=CH2), 134.7 (ArC), [136.5, 139.0, 139.5, 140.8, 141.2, 141.7,
141.76, 141.8, 142.3, 142.5, 142.6, 142.7, 142.9, 144.0, 144.3, 144.8, 145.0, 145.1,
145.3 (2 x C), 145.4, 145.7, 145.9, 146.0, 146.3, 146.8*, 147.0*, 148.5, 149.1, 153.1
(C60sp2)]; 155.3 (C=N), 161.2 (CO, Boc); 162.1 (CONH), 172.3 (CO, ester); HRMS
(ESI +ve) calcd for C89H35N3O5Na, 1248.2474, found 1248.2494.
(S)-6-(5,5-Diphenylfullerenyldihydropyrrole-2-carbonylamino)-1-(allyloxy)-1oxohexan-2-aminium 2,2,2-trifluoroacetate (202)
This compound was prepared via protocol 3, using 201
(0.10 g, 0.081 mmol) to afford the title compound 202
(0.082 g, 90%) as a fine brown solid. 1H NMR (CDCl3,
500 MHz): δ 1.25-1.28 (m, 2H, CHCH2CH2), 1.46-1.62
(m, 2H, CH2CH2NH), 1.78-1.82 (m, 2H, CHCH2CH2),
3.45-3.56 (m, 2H, CH2N (Lys)), 4.06 (bs, 1H, Lys-αproton), 4.62 (bs, 2H, OCH2), 5.25-5.38 (m, 2H, CH=CH2), 5.80-5.92 (m, 1H,
CH=CH2), 7.40 (t, J = 7.5 Hz, 2H, ArCH), 7.51 (t, J = 7.5 Hz, 4H, ArCH), 7.84 (bs, 1H,
NH), 8.02 (d, J = 7.5 Hz, 4H, ArCH); ESI-MS (+ve): m/z 1126 (100%, M+H+). This
compound was not sufficiently soluble to generate an adequate 13C NMR spectrum.
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(S)-6-(5,5-Diphenylfullerenyldihydropyrrole-2-carbonylamino)-2-(tert-butoxy
carbonyl)aminohexanoic acid (203)
The titled compound was prepared via protocol 4 using
201 (0.080 g, 0.065 mmol), 1,2-dichloroethane (80 mL)
and (CH3)3SnOH (0.047 g, 0.260 mmol x 2) to yield the
title 203 as a brown solid (0.068 g, 88%). 1H NMR (500
MHz, CDCl3): δ 1.23-1.25 (m, 2H, CHCH2CH2), 1.45 (s,
9H, Boc), 1.49-1.59 (m, 2H, CH2CH2NH), 1.66-1.82 (m,
2H, CHCH2CH2), 3.50-3.60 (m, 2H, CH2N (Lys)), 4.38 (bs, 1H, Lys-α-proton), 5.02
(bs, 1H, NHBoc), 7.40 (t, J = 7.5 Hz, 2H, ArCH), 7.56 (t, J = 7.5 Hz, 4H, ArCH); 7.88
(bs, 1H, NH), 8.02 (d, J = 7.5 Hz, 4H, ArCH); HRMS (ESI +ve) calcd for
C86H31N3O5Na, 1208.2161, found 1208.2145. This compound was not sufficiently
soluble to generate an adequate 13C NMR spectrum.
(S)-Allyl-6-((5,5-diphenylfullerenyldihydropyrrole-2-carbonyl)amino)-2-(S)-6-(5,5diphenylfullerenyldihydropyrrole-2-carbonylamino)-2-(tert-butoxycarbonyl)
aminohexanamido)hexanoate (204)
This compound was prepared via protocol
1, using 202 (0.056 g, 0.047 mmol) and 203
(0.053 g, 0.047 mmol) 0.056 mmol) to yield
the title compound as a brown solid (0.062
g, 57%). 1H NMR (500 MHz, CDCl3): δ
1.08-1.18 (m, 2H, CHCH2CH2), 1.20-1.30
(m, 2H, CHCH2CH2), 1.45 (s, 9H, Boc), 1.48-1.58 (m, 4H, CH2CH2NH), 1.60-1.98 (m,
4H, CHCH2CH2), 3.40-3.58 (m, 4H, CH2N (Lys)), 4.06 (bs, 1H, Lys-α-proton), 4.58141
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4.68 (m, 3H, OCH2 and Lys-α-proton), 5.04 (bs, 1H, NHBoc), 5.28 (d, J = 10.5 Hz, 1H,
CH=CH(Z)H), 5.30 (d, J = 17.0 Hz, 1H, CH=CH(E)H), 5.82-5.94 (m, 1H, CH=CH2),
6.68 (bs, 1H, NH), 7.40 (t, J = 7.5 Hz, 4H, ArCH), 7.48-7.58 (m, 8H, ArCH); 7.80-7.98
(m, 2H, 2 x NH), 8.08 (d, J = 7.5 Hz, 8H, ArCH); 13C NMR (CDCl3, 125 MHz): δ 22.8
(CHCH2CH2), 23.0 (CHCH2CH2), 28.6 (C(CH3)3), 29.0 (CH2CH2NH), 29.2
(CH2CH2NH), 32.4 (CHCH2CH2), 40.0 (2 x CH2NH), 52.1 (NHCHCO), 66.3 (OCH2),
80.8 (C(CH3)3), 82.5* (C60sp3), 83.6* (C60sp3), 95.6 (CPh2), 119.3 (CH=CH2), 128.7 (2
x ArCH), 130.0 (ArCH), 131.6 (CH=CH2), 135.0 (ArC), [136.6, 139.3, 139.8, 141.1,
141.5, 142.01, 142.04, 142.1, 142.6, 142.7, 142.97, 143.0, 143.1, 144.3, 144.5, 145.0,
145.3, 145.6, 145.7 (2 x C), 146.0, 146.2, 146.3*, 146.5*, 147.1, 147.3, 148.8, 149.4,
149.42, 153.4 (C60sp2)],; 155.3 (C=N), 161.6 (CO, Boc), 161.7 (CONH), 162.7
(CONH), 171.9 (CO, ester); HRMS (ESI +ve) calcd for C170H56N6O7Na, 2315.4108,
found 2315.4114.
(S)-1-(S)-1-Allyloxy-6-(5,5-diphenylfullerenyldihydropyrrole-2-carboxamido)-1oxohexan-2-ylamino)-6-(5,5-diphenylfullerenyldihydropyrrole-2-carboxamido)-1oxohexan-2-ammonium trifluoroacetate (205)
This

compound

was

prepared

via

protocol 3, using 204 (0.025 g, 0.010
mmol) to afford the title compound 205
(0.020 g, 86%) as a amorphous brown
solid. 1H NMR (CDCl3, 500 MHz): δ
1.21-1.35 (m, 4H, CHCH2CH2), 1.581.90 (m, 8H, CH2CH2NH and CHCH2CH2), 3.35-3.58 (m, 6H, 2x CH2N (Lys), 2 x Lysα-proton), 4.60-4.62 (m, 2H, OCH2), 5.28 (d, J = 10.5 Hz, 1H, CH=CH(Z)H), 5.30 (d, J
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= 17.0 Hz, 1H, CH=CH(E)H), 5.82-5.94 (m, 1H, CH=CH2), 7.38-7.58 (m, 4H, ArCH),
7.60-7.68 (m, 8H, ArCH), 7.78-7.98 (m, 2H, NH), 8.02-8.06 (m, 8H, ArCH); HRMS
(ESI +ve) calcd for C165H48N6O5, 2193.3794, found 2193.3764. This compound was not
sufficiently soluble to generate an adequate 13C NMR spectrum.
(S)-6-((5,5-Diphenylfullerenyldihydropyrrole-2-carbonyl)amino)-2-((S)-6-((5,5diphenylfullerenyldihydropyrrole-2-carbonyl)amino)-2-((tertbutoxycarbonyl)amino)hexanamido)hexanoic acid (206)
This compound was prepared via protocol
4, using 204 (0.025 g, 0.010 mmol), 1,2dichloroethane (30 mL) and (CH3)3SnOH
(0.008 g, 0.04 mmol x 2) to yield the title
compound 206 (0.018 g, 75%) as a brown
solid. 1H NMR (500 MHz, CDCl3): δ 1.211.35 (m, 4H, CHCH2CH2), 1.44 (s, 9H, Boc), 1.58-1.90 (m, 8H, CH2CH2NH and
CHCH2CH2), 3.35-3.38 (m, 4H, CH2N (Lys)), 4.08 (bs, 1H, NH), 4.38 (bs, 2H, Lys-αproton), 5.04 (bs, 1H, NHBoc), 7.41-7.42 (m, 4H, ArCH), 7.50-7.53 (m, 8H, ArCH);
7.88 (bs, 1H, NH), 8.02-8.07 (m, 8H, ArCH); ESI-MS (+ve): m/z 2254 (50%, M+H+),
2276 (100%, M+Na). This compound was not sufficiently soluble to generate an
adequate 13C NMR spectrum.
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Allyl (6S,9S,12S,15S)-6,9,12,15-tetrakis(4-(5,5-diphenylfullerenyldihydropyrrole-2carboxamido)butyl)-2,2-dimethyl-4,7,10,13-tetraoxo-3-oxa-5,8,11,14tetraazahexadecane-16-oate (207)
This compound was prepared via protocol 1, using 205 (0.022 g, 0.010 mmol) and 206
(0.021 g, 0.010 mmol) to yield the title compound 207 as a brown solid (0.022 g, 51%).

1

H NMR (500 MHz, CDCl3): δ 1.08-1.18 (m, 4H, CHCH2CH2), 1.22-1.38 (m, 4H,

CHCH2CH2), 1.44 (s, 9H, Boc), 1.48-1.98 (m, 16H, CH2CH2NH and CHCH2CH2),
3.20-3.64 (m, 8H, 4 x CH2N (Lys)), 4.02 (bs, 1H, Lys-α-proton), 4.12 (bs, 1H, Lys-αproton), 4.26 (bs, 1H, Lys-α-proton), 4.56-4.58 (m, 3H, OCH2 and Lys-α-proton), 4.80
(bs, 1H, NH), 4.98 (bs, 2H, NH), 5.25 (d, J = 9.0 Hz, 1H, CH=CH(Z)H), 5.27 (d, J =
17.0 Hz, 1H, CH=CH(E)H), 5.82-5.92 (m, 1H, CH=CH2), 7.32-7.37 (m, 8H, ArCH),
7.48-7.50 (m, 16H, ArCH); 7.80-7.84 (m, 4H, 4 x NH), 8.01 (d, J = 7.5 Hz, 16H,
ArCH); This compound was not sufficiently soluble to generate an adequate

13

C NMR

spectrum and not sufficiently soluble in MeOH to generate an adequate ESI-MS.
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6-(9H-fluoren-9-yl)methoxycarbonylamino-2-(S)-6-(9H-fluoren-9-

ylmethoxycarbonylamino)-2-((tert-butoxycarbonyl)amino)hexanamido) hexanoate
(212)
This compound was prepared via protocol 1
using

allyl

N6-(((9H-fluoren-9-

yl)methoxy)carbonyl)-L-lysinate (500 mg, 1.22
mmol) and Fmoc-(S)-Lys(Boc)-OH (573 mg,
1.22 mmol) to yield the desired product 212 as a
white foam (920 mg, 87%). IR (neat, cm-1): δ
3302 (w), [1665, 1662, 1641, 1558 (s)], 1507, 1198, 1131 (m); 1H NMR (500 MHz,
CDCl3): 1.29-1.39 (m, 4H, CHCH2CH2), 1.42 (s, 9H, Boc), 1.50-1.51 (m, 4H,
CH2CH2NH), 1.62-1.68 (m, 2H, CHCH2CH2), 1.85-1.86 (m, 2H, CHCH2CH2), 3.163.17 (bs, 4H, CH2N (Lys)), 4.12 (bs, 1H, Lys-α-proton), 4.18 (bs, 1H, Lys-α-proton),
4.19-4.20 (m, 2H, 2 x CH (Fmoc)), 4.37 (d, J = 6.5 Hz, 2H, CH2CH (Fmoc)), 4.41 (d, J
= 7.0 Hz, 2H, CH2CH (Fmoc)), 4.57-4.61 (m, 3H, CH2CH=CH2 and NH), 4.97 (bs, 1H,
NH), 5.03 (bs, 1H, NH), 5.22 (d, J = 10.5 Hz, 1H, CH=CH(Z)H), 5.29 (d, J = 17.5 Hz,
1H, CH=CH(E)H), 5.82-5.90 (m, 1H, CH=CH2), 6.75 (bs, 1H, NH), 7.29 (t, J = 7.5 Hz,
4H, ArCH), 7.38 (t, J = 7.5 Hz, 4H, ArCH), 7.57-7.60 (m, 4H, ArCH), 7.75 (d, J = 7.5
Hz, 4H, ArCH). MS (ESI +ve) m/z 881.7 ([M+Na]+, 60%).
(9S,12S)-9-((Allyloxy)carbonyl)-1,20-di-(9H-fluoren-9-yl)-3,11,18-trioxo-2,19dioxa-4,10,17-triazaicosan-12-ammonium trifluoroacetate (213)
This compound was prepared via protocol 3, using 212 (150 mg, 0.174 mmol) to yield
213 as a white foam (110 mg, 90%). IR (neat, cm-1): 3309 (w), [1667, 1662, 1635 (s)],
1194 (m), 1135 (m); 1H NMR (500 MHz, CDCl3): δ 1.34-1.46 (m, 4H, CHCH2CH2),
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1.53 (m, 4H, CH2CH2NH), 1.59 (bs, 2H,
CHCH2CH2), 1.74-1.77 (m, 2H, CHCH2CH2),
3.12 (bs, 1H, Lys-α-proton), 3.18-3.20 (m, 4H,
CH2N (Lys)), 3.43-3.44 (m, 2H, NH2), 4.12 (bs,
1H, Lys-α-proton), 4.20 (t, J = 6.5 Hz, 2H,
CH2CH (Fmoc)), 4.40 (d, J = 6.5 Hz, 4H, 2 x
CH2CH (Fmoc)), 4.57 (bs, 1H, NH), 4.61 (d, J = 5.5 Hz, 2H, CH2CH=CH2), 4.86 (bs,
2H, NH), 5.24 (d, J = 10.5 Hz, 1H,

CH=CH(Z)H), 5.32 (d, J = 17.0 Hz, 1H,

CH=CH(E)H), 5.88-5.94 (m, 1H, CH=CH2), 7.30 (t, J = 7.5 Hz, 4H, ArCH), 7.39 (t, J =
7.5 Hz, 4H, ArCH), 7.58 (d, J = 7.5 Hz, 4H, ArCH); 7.76 (d, J = 7.5 Hz, 4H, ArCH).
MS (ESI +ve) m/z 759 ([M+H]+, 100%).
Allyl

(9S,12S,15S)-12,15-bis(4-(9H-fluoren-9-yl)methoxycarbonylaminobutyl)-9-

(tert-butoxycarbonylamino)-1-(9H-fluoren-9-yl)-3,10,13-trioxo-2-oxa-4,11,14triazahexadecane-16-oate (214)
This compound was prepared via protocol
1,

using

(S)-6-((((9H-fluoren-9-

yl)methoxy)

carbonyl)amino)-2-(tert-

butoxycarbonyl)

amino

hexanoic

acid

(0.150 g, 0.320 mmol) and (9S,12S)-9((allyloxy)carbonyl)-1,20-di-(9H-fluoren-9-yl)-3,11,18-trioxo-2,19-dioxa-4,10,17triazaicosan-12-aminium 2,2,2-trifluoroacetate 213 (0.242 g, 0.320 mmol) to afford the
title compound 214 as a white solid (0.325 g, 83%). m.p: 147-149 ºC; [α]25
D -44.6 (c
3.18, CHCl3); IR (neat, cm-1): 3329 (w), [1719, 1679, 1532 (s)]; 1H NMR (500 MHz,
DMSO-d6): δ 1.18-1.33 (m, 6H, CHCH2CH2), 1.30 (s, 9H, Boc), 1.40-1.48 (m, 6H,
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CH2CH2NH), 1.48-1.68 (m, 6H, CHCH2CH2), 2.88-2.89 (m, 6H, CH2N(Lys)), 3.92 (bs,
1H, NH), 4.14-4.15 (m, 6H, 3 x CH2CH (Fmoc) and 3 x Lys-α-protons), 4.22 (bs, 6H, 3
x CHCH2 (Fmoc)), 4.48 (bs, 2H OCH2), 5.13 (d, J = 10.5 Hz, 1H, CH=CH(Z)H), 5.22
(d, J = 17.0 Hz, 1H, CH=CH(E)H), 5.78-5.82 (m, 1H, CH=CH2), 6.72 (bs, 1H, NH),
6.81 (bs, 1H, NH), 7.18 (t, J = 7.0 Hz, 2H, ArCH), 7.26 (t, J = 7.0 Hz, 6H, ArCH); 7.35
(t, J = 7.0 Hz, 6H, ArCH), 7.58 (bs, 1H, NH), 7.60-7.62 (m, 4H, ArCH), 7.67 (d, J =
8.0 Hz, 1H), 7.82 (d, J = 7.0 Hz, 6H, ArCH), 8.22 (bs, 2H, NH); ESI-MS (+ve): m/z
1231 (100%, M+Na+). This sample turned into a gum over a period of time, so without
measuring the

13

C NMR spectrum, the material was carried forward to the subsequent

reaction.
(9S,12S,15S)-12-(4-(9H-Fluoren-9-yl)methoxycarbonylaminobutyl)-9((allyloxy)carbonyl)-1,23-di(9H-fluoren-9-yl)-3,11,14,21-tetraoxo-2,22-dioxa4,10,13,20-tetraazatricosan-15-ammonium trifluoroacetate (215)
This compound was prepared via
protocol 3, using 214 (0.300 g, 0.248
mmol) to afford the title compound
215 (0.270 g, 98%) as a colourless
solid

initially

which

became

a

gummy mass. This material was taken for the next reaction by characterising only by
mass spectrometry. ESI-MS (+ve): m/z 1109 (100%, M+H+).
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Allyl-(9S,12S,15S,18S)-12,15,18-tris(4-(9H-fluoren-9-yl)methoxycarbonyl

amino

butyl)-9-((tert-butoxycarbonyl)amino)-1-(9H-fluoren-9-yl)-3,10,13,16-tetraoxo-2oxa-4,11,14,17-tetraazanonadecane-19-oate (216)
This

compound

was

prepared via protocol 1,
using

(S)-6-((((9Hfluoren-9-

yl)methoxy)carbonyl)a
mino)-2-(tertbutoxycarbonyl)aminohexanoic acid 210 (0.105 g, 0.225 mmol) and 215 (0.250 g, 0.225
mmol) to afford the title compound 216 as an off white solid (0.249 g, 70%). m.p: 136-1
1
138 ºC; [α]25
H NMR
D -37.2 (c 2.48, CHCl3); IR (neat, cm ): 3330, 1718, 1680, 1537;

(500 MHz, DMSO-d6): δ 1.12-1.30 (m, 8H, CHCH2CH2), 1.29 (s, 9H, Boc), 1.32-1.48
(m, 8H, CH2CH2NH), 1.50-1.68 (m, 8H, CHCH2CH2), 2.88 (bs, 8H, CH2N(Lys)), 3.82
(bs, 1H, NH), 4.12-4.14 (m, 8H, 4 x CH2CH (Fmoc), and 4 x Lys-α- protons), 4.16-4.22
(m, 8H, 4 x CHCH2 (Fmoc)), 4.46 (bs, 2H CH2CH=CH2), 5.11 (d, J = 10.5 Hz, 1H,
CH=CH(Z)H), 5.21 (d, 1H, J = 17.5 Hz, CH=CH(E)H), 5.78-5.82 (m, 1H, CH=CH2),
6.82 (d, 1H, J = 7.5 Hz, NH), 6.81 (bs, 1H, NH), 7.17 (m, 4H, ArCH), 7.25 (t, J = 7.5
Hz, 8H, ArCH); 7.33 (t, J = 7.5 Hz, 8H, ArCH), 7.55 (bs, 1H, NH), 7.60 (d, J = 7.0 Hz,
6H, ArCH), 7.70 (bs, 2H, NH), 7.81 (d, J = 7.5 Hz, 6H, ArCH), 8.18 (bs, 2H, NH); 13C
NMR (125 MHz, DMSO-d6): δ 22.5 (CHCH2CH2), 28.3 (C(CH3)3), 29.0 (CHCH2CH2),
29.3 (CH2CH2NH), 31.6 (CHCH2CH2), 38.4 (4 x CH2NH (Lys)), 47.2 (CH2CH
(Fmoc)), 55.0 (NHCHCO, Lys α carbon), 64.9 (CH2CH=CH2), 65.1 (CH2CH (Fmoc)),
78.2 (C(CH3)3), 109.8, 117.9 (CH=CH2), 120.2 (8 x ArCH), 121.5 (8 x ArCH), 123.3
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(ArCH), 127.4 (8 x ArCH), 129.1 (8 x ArCH), 132.5 (CH=CH2), 137.5 (8 x ArC), 139.5
(4 x ArC), 142.7 (4 x ArC), 152.8 (2 x CONH), 155.5 (CO, Boc), [158.2 (3 x CO),
169.1, 171.8 (CONH)], 172.3 (CO, ester); HRMS (ESI +ve) calcd for C92H102N8O15Na,
1581.7362, found 1581.7362.
Allyl

(6S,9S,12S,15S)-6,9,12,15-tetrakis(4-aminobutyl)-2,2-dimethyl-4,7,10,13-

tetraoxo-3-oxa-5,8,11,14-tetraazahexadecane-16-oate (217)
This

compound

was

prepared via protocol 2,
using 216 (0.050 g, 0.032
mmol) to afford a crude product (0.021 g, 100%), which was then taken through the
next reaction without further purification. ESI-MS (+ve): m/z 671 (100%, M+H+).
(9S,12S,15S,18S)-12,15-Bis(4-(9H-fluoren-9-yl)methoxycarbonylaminobutyl)-9((allyloxy)carbonyl)-1,26-di(9H-fluoren-9-yl)-3,11,14,17,24-pentaoxo-2,25-dioxa4,10,13,16,23-pentaazahexacosan-18-ammonium trifluoroacetate (218)

This compound was prepared via protocol 3, using 216 (0.300 g, 0.248 mmol) to afford
the title compound 218 (0.270 g, 98%) as a gummy mass. This material was carried
forward to the subsequent reaction. ESI-MS (+ve): m/z 1459 (100%, M+H+).
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Allyl

(9S,12S,15S,18S)-12,15,18-tris(4-(9H-fluoren-9-yl)methoxycarbonyl

aminobutyl)-9-acrylamido-1-(9H-fluoren-9-yl)-3,10,13,16-tetraoxo-2-oxa4,11,14,17-tetraazanonadecane-19-oate (219)
This

compound

was

prepared via protocol 1,
using acrylic acid (0.051 g,
0.684 mmol) and 218 (0.250
g, 0.171 mmol) to afford the
title compound 219 as an off
white solid (0.194 g, 75%). 1H NMR (500 MHz, (CDCl3/CD3OD (1:1)): δ 1.26-1.30 (m,
8H, CHCH2CH2), 1.32-1.48 (m, 8H, CH2CH2NH), 1.55-1.82 (m, 8H, CHCH2CH2),
3.11-3.18 (bs, 8H, CH2N(Lys)), 3.60 (bs, 1H, NH), 4.17-4.23 (m, 8H, 4 x CH2CH
(Fmoc) and 4 x Lys-α protons), 4.35 (bs, 2H, CHCH2 (Fmoc)), 4.47 (bs, 6H, CHCH2
(Fmoc)), 4.56 (bs, 2H OCH2), 5.20-5.33 (m, 2H, CH=CH2), 5.63-5.65 (m, 1H,
CH=CH2), 5.81-5.83 (m, 1H, CH=CHH), 6.06-6.20 (m, 1H, CH=CHH), 6.25-6.28 (m,
1H, CH=CHH), 7.28-7.29 (m, 6H, ArCH), 7.36-7.37 (m, 8H, ArCH), 7.39 (d, J = 7.0
Hz, 6H, ArCH), 7.58 (d, J = 7.5 Hz, 6H, ArCH), 7.74 (d, J = 7.5 Hz, 6H, ArCH); 13C
NMR (126 MHz,CDCl3/CD3OD (1:1)): This compound was not sufficiently soluble to
generate an adequate 13C NMR spectrum. ESI-MS (+ve): m/z 1513 (70% M+H+), 1535
(100%, M+Na+).
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Bis((9H-fluoren-9-yl)methyl)-(3R,6R,9R,12R,Z)-6,9-bis(4-(9H-fluoren-9ylmethoxycarbonylaminobutyl)-2,5,8,11,14-pentaoxo-1-oxa-4,7,10,13tetraazacycloheptadec-15-ene-3,12-diyl)bis(butane-4,1-diyl))dicarbamate (220)

A solution of 219 (0.110 g, 0.072 mmol) in CH2Cl2 (100 mL) was heated at reflux then
Grubbs’ II catalyst (0.006 g, 0.0072 mmol) was added in one portion. The colour
became pink then purple and then darkened to orange. The reaction was heated at reflux
for 4 h, after which TLC analysis showed complete consumption of 219. The crude
residue was then subjected to flash silica chromatography, elution with MeOH/CH2Cl2
(1:25) provided the title compound 220 (0.021 g, 19%) as an off white solid. This
compound was not sufficiently soluble to generate an adequate 1H or

13

C NMR

spectrum. ESI-MS (+ve): m/z 1486 (80%, M+H+).
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(6S,9S,12S)-9,12-bis(4-(9H-fluoren-9-yl)methoxycarbonylaminobutyl)-6-(4-

(5,5-diphenylfullerenyldihydropyrrole-2-carboxamido)butyl)-2,2-dimethyl-4,7,10trioxo-3-oxa-5,8,11-triazatridecane-13-oate (224)
This compound was prepared via
protocol 1, using 203 (0.120 g,
0.101 mmol) and 213 (0.076 g,
0.101 mmol) to yield the title
compound 224 as a brown solid
(0.122 g, 62%). 1H NMR (500
MHz, CDCl3): δ 1.34-1.47 (m, 6H, CHCH2CH2), 1.40 (s, 9H, Boc), 1.60-1.75 (m, 6H,
CH2CH2NH), 1.80-1.86 (m, 6H, CHCH2CH2), 3.11-3.18 (m, 5H, 2 x CH2NHFmoc and
Lys-α-proton), 3.47-3.48 (m, 2H, CH2N (Lys)), 4.08-4.20 (m, 3H, CHCH2 and CH2CH
(Fmoc)), 4.37-4.43 (m, 5H, OCH2CH=CH2, CHCH2 (Fmoc), and Lys-α-proton), 4.544.60 (m, 3H, CHCH2 and CH2CH (Fmoc), 5.07 (bs, 1H, NHBoc), 5.22-5.26 (m, 2H,
CH=CH2), 5.82-5.88 (m, 1H, CH=CH2), 6.74-6.82 (m, 2H, NH), 7.28-7.30 (m, 4H,
ArCH), 7.35-7.40 (m, 6H, ArCH); 7.50 (t, J = 7.5 Hz, 4H, ArCH (Fmoc)), 7.57 (t, J =
7.5 Hz, 4H, ArCH (Fmoc)), 7.73 (d, J = 7.0 Hz, 4H, ArCH (Fmoc)), 8.05 (d, J = 7.5
Hz, 4H, ArCH (Fmoc)); HRMS (ESI +ve) calcd for C131H79N7O11Na, 1948.5735, found
1948.5831. This compound was not sufficiently soluble to generate an adequate

13

C

NMR spectrum.
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(6S,9S,12S)-9,12-Bis(4-(9H-fluoren-9-yl)methoxycarbonylaminobutyl)-6-(4-(5,5diphenylfullerenyldihydropyrrole-2-carboxamido)butyl)-2,2-dimethyl-4,7,10trioxo-3-oxa-5,8,11-triazatridecane-13-oic acid (225)
This compound was prepared
via protocol 4, using 224 (0.060
g,

0.031

mmol),

1,2-

dichloroethane (80 mL) and
(CH3)3SnOH (0.024 g, 0.124
mmol x 2) to yield 225 (0.045 g,
77%) as a brown solid. 1H NMR (500 MHz, CDCl3): δ 1.25-1.48 (m, 6H, CHCH2CH2),
1.39 (s, 9H, Boc), 1.70-1.74 (m, 6H, CH2CH2NH), 1.80-1.88 (m, 6H, CHCH2CH2),
3.12-3.16 (m, 5H, 2 x CH2NHFmoc and Lys-α-proton), 3.47 (bs, 2H, CH2N (Lys)),
4.06-4.22 (m, 3H, CHCH2 and CH2CH (Fmoc)), 4.36-4.58 (m, 4H, CHCH2, Lys-αproton and CH2CH (Fmoc)), 4.96-5.18 (m, 2H, NHBoc and Lys-α-proton), 6.60-6.78
(m, 2H, NH), 7.28-7.29 (m, 4H, ArCH), 7.37-7.38 (m, 6H, ArCH); 7.50 (t, J = 7.0 Hz,
4H, ArCH (Fmoc)), 7.58 (bs, 4H, ArCH (Fmoc)), 7.73 (d, J = 6.0 Hz, 4H, ArCH
(Fmoc)), 8.05 (d, J = 8.0 Hz, 4H, ArCH (Fmoc)); HRMS (ESI +ve) calcd for
C128H75N7O11Na, 1909.5455, found 1909.5359. This compound was not sufficiently
soluble to generate an adequate 13C NMR spectrum.
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(9S,12S,15S)-12-(4-(9H-Fluoren-9-yl)methoxycarbonylaminobutyl)-9-((allyloxy)
carbonyl)-21-(5,5-diphenylfullerenyldihydropyrrolyl)-1-(9H-fluoren-9-yl)3,11,14,21-tetraoxo-2-oxa-4,10,13,20-tetraazahenicosan-15-ammonium
trifluoroacetate (226)
This compound was prepared
via protocol 3, using 225
(0.060 g, 0.031 mmol) to
afford the title compound 226
(0.050 g, 89%) as a fine brown
solid.

1

H NMR (500 MHz,

CDCl3): δ 1.22-1.38 (m, 6H, CHCH2CH2), 1.72-1.88 (m, 12H, CH2CH2NH and
CHCH2CH2), 3.10-3.20 (m, 5H, 2 x CH2NFmoc (Lys) and Lys-α-proton), 3.40 (bs, 2H,
CH2N (Lys)), 4.08-4.22 (m, 3H, CHCH2 (Fmoc) and CH2CH (Fmoc)), 4.34-4.60 (m,
4H, CHCH2, Lys-α-proton and CH2CH (Fmoc)), 4.96-5.18 (m, 2H, NH and Lys-αproton), 5.70-5.90 (bs, 2H, NH), 7.29-7.38 (m, 10H, ArCH), 7.45-7.49 (m, 4H, ArCH),
7.68-7.75 (m, 8H, ArCH), 8.01-8.04 (m, 4H, ArCH); HRMS (ESI +ve) calcd for
C126H71N7O9, 1826.5392, found 1826.5789. This compound was not sufficiently soluble
to generate an adequate 13C NMR spectrum.
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Attempted synthesis of Allyl (6S,9S,12S,15S,18S,21S)-9,12,18,21-tetrakis(4-(9Hfluorene-9-yl)methoxycarbonylaminobutyl)-6,15-bis(4-(5,5-diphenylfullerenyl
dihydropyrrole-2-carboxamido)butyl)-2,2-dimethyl-4,7,10,13,16,19-hexaoxo-3-oxa5,8,11,14,17,20-hexaazadocosane-22-oate (227)

This compound was prepared via protocol 1, using 225 (0.040 g, 0.021mmol) and 226
(0.038 g, 0.021 mmol) to yield the title compound 227 as a brown solid (0.035 g, 44%).
1

H NMR (500 MHz, CDCl3): δ 1.20-1.55 (m, 12H, CHCH2CH2), 1.39 (s, 9H, Boc),

1.64-1.76 (m, 12H, CH2CH2NH), 1.80-1.90 (m, 12H, CHCH2CH2), 3.06-3.20 (m, 8H, 4
x CH2NHFmoc), 3.40-3.48 (m, 4H, 2 x CH2N (Lys)), 3.67-3.69 (m, 1H, NH), 4.00 (bs,
1H, NH), 4.17-4.20 (m, 4H, 4 x CH2CH (Fmoc)), 4.37-4.46 (m, 8H, 4 x CHCH2
(Fmoc)), 4.50-4.62 (m, 8H, OCH2CH=CH2 and 6 x Lys-α-protons), 4.90 (bs, 1H, NH),
5.03-5.06 (m, 3H, 3 x NH), 5.20-5.22 (m, 2H, CH=CH2), 5.81-5.86 (m, 1H, CH=CH2),
6.83-6.84 (m, 2H, 2 x NH), 6.94-6.96 (m, 2H, 2 x NH), 7.29 (d, J = 6.5 Hz, 8H), 7.37
(m, 12H); 7.49 (d, J = 7.0 Hz, 8H), 7.56 (d, J = 7.5 Hz, 8H), 7.74 (t, J = 7.0 Hz, 8H),
8.05 (d, J = 8.0 Hz, 8H), 8.11-8.12 (bs, 2H, NH); This compound was not sufficiently
soluble to generate an adequate

13

C NMR spectrum and not sufficiently soluble in

MeOH to generate an adequate ESI-MS.
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of

Allyl

(6S,9S,12S,15S)-6,9,12,15-tetrakis(4-(5,5-

diphenylfullerenyldihydropyrrole-2-carboxamido)butyl)-2,2-dimethyl-4,7,10,13tetraoxo-3-oxa-5,8,11,14-tetraazahexadecane-16-oate (207)
To a suspension of 198 (0.118 g, 0.124 mmol) in pyridine/CHCl3 (90 mL) was added
HOBt (0.020 g, 0.148 mmol) and EDCI (0.028 g, 0.148 mmol) and the mixture was
stirred for 15 min before a solution of 217 (0.021 g, 0.031 mmol) in pyridine/CHCl3 (25
mL) was added dropwise. The resulting solution was stirred at rt for 8 h before the
solvent was removed

under reduced pressure. The crude residue was then subjected to flash silica gel
chromatography with gradient elution with MeOH/CHCl3 (1:49 to 1:19). This resulted
in the isolation of three different products (10 mg, 14 mg and 56 mg), none of them
were the desired product and these could not be characterised by 1H NMR spectroscopy
or mass spectrometry.
(S)-tert-Butyl-3-(phenyl)-2-((S)-3-(phenyl)-2-(9H-fluoren-9-yl)methoxycarbonyl
aminopropanamido)propanoate 143 (233)
This

compound

was

prepared

via

protocol

1,

using

(((9H-fluoren-9-

yl)methoxy)carbonyl)-L-phenylalanine 231 (0.220 g, 0.568 mmol) and tert-butyl Lphenylalaninate 232 (0.125 g, 0.568 mmol) to afford the title compound 233 as a
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colourless solid (0.310 g, 92%). 1H NMR (500
MHz, CDCl3): δ 1.36 (s, 9H, C(CH3)3), 3.01 (d, J
= 6.0 Hz, 2H, CH2Ph), 3.05 (bs, 2H, CH2Ph), 4.17
(t, J = 7.0 Hz, 1H, α-Phe proton), 4.28 (bs, 1H,
(CH2CH (Fmoc)), 4.40-4.43 (m, 2H, CH2CH (Fmoc)), 4.63 (m, 1H, α-Phe proton), 5.34
(bs, 1H, NH), 6.31 (bs, 1H, NH), 7.02 (d, J = 6.0 Hz, 2H, ArCH), 7.17-7.31 (m, 10H,
ArCH), 7.39 (t, J = 7.5 Hz, 2H, ArCH), 7.52 (t, J = 8.5 Hz, 2H, ArCH), 7.75 (d, J = 7.0
Hz, 2H, ArCH);

13

C NMR (125 MHz, CDCl3): δ 28.1 (C(CH3)3), 38.0 (CH2Ph), 38.2

(CH2Ph), 47.3 (CH2CH (Fmoc)), 53.9 (CHCH2Ph), 56.1 (CHCH2Ph), 67.2 (CH2
(Fmoc)), 82.5 (C(CH3)3)), [120.2, 125.0, 127.3, 127.6, 128.6, 128.9, 129.5, 129.6
(ArCH)], [136.0, 136.3, 141.4, 143.8 (ArC)], 155.9 (C=O (Fmoc)), 170.0 (C=O), 170.2
(C=O). HRMS (ESI +ve) calcd for C37H38N2O5 591.2859, found 591.2865.
(S)-3-(Phenyl)-2-((S)-3-(phenyl)-2-(9H-fluoren-9-yl)methoxycarbonylamino
propanamido)propanoic acid 234
This compound was prepared via protocol 3, using 233
(0.250 g, 0.423 mmol) to afford the title compound 234
(0.205 g, 90%) as a fine colourless solid. 1H NMR (500
MHz, CDCl3): δ 3.00-3.02 (m, 2H, CH2Ph), 3.07 (bs, 2H, CH2Ph), 4.16 (t, J = 7.0 Hz,
1H, α-Phe proton), 4.25 (bs, 1H, (CH (Fmoc)), 4.41-4.43 (m, 2H, CH2 (Fmoc)), 4.74
(m, 1H, α-Phe proton), 5.37 (bs, 1H, NH), 6.35 (bs, 1H, NH), 7.02-7.05 (m, 2H, ArCH),
7.20-7.32 (m, 10H, ArCH), 7.38 (t, J = 7.5 Hz, 2H, ArCH), 7.52 (t, J = 8.5 Hz, 2H,
ArCH), 7.75 (d, J = 7.0 Hz, 2H, ArCH); HRMS (ESI +ve) calcd for C33H30N2O5
535.2233, found 535.2238.
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Allyl-(5S,8S,11S)-5,8-dibenzyl-11-(4-(5,5-diphenylfullerenyldihydropyrrole-2carboxamido)butyl)-1-(9H-fluoren-9-yl)-3,6,9-trioxo-2-oxa-4,7,10-triazadodecane12-oate (235)
This compound was prepared
via protocol 1, using (S)-3(phenyl)-2-((S)-3-(phenyl)-2((((9H-fluoren-9yl)methoxy)carbonyl)amino)p
ropanamido)propanoic

acid

234 (0.052 g, 0.097 mmol) and (S)-6-((5,5-diphenylfullerenyldihydropyrrole-2carbonyl)amino)-1-(allyloxy)-1-oxohexan-2-aminium 2,2,2-trifluoroacetate 202 (0.109
g, 0.097 mmol) to afford the title compound 235 as a colourless solid (0.095 g, 60%).
1

H NMR (500 MHz, CDCl3): δ 1.25-1.36 (m, 2H, CHCH2CH2), 150-1.52 (m, 2H,

CH2CH2NH), 1.80-1.86 (m, 2H, CHCH2CH2), 2.95-3.01 (m, 4H, CH2N (Lys) and
CH2Ph), 3.42-3.45 (m, 2H, CH2Ph), 4.06-4.11 (m, 1H, CH2CH (Fmoc)), 4.22-4.30 (m,
2H, α-Phe proton), 4.39-4.59 (m, 5H, OCH2, CHCH2 (Fmoc), Lys-α-proton), 5.19-5.25
(m, 2H, CH=CH2), 5.84-5.90 (m, 1H, CH=CH2), 6.57 (bs, 2H, NH), 7.05-7.28 (m, 20H,
ArCH), 7.36-7.41 (m, 2H, ArCH); 7.45-7.48 (m, 2H, ArCH), 7.69-7.74 (m, 2H, ArCH),
8.01-8.06 (m, 4H, ArCH);

13

C NMR (CDCl3, 125 MHz): δ 22.8 (CHCH2CH2), 29.0

(CH2CH2NH), 31.9 (CHCH2CH2), 37.8 (CH2Ph), 39.8 (CH2NH), 47.1 (CH2CH
(Fmoc)), 52.3 (NHCHCO), 53.5 (CHCH2Ph), 54.6 (CHCH2Ph), 66.1 (CH2CH=CH2),
67.2 (OCH2 (Fmoc)), 83.4* (C60sp3), 83.6* (C60sp3), 95.5 (CPh2), 119.2 (CH=CH2),
[120.1, 125.1, 125.5, 127.2, 127.3, 127.9, 128.5, 128.7, 128.9, 129.3, 129.9, 131.5
(ArCH)], [134.8, 134.85 (ArC)], [136.2, 136.6, 139.2, 139.6, 141.0, 141.4, 141.9, 142.4,
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142.6 (C60sp2)], [142.6, 142.8(ArC)], [143.0, 144.2, 144.4, 144.9, 145.2, 145.3 (2 x C),
145.33, 145.5, 145.6, 145.9, 146.1, 146.4* (1/2 x C), 146.9* (1/2 x C), 147.2, 148.6,
149.2, 153.2 (2 x C) (C60sp2)], 153.3 (C=N), 161.4 (2 x CO), 162.4 (2 x CO), 171.3
(CO, ester); HRMS (ESI +ve) calcd for C117H55N5O7,1641.4101, found 1641.4235.
(5S,8S,11S)-5,8-Dibenzyl-11-(4-(5,5-diphenylfullerenyldihydropyrrole-2carboxamido) butyl)-1-(9H-fluoren-9-yl)-3,6,9-trioxo-2-oxa-4,7,10-triazadodecane12-oic acid (236)
This compound was prepared
via protocol 4, using 235
(0.042 g, 0.025mmol), 1,2dichloroethane (40 mL) and
(CH3)3SnOH (0.020 g, 0.100
mmol) mL) to yield 236
(0.030 g, 75%) as a brown solid. This compound was carried forward without any
spectroscopic characterisation.
Allyl

(S)-2-((S)-2-((S)-2-amino-3-phenylpropanamido)-3-phenylpropanamido)-6-

(5,5-diphenylfullerenyldihydripyrrole-2-carboxamido)hexanoate (237)
This

compound

was

prepared

via

protocol 2, using 235 (0.045 g, 0.027
mmol) to afford the title compound 237
(0.38 g, 99%) as a fine colourless solid.
HRMS (ESI +ve) calcd for C102H45N5O5
1419.3421,

found

1419.3529.

This
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compound was carried forward to the subsequent reaction without any further
characterisation.
Allyl-(5S,8S,11S,14S,17S,20S)-5,8,14,17-tetrabenzyl-11,20-bis(4-(5,5-diphenyl
fullerenyldihydropyrrole-2-carboxamido)butyl)-1-(9H-fluoren-9-yl)-3,6,9,12,15,18hexaoxo-2-oxa-4,7,10,13,16,19-hexaazahenicosane-21-oate (238)

This compound was prepared via protocol 1, using 236 (0.025 g, 0.015 mmol) and 237
(0.021 g, 0.015 mmol) to yield the title compound 238 as a colourless solid (0.018 g, 40
%). 1H NMR (500 MHz, CDCl3): δ 1.21-1.39 (m, 4H, CHCH2CH2), 146-1.57 (m, 4H,
CH2CH2NH), 1.80-1.88 (m, 4H, CHCH2CH2), 2.96-3.06 (m, 8H, 2 x CH2N (Lys) and 2
x CH2Ph), 3.41-3.45 (m, 4H, 2 x CH2Ph), 4.04-4.15 (m, 1H, CH2CH (Fmoc)), 4.20-4.30
(m, 4H, 4 x α-Phe proton), 4.37-4.61 (m, 6H, CH2CH=CH2, CH2 (Fmoc) and 2 x Lys-αproton), 5.17-5.25 (m, 2H, CH=CH2), 5.86-5.92 (m, 1H, CH=CH2), 6.60 (bs, 2H, NH),
6.65 (bs, 2H, NH), 7.18-7.36 (m, 32H, ArCH), 7.36-7.41 (m, 4H, ArCH), 7.45-7.48 (m,
8H, ArCH), 7.69-7.74 (m, 2H, ArCH), 8.01-8.06 (m, 2H, ArCH). This compound was
not sufficiently soluble to generate an adequate 13C NMR spectrum and not sufficiently
soluble in MeOH to generate an adequate ESI-MS.
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(S)-6-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-((S)-6-(9H-fluoren-9-

yl)methoxycarbonylamino-2-(2-(5,5-diphenylfullerenyldihydropyrrole-2carbonyl)aminoacetamido)hexanamido)hexanoate (243)
To

a

suspension

of

fullerenoprolineglycine-OH 242 (133
mg, 0.131 mmol) in CH2Cl2 (100 mL)
was added HBTU (59 mg, 0.157
mmol) and Et3N (22 µL, 0.157 mmol)
and the mixture was stirred for 15 min
before a solution of 213 (100 mg, 0.131 mmol) in CH2Cl2 (15 mL) was added dropwise.
The resulting solution was stirred at rt for 4 h, before the solvent was removed under
reduced pressure. The crude residue was then subjected to flash silica gel
chromatography, elution with MeOH/CH2Cl2 (1:99) provided the title compound 243 as
a brown solid (155 mg, 67%). IR (neat, cm-1): 3303 (w), [1695, 1683, 1653, 1647 (s)],
1246 (m), 1139;

1

H NMR (500 MHz, CDCl3:CS2 (4:1)): δ 1.23-1.25 (m, 4H,

CHCH2CH2), 142-1.49 (m, 4H, CH2CH2NH), 1.68-1.78 (m, 2H, CHCH2CH2), 1.85 (bs,
2H, CHCH2CH2), 3.10-3.18 (m, 4H, 2 x CH2N (Lys)), 4.16-4.22 (m, 4H, 2 x CH
(Fmoc) and 2 x Lys-α-proton), 4.36-4.40 (m, 5H, 2 x CH2CH (Fmoc) and NH), 4.51
(bs, 2H, NHCH2CO (Gly)), 4.60 (bs, 2 x NH), 4.90-5.11 (m, 2H, CH2CH=CH2), 5.21
(d, J = 10.5 Hz, 1H, CH=CH(Z)H), 5.28 (d, J = 17.0 Hz, 1H, CH=CH(E)H), 5.82-5.94
(m, 1H, CH=CH2), 6.86 (bs, 1H, NH), 7.27-7.40 (m, 10H, ArCH), 7.47 (t, J = 7.5 Hz,
4H, ArCH), 7.56 (bs, 4H, ArCH); 7.72 (d, J = 7.0 Hz, 4H, ArCH), 8.05 (d, J = 7.5 Hz,
4H, ArCH), 8.57 (bs, 1H, NH);

13

C NMR (125 MHz, CDCl3:CS2 (4:1)): δ 22.0

(CHCH2CH2), 22.3 (CHCH2CH2), 29.3 (CH2CH2NH), 31.1 (CHCH2CH2), 31.5
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(CHCH2CH2), 38.6 (CH2NH (Lys)), 40.2 (CH2NH (Lys)), 43.0 (NHCH2CO), 47.2
(CH2CH (Fmoc)), 52.3 (NHCHCO, Lys α carbon), 53.1 (NHCHCO, Lys α carbon),
66.0 (CH2CH=CH2), 66.5 (CH2CH (Fmoc)), 66.9 (CH2CH (Fmoc)), 95.5 (NCPh2),
118.9 (CH=CH2), [119.9, 125.0, 127.0, 127.6, 128.4, 129.7 (ArCH)], 131.4 (CH=CH2),
134.7 (2 x ArC), [136.6, 139.1, 139.4, 140.8, 141.2, 141.3, 141.7, 142.3, 142.4
(C60sp2)], 142.7 (2 x ArC), 142.9 (2 x ArC), 143.9 (4 x ArC), [144.0, 144.2 (2 x C),
144.8, 145.0, 145.3 (2 x C), 145.4, 145.7, 145.9, 146.3* (1/2 x C), 146.8* (1/2 x C),
147.0, 148.3, 148.9, 153.1 (2 x C) (C60sp2)], 156.7 (C=N), [156.8, 161.7, 165.7, 168.2,
171.3, 171.7 (CO)]; Two C60sp3 signals were not observed due to poor signal to noise.
MS (ESI +ve) m/z 1778.0 ([M+Na]+, 100%), HRMS (ESI +ve) calcd for
C122H62N6O9Na 1778.4509, found 1778.4565.
Isopentyl (9S,12S,15S)-12-(4-(9H-fluoren-9-yl)methoxycarbonylaminobutyl)-9-(2(5,5-diphenylfullerenyldihydropyrrole-2-carbonyl)aminoacetamido)-1-(9Hfluoren-9-yl)-15-isobutyl-3,10,13-trioxo-2-oxa-4,11,14-triazahexadecane-16-oate
(245)
This compound was prepared via
protocol 4 using 243 (110 mg, 0.062
mmol) to yield the desired carboxylic
acid precursor of 244 as a brown solid
(90 mg, 84%). This product was
carried into the next reaction without
any further purification, via protocol 1 using the acid 244 (75 mg, 0.043 mmol) and (S)isopentyl 2-amino-4-methylpentanoate (17 mg, 0.086 mmol) to yield the desired
product 245 as a brown solid (52 mg, 62%). IR (neat, cm-1): 3305 (w), [1669, 1663,
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1647, 1632, 1558 (s)], 1515 (m), 1196, 1132 (m); 1H NMR (500 MHz, CDCl3): δ 0.800.94 (m, 12H, 4 x CH3 (Leu and isopentyl)), 1.38-1.44 (m, 4H, CHCH2CH2), 1.51-1.57
(m, 7H, 2 x CH2CH2NH, OCH2CH2 and CH(CH3)2 (Leu)), 1.66-1.71 (m, 4H,
CHCH2CH2 (Lys)), 1.74-1.80 (m, 1H, CH(CH3)2 (isopentyl)), 1.87 (m, 2H,
CH2CH(CH3)2 (Leu)), 3.44 (t, J = 6.0 Hz, 4H, 2 x CH2N (Lys)), 4.04 (t, J = 6.5 Hz, 2H,
CO2CH2 (ester)), 4.11-4.17 (m, 4H, NHCH2CO and 2 x CHCH2 (Fmoc)), 4.19 (d, J =
6.0 Hz, 2H, CHCH2 (Fmoc)), 4.35-4.40 (m, 4H, CHCH2 (Fmoc) and 2 x Lys-α-proton),
4.49 (bs, 1H, Leu-α-proton), 5.08 (bs, 1H, NH), 5.19 (bs, 1H, NH), 6.50 (bs, 1H, NH),
6.97 (bs, 1H, NH), 6.40 (bs, 1H, NH), 7.27-7.41 (m, 14H, ArCH), 7.57 (bs, 4H, ArCH),
7.61 (d, J = 7.5 Hz, 4H, ArCH), 7.73-7.78 (m, 4H, ArCH), 8.05 (bs, 1H, NH); HRMS
(ESI +ve) calcd for C130H79N7O10 1898.5967, found 1898.6011. This compound was not
sufficiently soluble to generate an adequate 13C NMR spectrum.
(S)-5-(2-(5,5-Diphenylfullerenyldihydropyrrole-2-carbonyl)aminoacetamido)-6-(S)6-ammonio-1-(S)-1-(isopentyloxy)-4-methyl-1-oxopentan-2-yl)amino-1-oxohexan2-ylamino-6-oxohexan-1-ammonium chloride (247)
This compound was prepared via
protocol 2, followed by protocol 3,
using 245 (32 mg, 0.016 mmol) to yield
247 as a brown solid (17 mg, 70%). IR
(neat, cm-1): 3237 (w), 3064 (w), [1647,
1635, 1558, 1539 (s)], 1507, 1185, 1155 (m). This compound was not sufficiently
soluble to generate an adequate 1H NMR and

13

C NMR spectrum. HRMS (ESI +ve)

calcd for C100H59N7O6 1454.4604, found 1454.4750.
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(10S,13R,16R)-Isopentyl 10-(9H-fluoren-9-yl)methoxycarbonylamino-16-isobutyl2,2-dimethyl-4,11,14-trioxo-13-(3-(3-((2,2,4,6,7-pentamethyl-2,3dihydrobenzofuran-5-yl)sulfonyl)guanidino)propyl)-3-oxa-5,12,15triazaheptadecan-17-oate (259)
This compound was prepared via protocol
1

using

isopentyl

Nὼ-((2,2,4,6,7-

pentamethyl-2,3-dihydrobenzofuran-5yl)sulfonyl)-D-arginyl-D-leucinate
(250

mg,

0.410

mmol),

255

Fmoc-(L)-

Lys(Boc)-OH (192 mg, 0.410 mmol) to
yield the desired product 259 as a white foam (350 mg, 80%). IR (neat, cm-1): 3306 (w),
[1668, 1662, 1647, 1635, 1558 (s)], 1190, 1132 (m); 1H NMR (500 MHz, CDCl3): δ
0.84-0.88 (m, 12H, 4 x CH3 (Leu and isopentyl)), 1.40 (s, 9H, Boc), 1.43 (s, 6H,
C(CH3)2, Pbf), 1.46-1.49 (m, 4H, CHCH2CH2 (Lys) and CHCH2CH2 (Arg)), 1.57-1.72
(m, 6H, CHCH2CH2 (Lys), OCH2CH2 and CH2CH2NH (Lys)), 1.76 (bs, 1H, CH(CH3)2
(Leu)), 1.92 (bs, 2H, CHCH2 (Leu)), 1.99 (bs, 1H, CH(CH3)2 (isopentyl)), 2.07 (s, 3H,
CH3 (Pbf)), 2.50 (s, 3H, CH3 (Pbf)), 2.57 (s, 3H, CH3 (Pbf)), 2.92 (s, 2H, CH2 (Pbf)),
3.06 (bs, 2H, CH2N (Arg)), 3.23 (bs, 2H, CH2N (Lys)), 4.05-4.10 (m, 2H, NH), 4.18 (t,
J = 6.5 Hz, 2H, CO2CH2), 4.32-4.34 (m, 2H, CHCH2 (Fmoc) and Lys-α-proton), 4.434.45 (m, 2H, CHCH2 (Fmoc)), 4.56-4.57 (m, 2H, Leu-α-proton and NH), 4.82 (bs, 1H,
Arg-α-proton), 5.29 (bs, 1H, NH), 5.82 (bs, 1H, NH), 6.29 (bs, 2H, NH), 7.26-7.29 (m,
2H, ArCH), 7.35-7.38 (m, 2H, ArCH), 7.57 (t, J = 6.5 Hz, 2H, ArCH), 7.73 (d, J = 7.5
Hz, 2H, ArCH); 13C NMR (125 MHz, CDCl3): δ 12.8 (CH3, Pbf), 18.3 (CH3, Pbf), 19.6
(CH3, Pbf), 21.9 (CHCH2CH2 (Lys)), 22.6 (2 x CH3 (Leu)), 22.7 (2 x CH3 (isopentyl)),
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22.8 (CHCH2CH2 (Arg)), 23.0 (CH(CH3)2 (isopentyl)), 25.0 (CH(CH3)2 (Leu)), 25.2
(CHCH2CH2 (Lys)), 28.7 (C(CH3)3), 28.8 (C(CH3)2 (Pbf)), 29.6 (CHCH2CH2 (Arg)),
29.8 (CH2CH2NH (Lys)), 37.5 (CH2CH(CH3)2 (isopentyl) and CH2CH2NH (Lys)), 40.3
(CH2CH(CH3)2 (Leu)), 40.6 (NHCH2 (Lys)), 43.9 (NHCH2 (Arg)), 47.3 (CH2 (Pbf)),
51.6 (CH2CH (Fmoc)), 52.7 (NHCHCO (Leu)), 53.7 (NHCHCO (Lys)), 55.5
(NHCHCO (Arg)), 64.3 (OCH2 (isopentyl)), 67.4 (CH2CH (Fmoc)), 79.6 (OC(CH3)3),
86.6 (OC (Pbf)), 117.7 (ArC), 120.2 (ArCH), 124.8 (ArC), [125.4, 125.5, 126.3
(ArCH)], [128.0, 132.5, 133.1, 138.6, 141.4, 141.5, 143.9, 144.1 (ArC)], 156.6 (CO,
Boc), 156.7 (C=N), 159.0 (ArC of Pbf), 171.9 (CO), 172.5 (CO), 173.4 (CO, ester); MS
(ESI +ve) m/z 1060.0 ([M+H]+, 100%), 1082.6 ([M+Na]+, 90%).
(10S,13R,16R)-Isopentyl

10-amino-16-isobutyl-2,2-dimethyl-4,11,14-trioxo-13-(3-

(3-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino)propyl)3-oxa-5,12,15-triazaheptadecan-17-oate (263)
This compound was prepared via protocol 2 using 259
(320 mg, 0.301 mmol) to yield the desired product 263
as a white foam (195 mg, 77%). IR (neat, cm-1): 3300
(w), [1668, 1662, 1647, 1558, 1507 (s)], 1194, 1131
(m); 1H NMR (500 MHz, CDCl3): δ 0.90-0.91 (m, 12H,
4 x CH3), 1.42 (s, 9H, Boc), 1.46 (s, 6H, C(CH3)2 Pbf),
1.49-1.52 (m, 4H, CHCH2CH2 (Lys) and CHCH2CH2 (Arg)), 1.56-1.62 (m, 4H,
CHCH2CH2 (Lys), and CH2CH2NH (Lys)), 1.64-1.75 (m, 2H, OCH2CH2), 1.80 (bs, 1H,
CH(CH3)2 (Leu)), 1.96 (bs, 5H, CHCH2 (Leu),

CHCH2 (Arg) and CH(CH3)2

(isopentyl)), 2.08 (s, 3H, CH3 (Pbf)), 2.51 (s, 3H, CH3 (Pbf)), 2.58 (s, 3H, CH3 (Pbf)),
2.95 (s, 2H, CH2 (Pbf)), 3.06-3.09 (m, 2H, CH2N (Arg)), 3.24 (bs, 2H, CH2N (Lys)),
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3.40 (bs, 1H, NH), 4.10-4.14 (m, 2H, NH), 4.44-4.49 (m, 1H, Lys-α-proton), 4.52-4.53
(m, 1H, Leu-α-proton), 4.78 (bs, 1H, NH), 6.17 (bs, 1H, NH), 6.29 (bs, 2H, NH2), 7.30
(bs, 1H, NH), 7.90 (bs, 2H, NH), 13C NMR (125 MHz, CDCl3): δ 12.6 (CH3, Pbf), 18.0
(CH3, Pbf), 19.4 (CH3, Pbf), 21.9 (CHCH2CH2 (Lys)), 22.6 (2 x CH3 (Leu)), 22.8 (2 x
CH3 (isopentyl)), 23.0 (CHCH2CH2 (Arg)), 24.9 (CH(CH3)2 (isopentyl)), 25.1
(CH(CH3)2 (Leu)), 25.2 (CHCH2CH2 (Lys)), 28.6 (C(CH3)3), 28.7 (C(CH3)2 (Pbf)), 29.9
(CHCH2CH2 (Arg)), 30.1 (CH2CH2NH (Lys)), 34.6 (CH2CH(CH3)2 (isopentyl)), 37.3
(CH2CH2NH (Lys)), 40.4 (CH2CH(CH3)2 (Leu)), 40.7 (NHCH2 (Lys)), 43.4 (NHCH2
(Arg)), 51.3 (CH2 (Pbf)), 52.3 (NHCHCO (Leu)), 55.1 (NHCHCO (Arg)), 64.2 (OCH2
(isopentyl)), 79.3 (OC(CH3)3), 86.5 (OC(Pbf), [117.6, 124.7, 132.4, 133.1, 138.5
(ArC)]; 156.4 (CO, Boc), 156.5 (C=N), 158.9 (ArC, Pbf), 171.9 (CO), 173.3 (CO),
175.7 (CO, ester). MS (ESI +ve) m/z 738 ([M-Boc]+, 100%), 838 ([M+H]+, 95%), 860
([M+Na]+, 22%).
(8S,11R,14R)-Isopentyl 8-(4-(tert-butoxycarbonylamino)butyl)-1-(9H-fluoren-9-yl)14-isobutyl-3,6,9,12-tetraoxo-11-(3-(3-((2,2,4,6,7-pentamethyl-2,3dihydrobenzofuran-5-yl)sulfonyl)guanidino)propyl)-2-oxa-4,7,10,13tetraazapentadecan-15-oate (266)
This compound was prepared via
protocol 1 using 263 (170 mg, 0.203
mmol), Fmoc-Gly-OH (60 mg, 0.203
mmol) to yield the desired product 266
as a white foam (169 mg, 75%). IR
(neat, cm-1): 3302 (w), [1671, 1660,
1647, 1633, 1558, 1505 (s)], 1193, 1135 (m); 1H NMR (500 MHz, CDCl3): δ 0.85 (bs,
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12H, 4 x CH3 (Leu and isopentyl)), 1.38 (s, 9H, Boc), 1.42 (s, 6H, C(CH3)2 Pbf)), 1.461.50 (m, 4H, CHCH2CH2 (Lys) and CHCH2CH2 (Arg)), 1.56-1.66 (m, 4H, CHCH2CH2
(Lys), OCH2CH2)), 1.67-1.79 (m, 2H, CH2CH2NH (Lys)), 1.86 (bs, 1H, CH(CH3)2
(Leu)), 1.91 (bs, 1H, 1H, CH(CH3)2 (isopentyl)), 1.95 (s, 3H, CH3 (Pbf)), 2.06 (s, 3H,
CH3 (Pbf)), 2.57 (s, 3H, CH3 (Pbf)), 2.90 (s, 2H, CH2 (Pbf)), 3.06-3.08 (m, 2H, CH2N
(Arg)), 3.19 (bs, 2H, CH2N (Lys)), 3.94-4.00 (m, 2H, NH), 4.01-4.09 (m, 2H, CHCH2
(Leu)), 4.17 (t, J = 6.5 Hz, 1H, CHCH2 (Fmoc)), 4.33 (d, J = 7.0 Hz, 2H, CHCH2
(Fmoc)), 4.46-4.47 (m, 2H, CH2 (Gly)), 4.58 (bs, 1H, Leu-α-proton), 5.01 (bs, 1H, Lysα-proton), 6.31 (bs, 4H, Arg-α-proton and 3 x NH), 7.23-7.25 (m, 3H, 2 x ArCH and
NH), 7.34-7.37 (m, 2H, ArCH), 7.44 (bs, 2H, ArCH), 7.57 (d, J = 6.5 Hz, 2H, ArCH),
7.73 (d, J = 8.0 Hz, 2H, ArCH). 13C NMR (125 MHz, CDCl3): δ 12.6 (CH3, Pbf), 18.3
(CH3, Pbf), 19.4 (CH3, Pbf), 21.8 (CHCH2CH2 (Lys)), 22.4 (2 x CH3 (Leu)), 22.9 (2 x
CH3 (isopentyl)), 22.95 (CHCH2CH2 (Arg)), 23.0 (CH(CH3)2 (isopentyl)), 25.2
(CH(CH3)2 (Leu)), 25.25 (CHCH2CH2 (Lys)), 28.8 (C(CH3)3), 29.0 (C(CH3)2 Pbf), 29.5
(CHCH2CH2 (Arg)), 29.8 (CH2CH2NH (Lys)), 31.7 (CHCH2 (Leu)), 37.6 (2 x CH2
(CH2CH(CH3)2 (isopentyl) and CH2CH2NH (Lys)), 40.3 (CH2CH(CH3)2 (Leu)), 40.6
(NHCH2 (Lys)), 43.9 (NHCH2 (Arg)), 44.4 (CH (Gly)), 47.3 (CH2 (Pbf)), 51.3 (CH2CH
(Fmoc)), 52.7 (NHCHCO (Leu)), 53.7 (NHCHCO (Lys)), 55.9 (NHCHCO (Arg)), 64.3
(OCH2 (isopentyl)), 67.4 (CH2CH (Fmoc)), 79.6 (OC(CH3)3), 86.6 (OC(CH3)2), 117.6
(ArC), 121.9 (2 x ArCH), 124.9 (2 x ArCH), [125.4, 125.5, 128.0 (ArCH)], [132.5,
133.1, 138.6, 141.4, 141.5, 143.9, 144.3 (ArC)], 156.6 (C=N), 156.7 (CO, Boc), 158.9
(ArC), 172.0 (2 x CO), 172.9 (2 x CO), 173.7 (CO, ester); MS (ESI +ve) m/z 1017.6
([M-Boc]+, 100%), 1117.6 ([M+H]+, 95%), 1139.6 ([M+Na]+, 22%).
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(10S,13R,16R)-Isopentyl 10-(2-aminoacetamido)-16-isobutyl-2,2-dimethyl-4,11,14trioxo-13-(3-(3-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5yl)sulfonyl)guanidino)propyl)-3-oxa-5,12,15-triazaheptadecan-17-oate (269)
This compound was prepared via protocol 2 using
266 (140 mg, 0.125 mmol) to yield the desired
product 269 as a white foam (90 mg, 80%). IR
(neat, cm-1): 3300 (w), [1666, 1662, 1647, 1635,
1557, 1502 (s)], [1194, 1137 (m)]; 1H NMR (500
MHz, CDCl3): δ 0.87-0.91 (m, 12H, 4 x CH3 (Leu
and isopentyl)), 1.41 (s, 9H, Boc), 1.45 (s, 6H, C(CH3)2 Pbf), 1.48-1.52 (m, 4H,
CHCH2CH2 (Lys) and CHCH2CH2 (Arg)), 1.56-1.61 (m, 4H, CHCH2CH2 (Lys), and
CH2CH2NH (Lys)), 1.63-1.74 (m, 2H, OCH2CH2), 1.86-1.94 (m, 3H, CH(CH3)2 (Leu)
and CHCH2 (Arg)), 1.96 (bs, 1H, CH(CH3)2 (isopentyl)), 2.02 (bs, 2H, CHCH2 (Leu)
and ), 2.08 (s, 3H, CH3 (Pbf)), 2.51 (s, 3H, CH3 (Pbf)), 2.58 (s, 3H, CH3 (Pbf)), 2.95 (s,
2H, CH2 (Pbf)), 3.06-3.08 (m, 2H, CH2N (Arg)), 3.22 (bs, 2H, CH2N (Lys)), 3.41 (m,
2H, NH), 4.07-4.14 (m, 2H, CH2 (Gly)), 4.36 (bs, 1H, NH), 4.42-4.48 (m, 2H, Lys-αproton and Leu-α-proton), 4.91 (bs, 1H, NH), 6.40 (bs, 1H, NH), 6.35 (bs, 2H, NH2),
7.36 (d, J = 7 Hz, 1H, NH), 7.45 (bs, 1H, NH), 7.85 (bs, 1H, NH). 13C NMR (125 MHz,
CDCl3): δ 12.5 (CH3, Pbf), 18.0 (CH3, Pbf), 19.2 (CH3, Pbf), 21.8 (CHCH2CH2 (Lys)),
22.4 (CH3 (Leu)), 22.8 (2 x CH3 (isopentyl)), 22.9 (CHCH2CH2 (Arg)), 24.8 (CH(CH3)2
(isopentyl)), 25.0 (CH(CH3)2 (Leu)), 25.4 (CHCH2CH2 (Lys)), 28.4 (C(CH3)3), 28.6
(C(CH3)2 Pbf), 29.6 (CH2CH(CH3)2 (isopentyl)), 29.7 (CHCH2CH2 (Arg)), 31.7
(CH2CH2NH (Lys)), 37.2 (CH2CH2NH (Lys)), 40.2 (CH2CH(CH3)2 (Leu)), 40.6
(NHCH2 (Lys)), 43.3 (NHCH2 (Arg)), 44.4 (NHCH2CO (Gly)), 51.2 (CH2 (Pbf)), 52.9
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(NHCHCO (Leu)), 53.7 (NHCHCO (Arg)), 64.0 (OCH2 (isopentyl)), 79.1 (OC(CH3)3),
86.3 (OC(CH3)2 Pbf), [117.5, 124.5, 132.2, 133.0, 138.3 (ArC)], 156.4 (C=N), 156.7
(CO, Boc), 158.7 (ArC), 171.7 (2 x CO), 172.2 (CO), 173.0 (CO, ester). MS (ESI +ve)
m/z 895.6 ([M+H]+, 100%), 917.6 ([M+Na]+, 38%).
(10S,13R,16R)-Isopentyl-10-(2-(5,5-diphenylfullerenyldihydropyrrole-2carbonyl)aminoacetamido)-16-isobutyl-2,2-dimethyl-4,11,14-trioxo-13-(3-(3(2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonylguanidino)propyl)-3oxa-5,12,15-triazaheptadecan-17-oate (272)
This compound was prepared via
protocol

1,

using

[60]fullerenoproline acid 198 (75
mg, 0.067 mmol) and amine 269
(72 mg, 0.080 mmol) to yield the
product 272 as a brown solid (65
mg, 53%). IR (neat, cm-1): 3304
(w), [1669, 1662, 1647, 1635, 1558, 1507 (s)], [1194, 1135 (m)]; 1H NMR (500 MHz,
CDCl3)  0.87-0.90 (m, 12H, 4 x CH3 (Leu and isopentyl)), 0.95-1.05 (m, 2H,
CHCH2CH2 (Lys)), 1.42 (s, 9H, Boc), 1.46 (s, 6H, C(CH3)2 Pbf), 1.48-1.57 (m, 4H,
CHCH2CH2 (Arg) and CHCH2CH2 (Lys)), 1.63-1.66 (m, 6H, CH2CH2NH (Lys),
OCH2CH2 and CHCH2 (Arg)), 1.85-1.86 (m, 4H, CH(CH3)2 (isopentyl), CHCH2 (Leu)
and CH(CH3)2 (Leu)), 2.08 (s, 3H, CH3 (Pbf)), 2.50 (s, 3H, CH3 (Pbf)), 2.57 (s, 3H, CH3
(Pbf)), 2.95 (s, 2H, CH2 (Pbf)), 3.05 (bs, 2H, CH2N (Arg)), 3.16 (bs, 2H, CH2N (Lys)),
3.35 (m, 2H, NH), 3.62-3.76 (m, 2H, OCH2), 4.07-4.09 (m, 2H, Lys-α-proton and Leuα-proton), 4.28 (s, 2H, CH2 (Gly)), 4.34-4.44 (m, 3H, Arg-α-proton and 2 x NH), 5.33
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(bs, 1H, NH), 7.39-7.42 (m, 3H, 2 x ArCH, NH), 7.50-7.52 (m, 4H, ArCH), 7.81-7.83
(bs, 2H, NH), 8.08-8.10 (m, 4H, ArCH);

13

C NMR (125 MHz, CDCl3): δ 12.2 (CH3,

Pbf), 17.7 (CH3, Pbf), 19.0 (CH3, Pbf), 21.2 (CHCH2CH2 (Lys)), 22.1 (CH3 (Leu)), 22.2
(CH3 (Leu)), 22.8 (2 x CH3 (isopentyl)), 22.9 (CHCH2CH2 (Arg)), 24.6 (CH(CH3)2
(isopentyl)), 24.8 (CHCH2CH2 (Lys)), 25.0 (CH(CH3)2 (Leu)), 28.3 (C(CH3)), 28.6
(C(CH3)2 Pbf)), 29.2 (CH2CH(CH3)2 (isopentyl)), 29.6 (CHCH2CH2 (Arg)), 31.7
(CH2CH2NH (Lys)), 37.0 (CH2CH2NH (Lys)), 40.2 (CH2CH(CH3)2 (Leu)), 40.3, 40.6
(NHCH2 (Lys)), 42.5 (NHCH2 (Arg)), 43.0 (NHCH2CO (Gly)), 50.9 (CH2 (Pbf)), 51.0
(NHCHCO (Leu)), 52.4, 53.3 (NHCHCO (Arg)), 53.9, 63.9 (OCH2 (isopentyl)), 66.3,
79.2 (C(CH3)3), 82.2* (C60sp3), 83.3* (C60sp3), 86.3, 95.4 (NCPh2), [117.3, 124.3
(ArC)], 128.3 (ArCH), 129.6 (ArCH), [132.2, 132.8 (ArC)], 134.6 (ArCH)]; 136.5,
138.2 (ArC), [139.0, 139.3, 139.3 (C60sp2)]; 140.8 (ArCH), [141.2, 141.6, 141.7, 141.8,
142.3, 142.34, 142.6, 142.65, 142.8, 144.0, 144.1, 144.7, 144.9, 145.1, 145.13, 145.2,
145.3, 145.7, 145.8, 145.89, 146.2, 146.8* (1/2 x C), 146.9* (1/2 x C), 148.2, 148.9,
153.1 (C60sp2)], 156.7 (CO, Boc), 158.5 (2 x C=N), 161.8 (ArC, Pbf), [162.0, 169.2,
172.0, 172.4, 172.9 (CO)]. MS (ESI +ve) m/z 1857 ([M+Na]+, 100%), 1835 ([M+H]+,
60%). HRMS (ESI +ve) calcd for C118H83N9O11SNa 1856.5830, found 1856.5916.
1-(R)-4-(S)-2-(2-(5,5-Diphenylfullerenyldihydropyrrole-2-carbonyl
aminoacetamido)-6-ammoniohexanamido)-5-(R)-1-(isopentyloxy)-4-methyl-1oxopentan-2-yl)amino-5-oxopentylguanidinium 2,2,2-trifluoroacetate (276)
This compound was prepared via protocol 3, using 272 (30 mg, 0.016 mmol) to yield
276 as a brown solid (17 mg, 70%). IR (neat, cm-1): 3291 (w), [1734, 1669, 1647, 1635,
1558 (s)], [1186, 1158, 1146 (m)]; 1H NMR (500 MHz, CDCl3:CD3OD)  0.83-0.89 (m,
12H, 4 x CH3 (Leu and isopentyl)), 1.24-1.28 (m, 2H, CHCH2CH2 (Lys)), 1.42-1.54 (m,
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7H, CHCH2CH2 (Arg), CHCH2CH2
(Lys)

and

CHCH2

(Leu)

and

CH(CH3)2 (Leu)), 1.62-1.68 (m, 5H,
CH2CH2NH (Lys), OCH2CH2 and
CH(CH3)2 (isopentyl)), 1.70-1.79 (m,
2H,),

2.80 (bs, 2H, CH2N (Lys)),

3.10-3.12 (m, 2H, CH2N (Arg)), 3.26 (s, 2H, CH2 (Gly)), 3.55 (bs, 1H, NH), 4.00-4.02
(m, 2H, OCH2), 4.12-4.20 (m, 2H, Lys-α-proton and Leu-α-proton), 4.40-4.60 (bs, 2H,
Arg-α-proton and NH), 7.36 (t, 2H, J = 6.5 Hz, ArCH), 7.47 (t, 4H, J = 7.5 Hz, ArCH),
7.79-7.80 (bs, 1H, NH), 8.03 (d, 4H, J = 8.0 Hz, ArCH), 8.12 (bs, 1H, NH), 8.28 (bs,
1H, NH), 9.10 (bs, 1H, NH). This compound was not sufficiently soluble to generate an
adequate

13

C NMR spectrum. HRMS (ESI +ve) calcd for C100H59N9O6 1482.4667,

found 1482.4717.
Methyl

2-((10R,13S,16S)-10-(9H-fluoren-9-yl)methoxycarbonylamino-2,2,18-

trimethyl-4,11,14-trioxo-13-(3-(3-((2,2,5,7,8-pentamethylchroman-6yl)sulfonyl)guanidino)propyl)-3-oxa-5,12,15-triazanonadecan-16-yl)oxazole-4carboxylate (260)
This compound was prepared via protocol
1 using amine 256 (350 mg, 0.552 mmol)
and Fmoc-(D)-Lys(Boc)-OH (258 mg,
0.552 mmol) to yield the desired product
260 as a white foam (515 mg, 86%). 1H
NMR (500 MHz, CDCl3): δ 0.84-0.87 (m,
6H, 2 x CH3 (Leu)), 1.28 (s, 6H, 2 x CH3 (Pmc)), 1.39 (s, 9H, Boc), 1.46-1.65 (m, 7H,
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CHCH2CH2 (Lys), CHCH2CH2 (Arg), CH(CH3)2 (Leu) and CH2CH2NH (Lys)), 1.751.78 (m, 6H, CHCH2 (Leu), CHCH2CH2 (Lys) and CHCH2CH2 (Arg)), 1.96 (bs, 1H,
NH), 2.05 (s, 3H, CH3 (Pmc)), 2.08 (s, 3H, CH3 (Pmc)), 2.54 (s, 3H, CH3 (Pmc)), 2.592.60 (m, 4H, 2 x CH2 (Pmc)), 3.05 (bs, 2H, CH2N (Arg)), 3.20-3.26 (m, 2H, CH2N
(Lys)), 3.80 (s, 3H, OCH3), 4.12-4.17 (m, 2H, CH2 (Fmoc)), 4.25-4.32 (m, 2H, Lys-αproton and Arg-α-proton), 4.54-4.55 (m, 1H, CH (Fmoc)), 4.83 (bs, 1H, NH), 5.14-5.18
(m, 1H, α-CH to oxazole), 5.92 (bs, 1H, NH), 6.19 (bs, 1H, NH), 6.32 (bs, 2H, NH),
7.26-7.28 (m, 2H, ArCH), 7.36 (t, J = 7.5 Hz, 2H, ArCH), 7.54 (t, J = 8.5 Hz, 2H,
ArCH), 7.72 (d, J = 7.5 Hz, 2H, ArCH), 8.04 (s, 1H, oxazole);

13

C NMR (125 MHz,

CDCl3): δ 12.3 (CH3, Pmc), 17.7 (CH3, Pmc), 18.7 (CH3, Pmc), 21.6 (CHCH2CH2
(Lys)), 22.8 (CHCH2CH2 (Arg)), 22.9 (2 x CH3 (Leu)), 24.8 (CH(CH3)2 (Leu)), 26.9
(CHCH2 (Lys)), 27.0 (C(CH3)2 (Pmc)), 27.2 (CH2 (Pmc)), 28.6 (C(CH3)3), 29.8
(CHCH2CH2 (Arg) and (CH2CH2NH (Lys)), 33.0 (CH2 (Pmc)), 40.5 (NHCH2 (Lys)),
41.8 (NHCH2 (Arg)), 46.5 (CHCH2 (Leu)), 47.2 (CH2CH (Fmoc)), 51.8 (OCH3 ester),
52.3 (NHCH (Leu)), 53.6 (NHCHCO (Lys)), 55.2 (NHCHCO (Arg)), 67.3 (CH2
(Fmoc)), 73.8 (OC(CH3)2), 79.4 (OC(CH3)3), 118.1 (ArC), 120.1 (ArCH), 124.2 (ArC),
[125.3, 127.3, 127.9 (ArCH)], [132.9, 133.6, 135.0, 135.6 (ArC)], 141.4 (CH, oxazole),
143.9 (ArC), 144.3 (ArC), [153.8, 156.5 (CO)], 156.55 (C=N), 162.4 (ArC), [165.7,
170.3, 171.8 (CO)]. MS (ESI +ve) m/z 1085.0 ([M+H]+, 100%).
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2-((10R,13S,16S)-10-amino-2,2,18-trimethyl-4,11,14-trioxo-13-(3-(3-

((2,2,5,7,8-pentamethylchroman-6-yl)sulfonyl)guanidino)propyl)-3-oxa-5,12,15triazanonadecan-16-yl)oxazole-4-carboxylate (264)
This compound was prepared via protocol 2 using
260 (450 mg, 0.415 mmol) to yield the desired
product 264 as a white foam (298 mg, 84%). 1H
NMR (500 MHz, CDCl3): δ 0.87-0.90 (m, 6H, 2 x
CH3 (Leu)), 1.25-1.28 (m, 2H, CHCH2CH2 (Lys)),
1.29 (s, 6H, 2 x CH3 (Pmc)), 1.32-1.37 (m, 2H,
CHCH2CH2 (Arg)), 1.41 (s, 9H, Boc), 1.45-1.56 (m, 3H, CH2CH2NH (Lys) and
CH(CH3)2 (Leu)), 1.78-1.80 (m, 6H, CHCH2 (Leu), CHCH2CH2 (Lys) and CHCH2CH2
(Arg)), 2.09 (s, 3H, CH3 (Pmc)), 2.55-2.62 (m, 10H, 2 x CH3 (Pmc) and 2 x CH2
(Pmc)), 3.01-3.07 (m, 4H, CH2N (Arg) and CH2N (Lys)), 3.20-3.26 (bs, 2H, NH2), 3.80
(s, 3H, OCH3), 3.88 (bs, 1H, Lys-α-proton), 4.55 (bs, 1H, Arg-α-proton), 4.65 (bs, 1H,
NH), 5.14-5.21 (m, 1H, α-CH to oxazole), 6.21 (bs, 1H, NH), 6.36 (bs, 2H, NH), 7.86
(bs, 1H, NH), 8.15 (s, 1H, oxazole); 13C NMR (125 MHz, CDCl3): δ 12.2 (CH3, Pmc),
17.5 (CH3, Pmc), 18.5 (CH3, Pmc), 21.5 (CHCH2CH2 (Lys)), 21.8 (CHCH2CH2 (Arg)),
22.7 (2 x CH3 (Leu)), 24.7 (CH(CH3)2 (Leu)), 25.3 (CHCH2 (Lys)), 26.8 (C(CH3)2
(Pmc)), 28.5 (C(CH3)3), 29.6 (CH2 (Pmc)), 31.0 (CHCH2CH2 (Arg)), 32.9 (CH2CH2NH
(Lys) and CH2 (Pmc)), 40.3 (NHCH2 (Lys)), 41.9 (NHCH2 (Arg)), 46.0 (CHCH2 (Leu)),
52.2 (OCH3 ester), 52.3 (NHCH (Leu)), 55.2 (NHCHCO (Lys)), 58.5 (NHCHCO
(Arg)), 73.6 (OC(CH3)2), 79.6 (OC(CH3)3), [118.0, 124.0, 132.8, 133.6, 134.9, 135.5,
137.4 (ArC)], 144.2 (CH, oxazole), 153.6 (C=N), 156.5 (CO), 162.1 (ArC), [166.0,
170.8, 171.3 (CO)]. MS (ESI +ve) m/z 863.0 ([M+H]+, 100%).
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Methyl

2-((10R,13S,16S)-10-(5,5-diphenylfullerenyldihydropyrrole-2-carbonyl)

amino-2,2,18-trimethyl-4,11,14-trioxo-13-(3-(3-((2,2,5,7,8-pentamethylchroman-6yl)sulfonylguanidinopropyl)-3-oxa-5,12,15-triazanonadecan-16-yl)oxazole-4carboxylate (273)
This compound was prepared via protocol
1, using [60]fullerenoproline acid 198 (95
mg, 0.099 mmol) and amine 264 (102
mg, 0.118 mmol) to yield the product as a
white brown (98 mg, 55%). IR (neat, cm1

): 3309 (w), [1685, 1647, 1635, 1558,

1507 (s)], 1195 (m), 1136; 1H NMR (500 MHz, CDCl3): δ 0.84-0.87 (m, 6H, 2 x CH3
(Leu)), 1.29 (s, 6H, 2 x CH3 (Pmc)), 1.39 (s, 9H, Boc), 1.42-1.58 (m, 6H, CHCH2CH2
(Lys), CHCH2CH2 (Arg) and CH2CH2NH (Lys)), 1.66-1.71 (m, 2H, CHCH2CH2 (Lys)),
1.76-1.96 (m, 5H, CHCH2 (Leu), CHCH2CH2 (Arg) and CH(CH3)2 (Leu)), 1.99 (s, 3H
CH3 (Pmc)), 2.07 (s, 3H, CH3 (Pmc)), 2.54-2.58 (m, 7H, CH3, 2 x CH2 (Pmc)), 3.07 (bs,
2H, CH2N (Arg)), 3.25-3.62 (m, 2H, CH2N (Lys)), 3.20-3.26 (bs, 2H, NH), 3.80 (s, 3H,
OCH3), 4.60 (bs, 1H, Lys-α-proton), 4.66-4.68 (m, 1H, Arg-α-proton), 4.80 (bs, 1H,
NH), 5.12 (bs, 1H, α-CH to oxazole), 6.18 (bs, 1H, NH), 6.33 (bs, 2H, NH), 7.37-7.41
(m, 2H, ArCH), 7.46-7.52 (m, 4H, ArCH), 7.60 (d, J = 7.0 Hz, NH), 8.05 (t, 4H, J = 8.5
Hz, 4H, ArCH), 8.08 (s, 1H, oxazole), 8.37 (bs, 1H, NH); 13C NMR (125 MHz, CDCl3):
δ 12.3 (CH3, Pmc), 17.7 (CH3, Pmc), 18.7 (CH3, Pmc), 21.5 (CHCH2CH2 (Lys)), 21.7
(CHCH2CH2 (Arg)), 22.9 (2 x CH3 (Leu)), 24.7 (CH(CH3)2 (Leu)), 26.9 (C(CH3)2 (Pmc)
and CHCH2 (Lys)), 28.5 (C(CH3)3), 29.6 (CH2 (Pmc)), 32.9 (CHCH2CH2 (Arg)) and
CH2CH2NH (Lys)), 40.2 (NHCH2 (Lys)), 41.8 (NHCH2 (Arg)), 46.7 (CHCH2 (Leu)),
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52.3 (OCH3 ester), 54.2 (NHCH (Leu)), 55.2 (NHCHCO (Lys)), 58.5 (NHCHCO
(Arg)), 73.7 (OC(CH3)2), 82.2 (OC(CH3)3), 95.8 (NCPh2), 118.3 (ArC (Pmc)), 124.1
(ArC (Pmc)), [128.5, 128.6, 129.9 (ArCH)], 133.0 (ArC), [134.9, 135.6 (C60sp2)],
[136.7, 138.2 (ArC, Pmc)], [139.3, 139.5 (C60sp2)], [139.8, 140.8 (ArC)], 141.0 (CH,
oxazole ), [141.3, 141.8, 141.9, 142.0, 142.5, 142.8, 142.9, 143.0, 143.08, 144.2, 144.3,
144.4, 145.0, 145.2, 145.3, 145.5, 145.6, 145.9, 146.4* (1/2 x C), 146.5* (1/2 x C),
147.0, 147.2, 148.3, 148.6, 149.0, 153.4, (C60sp2)], 153.7 (C=N), 156.5 (CO, Boc),
157.8 (C=N), [161.5, 161.9 (CO)], 162.3 (ArC), 171.7 (2 x CO)]. Two C60sp3 signals
were not observed due to poor signal to noise. HRMS (ESI +ve) calcd for
C116H75N9O11SNa 1824.5204, found 1824.5183.
1-(S)-4-(R)-2-(5,5-Diphenylfullerenyldihydropyrrole-2-carbonylamino-6ammoniohexanamido)-5-(S)-1-(4-(methoxycarbonyloxazol-2-yl)-3methylbutylamino)-5-oxopentyl)guanidinium chloride (277)
This compound was prepared via protocol 3,
using 273 (60 mg, 0.033 mmol) to yield 277 as
a brown solid (25 mg, 53%). IR (neat, cm-1):
3336 (w), [1647, 1635, 1507 (s)], 1162 (m);
1

H NMR (500 MHz, DMSO-d6):  0.77-0.86

(m, 6H, 2 x CH3 (Leu)), 1.22-1.66 (m, 6H, CHCH2CH2 (Lys), CHCH2CH2 (Arg) and
CH2CH2NH (Lys))), 1.67-1.79 (m, 4H, CHCH2CH2 (Lys) and CHCH2CH2 (Arg)), 1.851.88 (m, 3H, CHCH2 (Leu) and CH(CH3)2 (Leu)), 2.73 (bs, 2H, NH2), 3.05 (bs, 2H,
CH2N (Arg)), 3.34-3.62 (m, 2H, CH2N (Lys)), 3.75 (s, 3H, OCH3), 4.17 (bs, 1H, Lys-αproton), 4.36 (t, 1H, J = 6.5 Hz, NH), 4.45 (bs, 1H, Arg-α-proton), 4.62 (t, 1H, J = 7.5
Hz, NH), 4.97-4.98 (m, 1H, α-CH to oxazole), 7.41-7.45 (m, 2H, ArCH), 7.53-7.58 (m,
175

Chapter 6

Experimental

4H, ArCH), 8.06-8.10 (m, 4H, ArCH), 8.17 (d, 1H, J = 7.5 Hz, NH), 8.38 (d, 1H, J =
8.0 Hz, NH), 8.43 (d, 1H, J = 8.0 Hz, NH), 8.56 (d, 1H, J = 8.0 Hz, NH), 8.68 (s, 1H,
oxazole), 9.50-9.55 (m, 2H, NH2 (Arg)). This compound was not sufficiently soluble to
generate an adequate

13

C NMR spectrum. HRMS (ESI +ve) calcd for C97H49N9O6

1436.3884, found 1436.3822.
Methyl 2-((8R,11S,14S)-8-(4-(tert-butoxycarbonyl)aminobutyl)-1-(9H-fluoren-9-yl)16-methyl-3,6,9,12-tetraoxo-11-(3-(3-((2,2,5,7,8-pentamethylchroman-6yl)sulfonyl)guanidino)propyl)-2-oxa-4,7,10,13-tetraazaheptadecan-14-yl)oxazole-4carboxylate (267)
This compound was prepared via
protocol 1 using 264 (136 mg, 0.157
mmol) and Fmoc-Gly-OH (47 mg,
0.157 mmol) to yield the desired
product 267 as a white foam (128
mg, 71%).

1

H NMR (500 MHz,

CDCl3): δ 0.82 (d, J = 6.0 Hz, 6H, 2 x CH3 (Leu)), 1.26 (s, 6H, 2 x CH3 (Pmc)), 1.38 (s,
9H, Boc), 1.43-1.66 (m, 7H, CHCH2CH2 (Lys), CHCH2CH2 (Arg), CH(CH3)2 (Leu) and
CH2CH2NH (Lys)), 1.74-1.76 (m, 6H, CHCH2 (Leu), CHCH2CH2 (Lys) and
CHCH2CH2 (Arg)), 1.96 (bs, 1H, NH), 2.06 (s, 3H, CH3 (Pmc)), 2.53 (s, 3H, CH3
(Pmc)), 2.55 (s, 3H, CH3 (Pmc)), 2.57-2.58 (m, 4H, 2 x CH2 (Pmc)), 3.01 (bs, 2H,
CH2N (Arg)), 3.18-3.26 (m, 3H, CH2N (Lys) and NH), 3.70 (s, 3H, OCH3), 3.90-4.13
(m, 3H, CH2 (Fmoc) and NH), 4.22 (bs, 2H, Lys-α-proton and Arg-α-proton), 4.53 (bs,
2H, CH2 (Gly)), 4.54-4.55 (m, 1H, CH (Fmoc)), 4.83 (bs, 1H, NH), 5.14-5.18 (m, 1H,
α-CH to oxazole), 5.92 (bs, 1H, NH), 6.19 (bs, 1H, NH), 6.32 (bs, 2H, NH), 7.26-7.28
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(m, 2H, ArCH), 7.36 (t, J = 7.5 Hz, 2H, ArCH), 7.54 (t, J = 8.5 Hz, 2H, ArCH), 7.72
(d, J = 7.5 Hz, 2H, ArCH), 8.04 (s, 1H, oxazole); 13C NMR (125 MHz, CDCl3): δ 12.3
(CH3, Pmc), 17.7 (CH3, Pmc), 18.7 (CH3, Pmc), 21.6 (CHCH2CH2 (Lys)), 22.8
(CHCH2CH2 (Arg)), 22.88 (2 x CH3 (Leu)), 24.8 (CH(CH3)2 (Leu)), 26.9 (CHCH2
(Lys)), 26.98 (C(CH3)2 (Pmc)), 27.2 (CH2 (Pmc)), 28.6 (C(CH3)3), 29.8 (CHCH2CH2
(Arg) and (CH2CH2NH (Lys)), 33.0 (CH2 (Pmc)), 40.5 (NHCH2 (Lys)), 41.8 (NHCH2
(Arg)), 44.2 (CH2 (Gly)), 46.5 (CHCH2 (Leu)), 47.2 (CH2CH (Fmoc)), 52.3 (NHCH
(Leu)), 53.6 (NHCHCO (Lys)), 55.2 (NHCHCO (Arg)), 67.3 (CH2, (Fmoc)), 73.8
(OC(CH3)2), 79.4 (OC(CH3)3), 118.1 (ArC), 120.1 (ArCH), 124.2 (ArC), [125.3, 127.3,
127.9 (ArCH)], [132.9, 133.6, 135.0, 135.6 (ArC)], 141.4 (CH, oxazole), 143.9 (ArC),
144.3 (ArC), [153.8, 156.5 (CO)], 156.6 (C=N), 165.7 (ArC), 170.6 (2 x CO), 171.8
(CO)]. MS (ESI +ve) m/z 1142.0 ([M+H]+, 100%).
Methyl

2-((10R,13S,16S)-10-(2-aminoacetamido)-2,2,18-trimethyl-4,11,14-trioxo-

13-(3-(3-(2,2,5,7,8-pentamethylchroman-6-yl)sulfonylguanidino)propyl)-3-oxa5,12,15-triazanonadecan-16-yl)oxazole-4-carboxylate (270)
This compound was prepared via protocol 2
using 267 (120 mg, 0.105 mmol) to yield the
desired product 270 as a white foam (85 mg,
88%). IR (neat, cm-1): 3303 (w), 3064, [1683,
1647, 1558, 1507 (s)], 1141 (m), 1106; 1H
NMR (500 MHz, CDCl3): δ 0.82 (d, J = 6.0 Hz,
6H, 2 x CH3), 1.25 (s, 6H, 2 x CH3 (Pmc)), 1.39 (s, 9H, Boc), 1.41-1.68 (m, 7H,
CHCH2CH2 (Lys), CHCH2CH2 (Arg), CH2CH2NH (Lys) and CH(CH3)2 (Leu)), 1.741.76 (m, 6H, CHCH2 (Leu), CHCH2CH2 (Lys) and CHCH2CH2 (Arg)), 1.96 (bs, 1H,
177

Chapter 6

Experimental

NH), 2.08 (s, 3H, CH3 (Pmc)), 2.51 (s, 3H, CH3 (Pmc)), 2.56 (s, 3H, CH3 (Pmc)), 2.572.58 (m, 4H, 2 x CH2 (Pmc)), 3.01 (bs, 2H, CH2N (Arg)), 3.18-3.26 (m, 3H, CH2N
(Lys) and NH), 3.80 (s, 3H, OCH3), 3.90-4.13 (m, 3H, CH2 (Gly) and Lys-α-proton),
4.22 (bs, 2H, NH2), 4.53 (bs, 2H, Arg-α-proton and NH), 4.83 (1H, NH), 5.14-5.18 (m,
1H, α-CH to oxazole), 5.92 (bs, 1H, NH), 6.19 (bs, 1H, NH), 6.32 (bs, 2H, NH), 8.04 (s,
1H, oxazole); 13C NMR (125 MHz, CDCl3): δ 12.3 (CH3, Pmc), 17.7 (CH3, Pmc), 18.7
(CH3, Pmc), 21.6 (CHCH2CH2 (Lys)), 21.9 (CHCH2CH2 (Arg)), 22.8 (2 x CH3 (Leu)),
24.8 (CH(CH3)2 (Leu)), 26.9 (CHCH2 (Lys)), 26.98 (C(CH3)2 (Pmc)), 28.6 (C(CH3)3),
29.8 (CH2 (Pmc)), 33.0 (CHCH2CH2 (Arg)), 33.1 (CH2CH2NH (Lys) and CH2 (Pmc)),
40.5 (NHCH2 (Lys)), 41.8 (NHCH2 (Arg)), 42.3 (CH2 (Gly)), 46.5 (CHCH2 (Leu)), 52.3
(OCH3 ester), 53.6 (NHCH (Leu)), 55.2 (NHCHCO (Lys) and (NHCHCO (Arg)), 73.8
(OC(CH3)2), 79.4 (OC(CH3)3), [118.1, 124.2, 125.3, 132.9, 133.6, 135.0, 135.6 (ArC)],
141.4 (CH, oxazole), [153.8, 156.4, 165.7, 171.8 (2 x CO) (CO)]. MS (ESI +ve) m/z
920.0 ([M+H]+, 100%).
Methyl-2-((10R,13S,16S)-10-(2-(5,5-diphenylfullerenyldihydropyrrole-2-carbonyl)
aminoacetamido)-2,2,18-trimethyl-4,11,14-trioxo-13-(3-(3-(2,2,5,7,8pentamethylchroman-6-yl)sulfonylguanidino)propyl)-3-oxa-5,12,15triazanonadecan-16-yl)oxazole-4-carboxylate (274)
This compound was prepared via
protocol 1 using 270 (75 mg,
0.0816 mmol) and fullerenoproline
acid 198 (65 mg, 0.0679 mmol) to
yield the desired product 274 as a
brown solid (64 mg, 51%). IR (neat,
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cm-1): 3285 (w), [1685, 1635, 1653, 1507 (s)], [1253, 1164, 1100 (m)]; 1H NMR (500
MHz, CDCl3): δ 0.86-0.90 (m, 6H, 2 x CH3 (Leu)), 1.30 (s, 6H, 2 x CH3 (Pmc)), 1.41 (s,
9H, Boc), 1.45-1.51 (m, 4H, CHCH2CH2 (Lys) and CHCH2CH2 (Arg)), 1.62-1.68 (m,
4H, CH2CH2NH (Lys) and CHCH2CH2 (Lys)), 1.79 (t, J = 6.5 Hz, 2H, CHCH2 (Leu)),
1.78-1.88 (m, 3H, CHCH2CH2 (Arg) and CH(CH3)2 (Leu)), 2.08 (s, 3H, CH3, (Pmc)),
2.54 (s, 3H, CH3, (Pmc)), 2.56 (s, 3H, CH3, (Pmc)), 2.61 (t, J = 6.5 Hz, 2H, CH2
(Pmc)), 3.02 (bs, 2H, CH2N (Arg)), 3.14-3.18 (m, 2H, CH2N (Lys)), 3.83 (s, 3H,
OCH3), 4.30 (d, J = 8.0 Hz, 2H (Gly)), 4.37-4.41 (m, 3H, Lys-α-proton, Arg-α-proton
and NH), 5.16-5.17 (m, 1H, α-CH to oxazole), 7.38 (t, J = 6.5 Hz, 2H, ArCH), 7.457.50 (m, 4H, ArCH), 7.75 (bs, 1H, NH), 7.84 (bs, 1H, NH), 8.05 (t, J = 7.5 Hz, 4H,
ArCH), 8.13 (s, 1H, oxazole), 8.90 (bs, 1H, NH); 13C NMR (125 MHz, CDCl3): δ 12.1
(CH3, Pmc), 17.5 (CH3, Pmc), 18.5 (CH3, Pmc), 21.4 (CHCH2CH2 (Lys)), 21.7
(CHCH2CH2 (Arg)), 22.7 (2 x CH3 (Leu)), 24.6 (CH(CH3)2 (Leu)), 25.5 CHCH2 (Lys)),
26.8 (C(CH3)2 (Pmc)), 28.4 (C(CH3)3), 29.6 (CH2 (Pmc)), 32.8 (CHCH2CH2 (Arg)) and
CH2CH2NH (Lys)), 40.2 (NHCH2 (Lys)), 41.8 (NHCH2 (Arg)), 44.4 (CH2 (Gly)), 46.0
(CHCH2 (Leu)), 52.3 (OCH3 ester), 52.5 (NHCH (Leu) and (NHCHCO (Lys)), 58.7
(NHCHCO (Arg)), 73.7 (OC(CH3)2), 79.2 (OC(CH3)3), 82.2* (C60sp3), 89.5* (C60sp3),
95.6 (NCPh2), [117.9 124.0 (ArC (Pmc)], 128.4 (ArCH), 129.8 (2 x ArCH), [132.8,
133.5, 134.7 (ArC)], [134.9, 135.5, 135.6, 136.6 (C60sp2)], [139.1, 139.5, 140.9 (ArC)],
141.3 (ArCH, oxazole), [141.8, 141.9, 142.4, 142.5, 142.7, 142.8, 143.0, 143.1, 144.2,
144.3, 144.9, 145.1, 145.3, 145.4, 145.5, 145.6, 145.8, 146.0, 146.1, 146.38* (1/2 x C),
146.4* (1/2 x C), 146.9, 147.1, 148.3, 149.5, 153.6, (C60sp2)], 155.9 (C=N), 156.5 (CO,
Boc), 157.8 (C=N), 162.0 (ArC, oxazole), [163.9 (CO), 167.3 (2 x CO), 171.5 (2 x CO).
HRMS (ESI +ve) calcd for C118H78N10O12SNa 1881.5419, found 1881.5436.
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1-(S)-4-(R)-2-(2-(5,5-Diphenylfullerenyldihydropyrrole-2-carbonyl
aminoacetamido-6-ammoniohexanamido)-5-(S)-1-(4-(methoxycarbonyl)oxazol-2yl-3-methylbutylamino)-5-oxopentylguanidinium chloride (278)
This compound was prepared via protocol
3, using 274 (35 mg, 0.0188 mmol) to
yield 278 as a brown solid (13 mg, 46%).
IR (neat, cm-1): 3305 (w), [1675, 1655,
1651, 1507 (s)], [1258, 1162, 1107 (m)];
1

H NMR (500 MHz, CDCl3:CD3OD (4:1)):  0.84-0.88 (m, 6H, 2 x CH3 (Leu)), 1.24-

1.28 (m, 2H, CHCH2CH2 (Lys)), 1.56-1.79 (m, 7H, CHCH2CH2 (Arg), CH2CH2NH
(Lys), CHCH2CH2 (Lys) and CH(CH3)2 (Leu)), 1.83-1.87 (m, 6H, CHCH2CH2 (Arg),
CHCH2 (Leu) and CH2NH2 (Lys)), 2.10 (s, 1H, NH), 2.65 (bs, 1H, NH), 2.88 (bs, 2H,
CH2N (Lys)), 2.93 (bs, 1H, NH), 3.08 (bs, 2H, CH2N (Arg)), 3.30 (s, 3H, OCH3), 3.403.41 (m, 2H, NH2), 3.80 (s, 2H (Gly)), 4.19 (d, 1H, J = 7.5 Hz, NH), 4.34-4.40 (m, 3H,
Lys-α-proton, Arg-α-proton and α-CH to oxazole), 7.40 (t, 2H, J = 7.5 Hz, ArCH), 7.51
(m, 4H, ArCH), 7.85 (s, 1H, NH), 8.11-8.15 (m, 4H, ArCH), 8.41 (s, 1H, oxazole); This
compound was not sufficiently soluble to generate an adequate

13

C NMR spectrum.

HRMS (ESI +ve) calcd for C99H52N10O7 1493.4099, found 1493.4077.
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2-((10R,13R,16S)-10-(9H-fluoren-9-yl)methoxycarbonylamino-13-(4-tert-

butoxycarbonylaminobutyl)-2,2,18-trimethyl-4,11,14-trioxo-3-oxa-5,12,15triazanonadecan-16-yl)oxazole-4-carboxylate (261)
This compound was prepared via protocol 1
using 257 (150 mg, 0.340 mmol) and Fmoc(D)-Lys(Boc)-OH (159

mg, 0.340 mmol) to

yield the desired product 261 as a white foam
(220 mg, 72%). 1H NMR (500 MHz, CDCl3): δ
0.91-0.94 (m, 6H, 2 x CH3 (Leu)), 1.34-1.49 (m,
7H, 2 x CHCH2CH2 (Lys), CH(CH3)2 (Leu) and CH2CH2NH (Lys)), 1.41 (s, 9H, Boc),
1.42 (s, 9H, Boc), 1.65-1.69 (m, 2H, CH2CH2NH (Lys)), 1.75-1.78 (m, 2H, CHCH2
(Leu)), 1.82-1.88 (m, 4H, 2 x CHCH2CH2 (Lys)), 3.04 (bs, 2H, CH2N (Lys)), 3.20 (bs,
2H, CH2N (Lys)), 3.77 (s, 3H, OCH3), 4.18 (t, J = 7 Hz, 1H, CH, Fmoc), 4.36-4.37 (m,
2H, CH2, Fmoc), 4.51 (bs, 1H, NH), 4.73 (bs, 1H, Lys-α-proton), 4.80 (bs, 1H, Lys-αproton), 5.20-5.29 (m, 1H, α-CH to oxazole), 5.95 (bs, 1H, NH), 7.08 (bs, 1H, NH),
7.26-7.30 (m, 3H, 2 x ArCH, NH), 7.36-7.40 (m, 2H, ArCH), 7.51 (d, J = 7.5 Hz, 2H,
ArCH), 7.57 (d, J = 7.5 Hz, 1H, NH), 7.74 (d, J = 7.5 Hz, 2H, ArCH), 8.00 (s, 1H,
oxazole);

13

C NMR (125 MHz, CDCl3): δ 21.6 (CHCH2CH2 (Lys)), 22.4 (CHCH2CH2

(Lys)), 22.8 (2 x CH3 (Leu)), 24.7 (CH(CH3)2 (Leu)), 28.4 (2 x C(CH3)3), 29.4 (CHCH2
(Lys)), 29.6 (CHCH2 (Lys)), 31.2 (2 x CH2CH2NH (Lys)), 39.5 (NHCH2 (Lys)), 40.1
(NHCH2 (Lys)), 46.0 (CHCH2 (Leu)), 47.0 (CH2CH (Fmoc)), 52.0 (OCH3 ester), 52.9
(NHCH (Leu)), 55.7 (2 x NHCHCO (Lys)), 67.2 (CH2, Fmoc), 79.2 (2 x OC(CH3)3),
[119.9, 124.9, 125.0, 127.0 (ArCH)], 132.9 (ArC, oxazole), 141.2 (CH, oxazole), 141.3
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(ArC), 143.9 (ArC), 156.5 (2 x CO, Boc), 161.3 (ArC, oxazole), [166.0, 171.4 (2 x CO),
172.2 (CO)]. MS (ESI +ve) m/z 891.0 ([M+H]+, 100%).
Methyl

2-((10R,13R,16S)-10-amino-13-(4-((tert-butoxycarbonyl)amino)butyl)-

2,2,18-trimethyl-4,11,14-trioxo-3-oxa-5,12,15-triazanonadecan-16-yl)oxazole-4carboxylate (265)
This compound was prepared via protocol 2 using 261 (200
mg, 0.224 mmol) to yield the desired product 265 as a white
foam (128 mg, 85%). 1H NMR (500 MHz, CDCl3): δ 0.930.95 (m, 6H, 2 x CH3 (Leu)), 1.34-1.39 (m, 4H, 2 x
CHCH2CH2 (Lys)), 1.43 (s, 18H, 2 x Boc), 1.50-1.57 (m,
5H, 2 x CH2CH2NH (Lys) and CH(CH3)2 (Leu)), 1.75-1.76
(m, 6H, CHCH2 (Leu) and 2 x CHCH2CH2 (Lys)), 1.90-1.96 (m, 1H, NH), 3.11 (bs, 4H,
2 x CH2N (Lys)), 3.48 (bs, 1H, Lys-α-proton), 3.87 (s, 3H, OCH3), 4.42-4.44 (m, 2H,
NH2), 4.62-4.66 (m, 2H, Lys-α-proton and NH), 5.18-5.24 (m, 1H, α-CH to oxazole),
7.18 (bs, 1H, NH), 7.82 (bs, 1H, NH), 8.12 (s, 1H, CH, oxazole); 13C NMR (125 MHz,
CDCl3): δ 22.0 (CHCH2CH2 (Lys)), 22.9 (CHCH2CH2 (Lys)), 23.0 (2 x CH3 (Leu)),
23.07 (CH(CH3)2 (Leu)), 25.0 (CHCH2 (Lys)), 28.6 (2 x C(CH3)3), 29.8 (CH2CH2NH
(Lys)), 30.0 (CH2CH2NH (Lys), 40.3 (NHCH2 (Lys)), 42.7 (NHCH2 (Lys)), 46.1
(CHCH2 (Leu)), 52.3 (NHCH (Leu)), 52.4 (NH2CHCO (Lys)), 55.1 (NHCHCO (Lys)),
79.2 (2 x OC(CH3)3), 133.3 (ArC, oxazole), 144.1 (ArCH, oxazole), 156.2 (2 x CO,
Boc), 161.7 (ArC, oxazole), [165.7, 171.8, 176.4 (CO)]. MS (ESI +ve) m/z 669.0
([M+H]+, 100%).
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Methyl 2-(8R,11R,14S)-8,11-bis(4-tert-butoxycarbonylaminobutyl-1-(9H-fluoren-9yl)-16-methyl-3,6,9,12-tetraoxo-2-oxa-4,7,10,13-tetraazaheptadecan-14-yl)oxazole4-carboxylate (268)
This

compound

was

prepared

via

protocol 1 using 265 (65 mg, 0.0973
mmol) and Fmoc-Gly-OH (30 mg,
0.0973 mmol) to yield the desired
product 268 as a white foam (76 mg,
82%). 1H NMR (500 MHz, CDCl3): δ
0.88-0.89 (m, 6H, 2 x CH3 (Leu)), 1.30-1.45 (m, 4H, 2 x CHCH2CH2 (Lys)), 1.41 (s,
18H, 2 x Boc), 1.60-1.95 (m, 7H, CH(CH3)2 (Leu), 2 x CH2CH2NH (Lys) and CHCH2
(Leu)), 2.61 (bs, 1H, NH), 3.05 (bs, 4H, 2 x CH2N (Lys)), 3.81 (s, 3H, OCH3), 4.05 (bs,
2H, CH2 (Gly)), 4.18 (bs, 1H, CH, Fmoc), 4.22-4.37 (m, 2H, CH2, Fmoc), 4.55 (bs, 1H,
NH), 4.62 (bs, 1H, Lys-α-proton), 4.90 (bs, 1H, Lys-α-proton), 5.08 (bs, 1H, NH), 5.205.29 (m, 1H, α-CH to oxazole), 6.50 (bs, 1H, NH), 7.25 (t, J = 7.0 Hz, 2H, ArCH), 7.36
(t, J = 7.5 Hz, 2H, ArCH), 7.73 (d, J = 7.5 Hz, 2H, ArCH), 7.77 (m, 3H, 2 x ArCH and
NH), 8.09 (s, 1H, CH, oxazole);

13

C NMR (125 MHz, CDCl3): δ 21.9 (CHCH2CH2

(Lys)), 22.8 (CHCH2CH2 (Lys)), 22.9 (2 x CH3 (Leu)), 24.9 (CH(CH3)2 (Leu)), 28.6 (2
x C(CH3)3), 29.8 (2 x CHCH2 (Lys)), 31.9 (2 x CH2CH2NH (Lys)), 40.1 (NHCH2
(Lys)), 40.5 (NHCH2 (Lys)), 42.6 (CH2 (Gly)), 44.7 (CHCH2 (Leu)), 47.2 (CH2CH
(Fmoc)), 52.3 (OCH3 ester), 53.1 (NHCH (Leu)), 54.2 (2 x NHCHCO (Lys)), 67.3
(OCH2, Fmoc), 79.2 (2 x OC(CH3)3), [120.1, 125.3, 127.2, 127.9 (ArCH)], 133.1 (ArC,
oxazole), 141.4 (CH, oxazole), 143.9 (ArC), 144.1 (ArC), 156.6 (2 x CO, Boc), 161.7
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(ArC, oxazole), [165.9 (CO), 171.6 (2 x CO), 171.7 (2 x CO)]. MS (ESI +ve) m/z 948.0
([M+H]+, 100%).
Methyl-2-((10R,13R,16S)-10-(2-aminoacetamido)-13-(4-tertbutoxycarbonylamino)butyl-2,2,18-trimethyl-4,11,14-trioxo-3-oxa-5,12,15triazanonadecan-16-yl)oxazole-4-carboxylate (271)
This compound was prepared via protocol 2 using 268
(60 mg, 0.0633 mmol) to yield the desired product 271
as a white foam (39 mg, 86%). 1H NMR (500 MHz,
CDCl3): δ 0.91-0.95 (m, 6H, CH(CH3)2 (Leu)), 1.241.58 (m, 9H, 2 x CHCH2CH2 (Lys), 2 x CH2CH2NH
(Lys) and CH(CH3)2 (Leu)), 1.42 (s, 18H, 2 x Boc),
1.60-1.68 (m, 2H, CHCH2 (Leu)), 1.75-1.80 (m, 2H, CHCH2CH2 (Lys)), 1.82-1.88 (m,
2H, CHCH2CH2 (Lys)), 1.90-1.96 (m, 1H, NH), 2.22-2.40 (bs, 2H, NH2), 3.07 (t, J =
6.0 Hz, 4H, CH2N (Lys)), 3.36-3.45 (m, 2H, (CH2 (Gly)), 3.87 (s, 3H, OCH3), 4.30-4.35
(m, 1H, Lys-α-proton), 4.48-4.55 (m, 1H, Lys-α-proton), 4.85-4.95 (m, 1H, NH), 5.205.38 (m, 1H, α-CH to oxazole), 7.28 (bs, 1H, NH), 7.48 (bs, 1H, NH), 7.88 (bs, 1H,
NH), 8.15 (s, 1H, CH, oxazole);

13

C NMR (125 MHz, CDCl3): δ 21.7 (CHCH2CH2

(Lys)), 22.7 (CHCH2CH2 (Lys)), 22.8 (2 x CH3 (Leu)), 24.7 (CH(CH3)2 (Leu)), 28.4 (2
x C(CH3)3), 29.4 (CH2CH2NH (Lys)), 29.6 (CH2CH2NH (Lys), 31.1 (CHCH2 (Lys)),
31.3 (CHCH2 (Lys)), 40.0 (NHCH2 (Lys)), 40.1 (NHCH2 (Lys)), 44.6 (CHCH2 (Leu)),
45.9 (CH2 (Gly)), 52.1 (NHCH (Leu)), 52.7 (NHCHCO (Lys)), 53.8 (NHCHCO (Lys)),
79.0 (2 x OC(CH3)3), 132.9 (ArC, oxazole), 143.9 (CH, oxazole), 156.2 (2 x CO, Boc),
161.5 (ArC, oxazole), [165.9, 171.4, 172.0, 174.1 (CO)]. MS (ESI +ve) m/z 726.0
([M+H]+, 100%).
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Methyl-2-((10R,13R,16S)-10-(2-(5,5-diphenylfullerenyldihydropyrrole-2carbonyl)aminoacetamido)-13-(4-((tert-butoxycarbonyl)amino)butyl)-2,2,18trimethyl-4,11,14-trioxo-3-oxa-5,12,15-triazanonadecan-16-yl)oxazole-4carboxylate (275)
To a suspension of acid 198 (46 mg,
0.048 mmol) in CH2Cl2/CHCl3 (1:1),
(100 mL) was added HOBt (7.7 mg,
0.057 mmol) and EDCI (11 mg, 0.057
mmol) and the mixture was stirred for 15
min before a solution of 271 (35 g, 0.048
mmol) and triethylamine (8.0 µL, 0.057 mmol) in CH2Cl2 (10 mL) was added dropwise.
The resulting solution was stirred at rt for a further 4 h before the solvent was removed
under reduced pressure. The crude residue was then subjected to flash silica gel
chromatography, elution with MeOH/CH2Cl2 (1:49) provided the title compound 275 as
a brown solid (52 mg, 65%). IR (neat, cm-1): 3321 (w), [1695, 1647, 1635 (s)], [1363,
1248, 1153 (m)]; 1H NMR (500 MHz, CDCl3 + CD3OD (9:1)): δ 0.91-0.94 (m, 6H,
CH(CH3)2 (Leu)), 1.34-1.51 (m, 8H, 2 x CHCH2CH2 (Lys) and 2 x CH2CH2NH (Lys)),
1.42 (s, 18H, 2 x Boc), 1.58-1.76 (m, 4H, 2 x CHCH2CH2 (Lys)), 1.79-1.88 (m, 2H,
CHCH2 (Leu)), 1.95 (bs, 1H, CH(CH3)2 (Leu)), 3.07 (bs, 4H, CH2N (Lys)), 3.37 (s, 2H,
(CH2 (Gly))), 3.83 (s, 3H, OCH3), 4.20-4.32 (m, 1H, NH), 4.34 (bs, 2H, Lys-α-proton
and NH), 4.50 (bs, 1H, Lys-α-proton), 5.18-5.20 (m, 1H, α-CH to oxazole), 5.26 (bs,
1H, NH), 5.34 (bs, 1H, NH), 7.34, (s, 1H, CH, oxazole), 7.39-7.43 (m, 2H, ArCH),
7.48-7.52 (m, 4H, ArCH), 7.69 (d, J = 7.0 Hz, 1H, NH), 7.92 (d, J = 7.5 Hz, 1H, NH),
8.03 (d, J = 8 Hz, 4H, ArCH), 8.08 (bs, 1H, NH);

13

C NMR (125 MHz, CDCl3 +
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CD3OD (9:1)): δ 21.5 (CHCH2CH2 (Lys)), 22.9 (2 x CH3 (Leu)), 24.8 (CH(CH3)2
(Leu)), 28.4 (2 x C(CH3)3), 29.5 (CH2CH2NH (Lys) and (CHCH2 (Lys)), 42.6 (NHCH2
(Lys)), 46.0 (CHCH2 (Leu)), 48.6 (CH2 (Gly)), 48.8 (NHCH2 (Lys)), 49.0 (NHCH
(Leu)), 49.7 (NHCHCO (Lys)), 52.3 (NHCHCO (Lys)), 95.7 (CPh2), [128.5, 128.6,
129.9 (ArCH)], 134.7, (ArC, oxazole), [134.9, 136.7, 139.2, 139.3, 139.5, 139.6, 140.9,
141.0, 141.4, 141.9 (C60sp2)], 142.0 (CH, oxazole), 142.5 (ArC), [142.6, 142.9, 143.1,
143.2, 144.2, 144.4, 144.9, 145.0, 145.2, 145.3, 145.5, 145.6, 145.9, 146.1, 146.5,
147.0* (1/2 x C), 147.2* (1/2 x C), 148.4, 149.1 (C60sp2)], 153.2 (C=N), 153.3 (2 x CO,
Boc), 161.6 (ArC, oxazole), [166.2 (2 x CO), 171.0 (2 x CO), 171.2 (CO, ester). Two
C60sp3 signals and Boc tert-carbons were not observed due to poor signal to noise.
HRMS (ESI +ve) calcd for C109H68N8O11 1665.5085, found 1665.5359.
(R)-5-(2-(5,5-Diphenylfullerenyldihydropyrrole-2-carbonyl)-aminoacetamido)-6(R)-6-ammonio-1-(S)-1-(4-(methoxycarbonyloxazol-2-yl)-3-methylbutylamino-1oxohexan-2-yl)amino-6-oxohexan-1-aminium 2,2,2-trifluoroacetate (279)
This

compound

was

prepared

via

protocol 3, using 275 (35 mg, 0.0210
mmol) to yield 279 as a brown solid (17
mg, 56%). IR (neat, m-1): 3309 (w),
[1685, 1647, 1558 (s)], [1457, 1193,
1135 (m)]; HRMS (ESI +ve) calcd for
C99H52N8O7 1465.4037, found 1465.4045. This compound was not sufficiently soluble
to generate an adequate 1H NMR and 13C NMR spectrum.

186

Chapter 6

Experimental

(10R,13R,16R)-Isopentyl 10-(9H-fluoren-9-yl)methoxycarbonylamino-16-isobutyl2,2-dimethyl-4,11,14-trioxo-13-(3-(3-((2,2,5,7,8-pentamethylchroman-6yl)sulfonyl)guanidino)propyl)-3-oxa-5,12,15-triazaheptadecan-17-oate (258)
This compound was prepared via protocol
1 using 254 (220 mg, 0.353 mmol) and
Fmoc-(S)-Lys(Boc)-OH (165 mg, 0.353
mmol) to yield the desired product 258 as
a white foam (300 mg, 79%). 1H NMR
(500 MHz, CDCl3): δ 0.84-0.88 (m, 12H,
4 x CH3 (Leu and isopentyl)), 1.40 (s, 9H, Boc), 1.43 (s, 6H, C(CH3)2, (Pmc)), 1.46-1.49
(m, 4H, CHCH2CH2 (Arg) and CHCH2CH2 (Lys)), 1.57-1.72 (m, 6H, CH2CH2NH
(Lys), OCH2CH2 and CHCH2 (Arg)), 1.76 (bs, 1H, CH(CH3)2 (isopentyl)), 1.92 (m, 2H,
CHCH2 (Leu)), 1.99 (bs, 1H, CH(CH3)2 (Leu)), 2.07 (s, 3H, CH3, (Pmc)), 2.50 (s, 3H,
CH3, (Pmc)), 2.57 (s, 3H, CH3, (Pmc)), 2.92 (m, 4H, CH2, (Pmc)), 3.06 (bs, 2H, CH2N
(Arg)), 3.23 (bs, 2H, CH2N (Lys)), 4.05-4.10 (m, 2H, Lys-α-proton and CHCH2
(Fmoc)), 4.16-4.20 (m, 2H, CO2CH2), 4.32-4.34 (m, 2H, CHCH2 (Fmoc)), 4.43-4.45
(m, 1H, Arg-α-proton), 4.56-4.57 (m, 1H, Leu-α-proton), 4.82 (bs, 1H, NH), 5.29 (s,
1H, NH), 5.82 (bs, 1H, NH), 6.29 (bs, 2H, NH), 7.26-7.29 (m, 3H, 2 x ArCH, NH),
7.35-7.38 (m, 2H, ArCH), 7.56-7.58 (m, 2H, ArCH), 7.73 (d, J = 7.5 Hz, 2H, ArCH);
13

C NMR (125 MHz, CDCl3): δ 12.8 (CH3, Pmc), 18.3 (CH3, Pmc), 19.6 (CH3, Pmc),

21.9 (CHCH2CH2 (Lys)), 22.6 (2 x CH3 (isopentyl)), 22.7 (2 x CH3 (Leu)), 22.8 (2 x
CH3 (isopentyl)), 23.0 (CHCH2CH2 (Arg) and (CH(CH3)2 (isopentyl)), 25.0 (CH(CH3)2
(Leu)), 25.2 (CHCH2CH2 (Lys)), 28.7 (C(CH3)3), 28.8 (2 x CH3 (Pmc) and (CH2
(Pmc)), 29.6 (CHCH2CH2 (Arg)), 29.8 (CH2CH2NH (Lys)), 31.7 (CH2 (Pmc)), 37.5
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(CH2CH(CH3)2 (isopentyl)), 40.3 (CH2CH(CH3)2 (Leu)), 40.6 (NHCH2 (Lys)), 43.9
(NHCH2 (Arg)), 51.6 (CH2CH (Fmoc)), 52.7 (NHCHCO (Leu)), 53.7 (NHCHCO
(Lys)), 55.5 (NHCHCO (Arg)), 64.3 (OCH2 (isopentyl)), 67.4 (CH2CH (Fmoc)), 79.6
(OC(CH3)3), 86.6 (OC(CH3)2), 117.7 (ArC, Pmc), 120.2 (ArCH), 124.8 (ArC, Pmc),
[125.4, 125.5, 128.0 (ArCH)], [132.5, 138.6, 141.4, 141.5 (ArC, Pmc)], [143.9, 144.1
(ArC)], 156.6 (CO, Boc), [159.0, 171.9, 172.5 (CO)], 173.4 (CO, ester); MS (ESI +ve)
m/z 1074.0 ([M+H]+, 100%).
(10R,13R,16R)-Isopentyl

10-amino-13-(3-(3-((2,2-dimethylchroman-6-yl)sulfonyl)

guanidino)propyl)-16-isobutyl-2,2-dimethyl-4,11,14-trioxo-3-oxa-5,12,15triazaheptadecan-17-oate (262)
This compound was prepared via protocol 2 using 258
(275 mg, 0.256 mmol) to yield the desired product 262
as a white foam (185 mg, 85%). This compound was
carried through the subsequent reaction without any
further purification.

trans-4-Bis-(5,5-diphenylfullerenyldihydropyrrole-2-carboxylic acid) (284)
To a solution of the bis ester 283 (0.128 g, 0.098 mmol) in 1,2dichloroethane (80 mL) at rt was added (CH3)3SnOH (0.077 g,
0.392 mmol) and the solution was heated at 80 oC for 4 h, then
(CH3)3SnOH (0.077 g, 0.392 mmol) was added at the same
temperature and the reaction was continued for 4 h. The reaction
mixture was evaporated under reduced pressure and the resulting residue was taken in
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CH2Cl2 (100 mL). The organic layer was washed with 5% HCl (3 x 50 mL), brine (3 x
50 mL), dried (Mg2SO4) and evaporated under reduced pressure to yield 284 (0.109 g,
93%) as a brown solid. 1H NMR (500 MHz, CDCl3): 7.28-7.29 (m, 1H, ArCH), 7.39
(t, 2H, J = 7.2 Hz, ArCH), 7.46 (t, 1H, J = 7.2 Hz, ArCH), 7.56 (t, 2H, J = 7.2 Hz,
ArCH), 7.94 (d, 2H, J = 7.2 Hz, ArCH), 8.08 (d, 2H, J = 7.2 Hz, ArCH), 8.71 (bs, 1H,
CO2H). ESI-MS (+ve): m/z 1195 (40%, [M+H]+), 1200 (100%, [M+Li]+).
trans-4-Bis-(isopentyl

(10R,13R,16R)-10-(5,5-diphenylfullerenyldihydropyrrole-2-

carboxamido)-16-isobutyl-2,2-dimethyl-4,11,14-trioxo-13-(3-(3-((2,2,5,7,8pentamethylchroman-6-yl)sulfonyl)guanidino)propyl))-3-oxa-5,12,15triazaheptadecane-17-oate (285)
To a suspension of bis[60]fullerenoproline
acid 284 (96 mg, 0.080 mmol) in
CHCl3/pyridine (2:1) (90 mL) was added
HOBt (27 mg, 0.200 mmol) and EDCI (45
mg, 0.240 mmol) and the mixture was
stirred for 15 min before a solution of 262
(171 mg, 0.200 mmol) in CHCl3/pyridine
(2:1) (15 mL) was added dropwise. The
resulting solution was stirred at rt for a further 4 h, before the solvent was removed
under reduced pressure. The crude residue was then subjected to flash silica gel
chromatography, elution with MeOH/CH2Cl2 (1:49) provided the title compound 285 as
a brown solid (0.115 g, 50%). IR (neat, cm-1): 3277 (w), [1685, 1647, 1635, 1558 (s)],
[1260, 1187, 1156 (m)]; 1H NMR (500 MHz, CDCl3): δ 0.79-0.90 (m, 24H, 8 x CH3
(Leu and isopentyl)), 1.23-1.25 (m, 4H, 2 x CHCH2CH2 (Lys)), 1.28 (s, 18H, 6 x CH3 (2
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x Boc)), 1.30-1.38 (m, 12H, 4 x CH3 (Pmc)), 1.42-1.48 (m, 14H, 2 x CHCH2CH2 (Arg),
2 x CH2CH2NH (Lys), 2 x OCH2CH2 and 2 x CH(CH3)2 (isopentyl)), 1.55-1.68 (m,
10H, 2 x CHCH2 (Arg), 2 x CHCH2CH2 (Lys) and 2 x CH(CH3)2 (Leu)), 1.77 (t, J = 6.5
Hz, 4H, 2 x CHCH2 (Leu)), 2.05 (m, 4H, 2 x CH2 (Pmc)), 2.07 (s, 6H, 2 x CH3, (Pmc)),
2.31 (t, J = 7.5 Hz, 4H, 2 x CH2 (Pmc)), 2.52-2.59 (m, 12H, 4 x CH3, (Pmc)), 3.01-3.08
(m, 4H, CH2N, (Lys)), 4.00-4.10 (m, 4H, 2 x OCH2), 4.53-4.56 (m, 6H, 2 x Leu-αproton and CH2N (Arg)), 4.65-4.68 (m, 2H, 2 x Lys-α-proton), 5.38 (bs, 4H, NH), 5.505.58 (m, 2H, 2 x Arg-α-proton)), 6.24 (bs, 4H, NH), 7.08-7.16 (m, 2H, NH), 7.33-7.37
(m, 6H, ArCH), 7.44-7.46 (m, 2H, ArCH), 7.51-7.54 (m, 4H, ArCH), 7.80-7.90 (m, 4H,
ArCH), 8.02-8.05 (m, 4H, ArCH);

13

C NMR (125 MHz, CDCl3): δ 12.1 (CH3, Pmc),

14.1 (CH3, Pmc), 17.5 (CH3, Pmc), 18.5 (CH3, Pmc), 19.7 (CH3, Pmc), 21.5
(CHCH2CH2 (Lys)), 21.6 (CHCH2CH2 (Lys)), 22.5 (2 x CH3 (isopentyl)), 22.6 (2 x CH3
(isopentyl)), 22.7 (4 x CH3 (Leu)), 23.2 (CHCH2CH2 (Arg)), 24.8 (CH(CH3)2
(isopentyl)), 24.9 (CH(CH3)2 (Leu)), 25.0 (CH(CH3)2 (Leu)), 25.1 (CHCH2CH2 (Lys)),
26.8 (CHCH2CH2 (Lys)), 28.4 (C(CH3)3), 28.5 (C(CH3)3), 29.3 (CH2 (Pmc)), 29.7 (CH2
(Pmc)), 30.0 (CHCH2CH2 (Arg)), 30.1 (CHCH2CH2 (Arg)), 31.9 (CH2CH2NH (Lys)),
32.8 (CH2 (Pmc)), 37.1 (CH2CH(CH3)2 (isopentyl)), 37.14 (CH2CH(CH3)2 (isopentyl)),
40.5 (CH2CH(CH3)2 (Leu) and (NHCH2 (Lys)), 51.0 (NHCHCO (Leu)), 52.8
(NHCHCO (Leu)), 54.3 (NHCHCO (Lys) and (NHCHCO (Arg)), 62.9 (OCH2
(isopentyl)), 64.0 (OCH2 (isopentyl)), 73.6 (2 x C(CH3)2), 79.2 (2 x C(CH3)3), [82.2*,
83.4*, (C60sp3)], 96.2 (CPh2), [117.9, 121.0, 124.0, 128.2 (ArC, Pmc)], [128.4, 129.7,
129.8, 130.0 (ArCH)], [134.9, 135.5 (ArC, Pmc)], [136.6, 139.0, 139.4, 140.7, 140.9,
141.2, 141.5, 141.7, (C60sp2)], [141.8, 141.9, 1 (ArC)], [142.39* (1/2 x C), 142.4, 142.6,
142.7, 142.9, 143.9, 144.2, 144.8, 145.1, 145.3, 145.39, 145.4* (1/2 x C), 145.9, 146.0,
146.3, 146.9, 147.0, 147.5, 148.4* (1/2 x C), 148.8, 149.0, 150* (1/2 x C) (C60sp2)],
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153.2 (C=N), 153.3 (C=N), [153.5, 156.3 (CO, Boc), 160.8, 161.5, 162.0, 171.2, 171.4,
172.8, 173.3 (CO)]. HRMS (ESI +ve) calcd for C174H164N16O20S2Na 2884.1647, found
2884.1675.
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Appendix

Monopeptide 201
1H NMR 500 MHz
CDCl3

Monopeptide amine 202
1H NMR 500 MHz
CDCl3
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Monopeptide acid 203
1H NMR 500 MHz
CDCl3

Dipeptide 204
1H NMR 500 MHz
CDCl3

200

